iKang Healthcare (KANG) 20-F 29 Jul 16 2016 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Mar. 31, 2016shares
Entity Registrant Name	iKang Healthcare Group, Inc.
Entity Central Index Key	1,524,190
Document Type	20-F
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Class A common shares
Entity Common Stock, Shares Outstanding	33,556,439
Class C common shares
Entity Common Stock, Shares Outstanding	805,100

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 108,111	$ 97,336
Restricted cash	31,836	54,417
Term deposits	12,202	14,621
Accounts receivable, net of allowance for doubtful accounts of $8,055 and $14,329 as of March 31, 2015 and 2016, respectively	74,163	59,650
Inventories	4,015	2,661
Deferred tax assets-current	8,064	5,949
Amounts due from a related party	4,653
Prepaid expenses and other current assets	62,659	44,031
Total current assets	305,703	278,665
Property and equipment, net	130,170	105,022
Acquired intangible assets, net	37,179	30,634
Goodwill	108,839	72,101
Long-term investments	200,108	129
Deferred tax assets-non-current	8,077	2,212
Rental deposit and other non-current assets	13,565	10,238
TOTAL ASSETS	803,641	499,001
Current liabilities
Accounts payable (including accounts payable of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $19,530 and $22,685 of March 31, 2015 and 2016, respectively)	28,135	23,526
Accrued expenses and other current liabilities (including accrued expenses and other current liabilities of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $30,631 and $41,319 of March 31, 2015 and 2016, respectively)	47,404	36,790
Income tax payable (including income tax payable of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $6,254 and $7,386 of March 31, 2015 and 2016, respectively)	8,216	7,539
Deferred revenues (including deferred revenues of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc.of $31,786 and $52,210 of March 31, 2015 and 2016, respectively)	61,881	38,457
Deferred government subsidy-current (including deferred government subsidy - current of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $63 and nil of March 31, 2015 and 2016, respectively)		63
Short-term borrowings (including short-term borrowings of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $56,772 and $53,364 of March 31, 2015 and 2016, respectively)	53,364	56,772
Total current liabilities	199,000	163,147
Long-term borrowings (including long term borrowings of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of nil and $229,467 of March 31, 2015 and 2016, respectively)	229,467
Deferred tax liabilities-non-current (including deferred tax liabilities-non-current of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $6,670 and $9,422 of March 31, 2015 and 2016, respectively)	9,772	7,506
TOTAL LIABILITIES	438,239	170,653
Commitments and contingencies (Note 23)
iKang Healthcare Group, Inc. shareholders' equity
Additional paid-in capital	436,746	419,862
Statutory reserve	11,529	8,399
Accumulated deficit	(98,215)	(113,410)
Accumulated other comprehensive income/(loss)	(7,577)	3,936
Total iKang Healthcare Group, Inc. shareholders' equity	342,826	319,130
Non-controlling interests	22,576	9,218
TOTAL EQUITY	365,402	328,348
TOTAL LIABILITIES AND EQUITY	803,641	499,001
Class A common shares
iKang Healthcare Group, Inc. shareholders' equity
Common shares	335	335
Class C common shares
iKang Healthcare Group, Inc. shareholders' equity
Common shares	$ 8	$ 8

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Allowance for doubtful accounts	$ 14,329	$ 8,055
Accounts payable	28,135	23,526
Accrued expenses and other current liabilities	47,404	36,790
Income tax payable	8,216	7,539
Deferred revenues	61,881	38,457
Deferred government subsidy-current		63
Short term borrowings	53,364	56,772
Long-term borrowings	229,467
Deferred tax liabilities-non-current	9,772	7,506
Consolidated VIEs without recourse to iKang Healthcare Group, Inc.
Accounts payable	22,685	19,530
Accrued expenses and other current liabilities	41,319	30,631
Income tax payable	7,386	6,254
Deferred revenues	52,210	31,786
Deferred government subsidy-current	0	63
Short term borrowings	53,364	56,772
Long-term borrowings	229,467	0
Deferred tax liabilities-non-current	$ 9,422	$ 6,670
Class A common shares
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	37,648,485	37,648,485
Common shares, issued	33,556,439	33,556,439
Common shares, outstanding	33,556,439	33,556,439
Class C common shares
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	2,000,000	2,000,000
Common shares, issued	805,100	805,100
Common shares, outstanding	805,100	805,100

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS
Net revenues	$ 370,812	$ 290,781	$ 202,304
Cost of revenues	210,909	154,943	106,405
Gross profit	159,903	135,838	95,899
Operating expenses:
Selling and marketing expenses	64,763	41,059	28,879
General and administrative expenses (including share-based compensation expenses of $930, $9,153 and $1,949 in 2014, 2015 and 2016, respectively)	65,422	52,331	32,053
Research and development expenses	3,716	1,401	1,603
Total operating expenses	133,901	94,791	62,535
Income from operations	26,002	41,047	33,364
Gain/(loss) from forward contracts		(8)	57
Interest expense	(4,603)	(2,466)	(1,331)
Interest income	785	699	93
Other income	1,874	883
Income before provision for income taxes and (loss)/gain from equity method investments	24,058	40,155	32,183
Income tax expenses	5,838	13,280	10,101
Income before (loss)/gain from equity method investments	18,220	26,875	22,082
(Loss)/gain from equity method investments	(1,732)	521	(156)
Net income	16,488	27,396	21,926
Less: Net income/(loss) attributable to non-controlling interest	(1,837)	283	319
Net income attributable to iKang Healthcare Group, Inc.	18,325	27,113	21,607
Deemed dividend to preferred shareholders		100	20,436
Undistributed earnings allocated to preferred shareholders		201	7,310
Net (loss)/income attributable to common and preferred shareholders of iKang Healthcare Group, Inc	$ 18,325	$ 26,812	$ (6,139)
Net (loss)/income per share attributable to common shareholders of iKang Healthcare Group, Inc.
Basic (in dollars per share)	$ 0.55	$ 0.82	$ (0.97)
Diluted (in dollars per share)	$ 0.54	$ 0.79	$ (0.97)
Weighted average shares used in calculating net (loss)/income per common share
Basic (in shares)	33,583,005	32,884,357	6,340,005
Diluted (in shares)	34,235,542	34,114,872	6,340,005

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS
Share-based compensation	$ 1,949	$ 9,153	$ 930

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$ 16,488	$ 27,396	$ 21,926
Other comprehensive income/(loss):
Foreign currency translation adjustment	(12,187)	196	(779)
Unrealized gain on available-for-sale investments	186
Comprehensive income	4,487	27,592	21,147
Less: comprehensive income/(loss) attributable to non-controlling interest	(2,321)	307	298
Comprehensive income attributable iKang Healthcare Group, Inc.	$ 6,808	$ 27,285	$ 20,849

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT) - USD ($) $ in Thousands		iKang's shareholder's equity/(deficit)IPO	iKang's shareholder's equity/(deficit)Green Shoe	iKang's shareholder's equity/(deficit)Shanghai Jianwei Management	iKang's shareholder's equity/(deficit)WA HK	iKang's shareholder's equity/(deficit)iKang Shanghai Lujiazui	iKang's shareholder's equity/(deficit)iKang Shanghai Gubei	iKang's shareholder's equity/(deficit)	CommonIPO	CommonGreen Shoe	Common	Additional paid-in capitalIPO	Additional paid-in capitalGreen Shoe	Additional paid-in capitalShanghai Jianwei Management	Additional paid-in capitalWA HK	Additional paid-in capitaliKang Shanghai Lujiazui	Additional paid-in capitaliKang Shanghai Gubei	Additional paid-in capital	Statutory reserve	Accumulated deficitShanghai Jianwei Management	Accumulated deficit	Accumulated other comprehensive income	Non-controlling InterestShanghai Jianwei Management	Non-controlling InterestBeijing Jiandatong	Non-controlling InterestiKang Changzhou	Non-controlling InterestMediFast	Non-controlling InterestWA HK	Non-controlling InterestiKang Shanghai Lujiazui	Non-controlling InterestiKang Shanghai Gubei	Non-controlling InterestBeijing Tianzhikangjian	Non-controlling InterestYinchuan Ciming	Non-controlling InterestShandong Ciming Clinics	Non-controlling InterestXi'an iKang	Non-controlling InterestGuizhou Wishstar	Non-controlling InterestChina Physician Alliance	Non-controlling InterestWuhu iKang	Non-controlling Interest	IPO	Green Shoe	Beijing Jiandatong	iKang Changzhou	MediFast	WA HK	iKang Shanghai Lujiazui	iKang Shanghai Gubei	Beijing Tianzhikangjian	Yinchuan Ciming	Shandong Ciming Clinics	Xi'an iKang	Guizhou Wishstar	China Physician Alliance	Wuhu iKang	Total
Balance at Mar. 31, 2013								$ (124,195)			$ 65							$ 4,341	$ 2,267		$ (135,390)	$ 4,522															$ 1,030																$ (123,165)
Balance (in shares) at Mar. 31, 2013											6,481,245
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve																			2,738		(2,738)																																2,738
iKang Healthcare Group, Inc. one common share of $0.01 entered into a share swap agreement											1
Redesignation to Series F convertible redeemable participating preferred shares								(3,749)			$ (4)							(3,745)																																			(3,749)
Redesignation to Series F convertible redeemable participating preferred shares (in shares)											(311,572)
Share-based compensation expenses								930										930																																			930
Addition of non-controlling interest in connection with acquisition				$ (172)																$ (172)			$ 172	$ 82	$ 732	$ 1,690														$ 82	$ 732	$ 1,690
Dividend distribution to non-controlling interest holder																													$ (44)																$ (44)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium								(20,436)													(20,436)																																(20,436)
Purchase of non-controlling interest						$ (184)										$ (184)												$ (142)																$ (326)									(142)
Net income								21,607													21,607																319																21,926
Foreign currency translation adjustment								(758)														(758)															(21)																(779)
Balance at Mar. 31, 2014								(126,957)			$ 61							1,342	5,005		(137,129)	3,764															3,818																(123,139)
Balance (in shares) at Mar. 31, 2014											6,169,674
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve																			3,394		(3,394)																																3,394
Conversion of participating convertible redeemable preferred shares to common shares								264,509			$ 208							264,301																																			264,509
Conversion of participating convertible redeemable preferred shares to common shares (in shares)											20,781,515
Share-based compensation expenses								9,153										9,153																																			9,153
Issuance of common shares		$ 132,937	$ 13,399						$ 52	$ 5		$ 132,885	$ 13,394																									$ 132,937	$ 13,399
Issuance of common shares (in shares)									5,215,794	514,556
Issuance of common shares in connection with exercise of options								822			$ 1							821																																			$ 822
Issuance of common shares in connection with exercise of options (in shares)											80,000																																										277,319
Issuance of common shares in connection with share-based compensation arrangement	[1]							16			$ 16																																										$ 16
Issuance of ordinary shares in connection with share-based compensation arrangements (in shares)	[1]										1,600,000
Addition of non-controlling interest in connection with acquisition																											$ 3,388																$ 3,388
Capital contribution of non-controlling interest holder				$ (50)	$ (1,984)									$ (50)	$ (1,984)								$ 50	$ 58			$ 1,984													$ 58
Dividend distribution to non-controlling interest holder																										(387)																(387)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium																																																					(100)
Net income								27,113													27,113																283																27,396
Foreign currency translation adjustment								172														172															24																196
Balance at Mar. 31, 2015								319,130			$ 343							419,862	8,399		(113,410)	3,936															9,218																328,348
Balance (in shares) at Mar. 31, 2015											34,361,539
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve																			3,130		(3,130)																																3,130
Share-based compensation expenses								1,949										1,949																																			1,949
Issuance of common shares in connection with exercise of options	[1]							8,035										8,035																																			$ 8,035
Issuance of common shares in connection with exercise of options (in shares)																																																					995,255
Settlement of acquisition payable of Huajian								7,206										7,202				4																															$ 7,206
Addition of non-controlling interest in connection with acquisition																														$ 5,050	$ 1,613	$ 2,416	$ 3,242	$ 4,446	$ 551	$ 182										$ 5,050	$ 1,613	$ 2,416	$ 3,242	$ 4,446	$ 551	$ 182	16,767
Capital contribution of non-controlling interest holder																																	$ 457																$ 457				457
Dividend distribution to non-controlling interest holder																										$ (57)			(557)													$ (57)			(557)								(614)
Purchase of non-controlling interest							$ (302)										$ (302)												$ (486)	$ (1,178)															$ (788)	$ (1,178)							(1,664)
Net income								18,325													18,325																(1,837)																16,488
Foreign currency translation adjustment								(11,703)														(11,703)															(484)																(12,187)
Unrealized gain on available-for-sale investments								186														186																															186
Balance at Mar. 31, 2016								$ 342,826			$ 343							$ 436,746	$ 11,529		$ (98,215)	$ (7,577)															$ 22,576																$ 365,402
Balance (in shares) at Mar. 31, 2016											34,361,539
[1]	Shares were previously issued during the year ended March 31, 2015.

CONSOLIDATED STATEMENTS OF CHA8

CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT)
Common shares, par value (in dollars per share)		$ 0.01
Offering costs	$ 2,882

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 16,488	$ 27,396	$ 21,926
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	30,394	19,912	10,759
Share-based compensation	1,949	9,153	930
Loss on disposal of property and equipment	281	1	163
Loss on liquidation of a subsidiary	106
Gain from disposal of cost method investment	(1,772)
Allowance for doubtful accounts	8,509	3,758	1,100
(Loss)/gain from equity method investments	1,732	(521)	156
Fair value change of previously held 33% equity interest of Shanghai Huajian Health Examination Management Co., Ltd		(883)
Changes in assets and liabilities
Accounts receivable	(22,632)	(22,324)	(3,802)
Inventories	(1,279)	(698)	(459)
Prepaid expenses and other current assets	(10,069)	(5,300)	(1,193)
Deferred tax assets	(8,296)	(2,147)	(1,232)
Rental deposit and other long-term assets	(2,781)	(2,253)	(1,485)
Accounts payable	4,766	6,115	(955)
Accrued expenses and other current liabilities	3,979	2,123	2,884
Income tax payable	702	1,129	3,824
Deferred revenues	23,914	6,546	1,774
Deferred government subsidy	(61)	(47)	(79)
Deferred tax liabilities	(2,328)	(863)	(512)
Net cash generated from operating activities	43,602	41,097	34,303
CASH FLOWS FROM INVESTING ACTIVITIES
Restricted cash	20,772	(36,232)	(18,429)
Term deposits	2,361	(14,621)
Purchase of property and equipment	(37,024)	(39,767)	(35,838)
Proceeds from disposal of property and equipment			13
Purchase of intangible assets	157	339
Payments for business acquisitions (net of cash acquired of $2,749, $1,270 and $10,165 for years ended March 31, 2014, 2015 and 2016, respectively)	(37,249)	(56,654)	(41,311)
Payment for long-term investments	(204,414)
Proceeds from sale of cost method investment	1,897
Loan provided to related parties	(4,719)		(4,306)
Repayment of loan by a related party		1,291	3,483
Payment for loan receivables	(1,000)	(740)
Net cash used in investing activities	(261,533)	(147,062)	(96,714)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible redeemable preferred shares			25,181
Proceeds from redesignation of convertible redeemable preferred shares			669
Proceeds from redesignation of Class A common shares			612
Payments for professional fees in connection of issuance of series F convertible preferred shares			(2,847)
Proceeds from issuance of common shares upon initial public offering		135,819
Proceeds from issuance of common shares upon Green Shoe		13,399
Payments of initial public offering cost		(3,574)
Proceeds from exercise of share options	8,035	824
Capital contribution from non-controlling interest shareholders	567	58	732
Payments for business acquisitions	(1,853)	(1,329)	(3,010)
Payments for assets acquisition		(32)
Proceeds from long-term loans	220,223
Proceeds from short-term borrowings	54,126	59,404	20,298
Proceeds from long-term borrowings	12,521		1,901
Repayment of convertible loan			(2,000)
Repayments of short-term borrowings	(55,359)	(20,860)	(7,383)
Repayments of long-term borrowings		(1,869)
Net cash provided by financing activities	237,465	173,570	29,342
Effect of exchange rate on cash and cash equivalent	(8,759)	(490)	136
Net increase (decrease) in cash and cash equivalent	10,775	67,115	(32,933)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	97,336	30,221	63,154
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	108,111	97,336	30,221
Supplemental cash flow information
Income tax paid	13,327	13,678	8,224
Interest paid	1,957	2,392	1,068
Supplemental non-cash financing and investing activities
Payable for purchase of non-controlling interest of Shanghai Guobin Medical Center Co., Ltd.			8,049
Payable for business acquisitions	9,350	11,795	3,628
Payable for purchase of long term investments	3,743
Payable for purchase of property and equipment	7,109	7,902	8,568
Prepayment for business acquisitions	10,570	22,215	1,705
Prepayment for long term investment	4,000
Prepayment for purchase of property and equipment	11,318	5,435	7,312
iKang Shanghai Xikang Road
Adjustments to reconcile net income to net cash provided by operating activities
Amortization of discount on payable purchase of non-controlling interest of Shanghai Guobin Medical Center Co., Ltd			504
CASH FLOW FROM FINANCING ACTIVITIES
Purchase of non-controlling interest of Shanghai Guobin Medical Center Co., Ltd.		(8,077)	(4,767)
Dividend distribution to a non-controlling interest shareholder			(44)
iKang Shanghai Lujiazui
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of non-controlling interest			$ 326
iKang Shanghai Gubei
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of non-controlling interest	788
CASH FLOW FROM FINANCING ACTIVITIES
Dividend distribution to a non-controlling interest shareholder	(545)
Beijing Tianzhikangjian
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of non-controlling interest	1,212
MediFast
CASH FLOW FROM FINANCING ACTIVITIES
Dividend distribution to a non-controlling interest shareholder	$ (250)	$ (193)

CONSOLIDATED STATEMENTS OF CA10

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Jul. 01, 2014
Cash acquired	$ 10,165	$ 1,270	$ 2,749
Shanghai Huajian Management
Equity Interest (as a percentage)				33.00%

ORGANIZATION AND PRINCIPAL ACTI

ORGANIZATION AND PRINCIPAL ACTIVITIES	12 Months Ended
	Mar. 31, 2016
ORGANIZATION AND PRINCIPAL ACTIVITIES
ORGANIZATION AND PRINCIPAL ACTIVITIES	1. ORGANIZATION AND PRINCIPAL ACTIVITIES iKang Healthcare Group, Inc. (the “Company”), was incorporated on May 25, 2011 as a limited liability company in the Cayman Islands. The Company has no operations and has been created for the initial public offering (“IPO”) purpose. On March 1, 2014, the Company entered into a share swap agreement and became the ultimate holding company of iKang Guobin Healthcare Group, Inc. with the completion of the one to one share exchange to the existing shareholders of iKang Guobin Healthcare Group, Inc. for all shares of equivalent classes. The Company, its subsidiaries, its variable interest entities (“VIEs”) and its VIEs’ subsidiaries (collectively the “Group”) are primarily engaged in providing medical examination services, disease screening services, and other healthcare related services in the People’s Republic of China (the “PRC”). As of March 31, 2016, details of the Group’s subsidiaries, VIEs and the VIEs’ subsidiaries were as follows: Percentage of Later date of beneficial interest incorporation/ Place of by iKang Names acquisition incorporation Healthcare Group, Inc. Principal activities Subsidiaries: iKang Guobin Healthcare Group, Inc.(“iKang Guobin”) December 24, 2003 BVI % Holding company ShanghaiMed iKang, Inc. (“Beijing iKang”) February 27, 2004 PRC % Sales of healthcare service Shanghai iKang Co., Ltd. (“Shanghai iKang”) December 27, 2004 PRC % Sales of healthcare service iKang Zhejiang, Inc. (“iKang Zhejiang BVI”) April 5, 2006 BVI % Holding company iKang HealthManagement (Zhejiang) Co., Ltd. (“Zhejiang iKang”) July 11, 2006 PRC % Sales of healthcare service Bayley & Jackson (China) Medical Services Limited (“Bayley & Jackson (Hong Kong)”) October 10, 2006 Hong Kong % Holding company Beijing Bayley & Jackson Clinic Co., Ltd. (“iKang Beijing Ritan”) October 10, 2006 PRC % Medical examinations & clinical services Yuanhua Healthcare Limited (HongKong) (“Yuanhua HK”) July 31, 2013 Hong Kong % Holding company MediFast (Hong Kong) Limited (“MediFast”) January 14, 2014 Hong Kong % Medical examinations & clinical services Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. (“Yuanhua WFOE”) July 31, 2013 PRC % Sales of healthcare service WA Centers HK Limited (“WA HK ”) March 3, 2015 Hong Kong % Holding company iKang Health Cloud Technology Limited (“iKang Cloud HK”) January 5, 2015 Hong Kong % Holding company iKang(Shanghai) Financing Lease Co., Ltd. (“iKang(Shanghai) Financing Lease”) December 19, 2014 PRC % Lease services VIEs: iKang Healthcare Technology Group Co., Ltd. (formerly named as “Shanghai iKang Guobin Holding Co., Ltd.”) (“iKang Holding”) April 27, 2007 PRC % Holding company Hangzhou iKang Guobin Clinic Co., Ltd. (“iKang Hangzhou Xixi”) September 26, 2010 PRC % Medical examinations Shanghai Yuanhua Information Technology Co., Ltd. (“Yuanhua Information”) July 31, 2013 PRC % Holding company Jiandatong Health Technology (Beijing) Co., Ltd. (“Beijing Jiandatong”) April 1, 2013 PRC % Sales of healthcare service VIEs’ subsidiaries: iKang Guobin Healthcare Group Co., Ltd. (formerly named as “Beijing iKang Online Technology Co., Ltd.”) (“iKang Online”) September 13, 2004 PRC % Sales of healthcare service Beiijng iKang Medical Examination Application Technology Co., Ltd. February 3, 2005 PRC % Sales of healthcare service Shenzhen iKang Co., Ltd. (“Shenzhen iKang”) July 12, 2006 PRC % Sales of healthcare service Shanghai Yalong Daoyi Services Co., Ltd. (“Yalong Daoyi”) December 20, 2006 PRC % Sales of healthcare service Guangzhou iKang Guobin Health Examination Co., Ltd. (“iKang Guangzhou Huanshi East/Tianhe”) April 27, 2007 PRC % Medical examinations Shanghai Guobin Medical Center Co., Ltd. (“iKang Shanghai Xikang Road”) April 27, 2007 PRC % Medical examinations & clinical services Shanghai Wangzu Guobin Medical Center Co., Ltd. (“iKang Shanghai Gubei”) April 27, 2007 PRC % Medical examinations Shanghai iKang Guobin Mingmen Clinic Co., Ltd. (“iKang Shanghai Pudong Avenue”) April 27, 2007 PRC % Medical examinations Shenzhen iKang Guobin Hospital Management Co., Ltd. (“Shenzhen Hospital Management”) September 10, 2007 PRC % Holding company Shenzhen iKang Guobin Puji Clinic Co., Ltd. (formerly named as “Shenzhen Puji Clinic”) (“iKang Shenzhen Nanshan”) September 10, 2007 PRC % Medical examinations & clinical services Beijing iKang Guobin Lidu Clinic Co., Ltd. (“iKang Beijing Lidu”) December 3, 2007 PRC % Medical examinations Nanjing iKang Guobin Xinjie Clinic Co., Ltd. January 10, 2008 PRC % Medical examinations Shenzhen iKang Guobin Clinic Co., Ltd. (formerly named as “Shenzhen iKang Guobin Clinic”) (“iKang Shenzhen Luohu”) March 25, 2008 PRC % Medical examinations Beijing iKang Guobin Jianwai Clinic Co., Ltd. (“iKang Beijing Jianguomen”) September 9, 2008 PRC % Medical examinations Beijing iKang Guobin Zhongguan Clinic Co., Ltd. (“iKang Beijing Zhongguancun”) September 19, 2008 PRC % Medical examinations Beijing iKang Guobin Zhengqingyuan Clinic Co., Ltd. (“iKang Beijing Kunming Lake”) December 1, 2008 PRC % Medical examinations Beijing iKang Guobin Jiuxianqiao Clinic Co., Ltd. (“iKang Beijing Yansha East”) December 1, 2008 PRC % Medical examinations Shanghai iKang Guobin Renren Clinic Co., Ltd. (“iKang Shanghai Yangpu”) December 9, 2008 PRC % Medical examinations Chengdu iKang Guobin Health Examination Hospital Co., Ltd. (“iKang Chengdu Waishuangnan”) January 15, 2009 PRC % Medical examinations Shanghai iKang Guobin Blue Cross Clinic Co., Ltd. (“iKang Shanghai Lujiazui”) January 28, 2010 PRC % Medical examinations Shanghai Wenzhong Clinic Co., Ltd. (“Shanghai Wenzhong”) February 12, 2010 PRC % Medical examinations Beijing iKang Guobin Clinic Co., Ltd. (“iKang Beijing Xuanwumen”) August 5, 2010 PRC % Medical examinations Nanjing iKang Guobin Clinic Co., Ltd. (“iKang Nanjing Gulou”) January 19, 2011 PRC % Medical examinations Shenzhen Xinglin Clinic Co., Ltd. (formerly named as “Shenzhen Xinglin Clinic”) (“iKang Shenzhen Futian”) January 25, 2011 PRC % Medical examinations Fujian iKang Guobin Health Management Co., Ltd. (“Fujian iKang”) April 1, 2011 PRC % Sales of healthcare service Fuzhou iKang Guobin Clinic Co., Ltd. (“iKang Fuzhou Gulou”) November 14, 2011 PRC % Medical examinations Beijing iKang Guobin Xinei Clinic Co., Ltd. (“iKang Beijing Xinei”) January 30, 2012 PRC % Medical examinations Shanghai iKang Guobin Fukang Clinic Co., Ltd. (“Yan’an West Road”) January 18, 2012 PRC % Medical examinations Shanghai iKang Guobin Zhonghuan Yipin Clinic Co., Ltd. (formerly named as “Shanghai Zhonghuan Yipin Clinic Co., Ltd.”) (“iKang Shanghai Zhonghuan”) January 21, 2012 PRC % Medical examinations Shanghai iKang Guobin Yipin Clinic Co., Ltd. (formerly named as “Shanghai Yipin Clinic Co., Ltd.”) (“iKang Shanghai Jing’an”) January 21, 2012 PRC % Medical examinations Shanghai iKang Guobin Waizhitan Clinic Co., Ltd. (“iKang Shanghai Yan’an East Road”) May 29, 2012 PRC % Medical examinations Shanghai iKang Guobin Jianwei Clinic Co., Ltd. (formerly named as “Shanghai Jianzhiwei Clinic Co., Ltd.”) (“iKang Shanghai Jianzhiwei”) August 17, 2012 PRC % Medical examinations Hangzhou iKang Guobin Wenhui Clinic Co., Ltd. (“iKang Hangzhou Wenhui”) September 3, 2012 PRC % Medical examinations Tianjin Heping Aibin Clinic Co., Ltd. (“iKang Tianjin Heping”) October 15, 2012 PRC % Medical examinations Suzhou iKang Guobin Clinic Co., Ltd. (formerly named as “Suzhou Aibin Clinic, Co., Ltd.”) (“iKang Suzhou”) November 13, 2012 PRC % Medical examinations Suzhou Zhuoyue Clinic Co., Ltd. (“Suzhou Zhuoyue”) October 15, 2014 PRC % Medical examinations Changchun iKang Guobin Jiachang General Clinic Co., Ltd. (“iKang Changchun”) November 5, 2012 PRC % Medical examinations Chengdu Jinjiang iKang Guobin Hongzhaobi Health Co., Ltd. (“iKang Chengdu Hongzhaobi”) December 21, 2012 PRC % Examination General Clinic Medical examinations Chongqing Aibin Clinic Co., Ltd. (“iKang Chongqing”) December 18, 2012 PRC % Medical examinations Guangzhou Wokang Medical Clinic (“iKang Guangzhou Wokang”) December 3, 2012 PRC % Medical examinations Shenzhen iKang Guobin Kefa Clinic Co., Ltd. (formerly named as “Shenzhen iKang Guobin Kefa Clinic”) (“Shenzhen Kefa”) March 26, 2013 PRC % Medical examinations Shanghai iKang Jianwei Health Management Co., Ltd. (“Shanghai Jianwei Management”) September 6, 2013 PRC % Sales of healthcare services Shanghai Yuanhua Clinic Co., Ltd. (“Yuanhua Clinic”) July 31, 2013 PRC % Medical examinations Nanjing iKang Jun’an TCM Clinic Co., Ltd. (“iKang Nanjing Jun’an”) September 1, 2013 PRC % Medical examinations Nanjing Aibin Health Information Consultancy Co., Ltd. (“Nanjing Aoyang Shunkang”) September 1, 2013 PRC % Sales of healthcare service Jiangyin iKang Guobin Clinic Co., Ltd. (“iKang Jiangyin”) December 16, 2013 PRC % Medical examinations Zhejiang Huzhou Ailikang Investment Management Co., Ltd. (“Zhejiang Ailikang”) December 31, 2013 PRC % Sales of healthcare services Hangzhou iKang Jun’an Clinic Co., Ltd. (formerly named as “Hangzhou Aibo Huagang Clinic Co. Ltd.”) (“Hangzhou Aibo”) December 31, 2013 PRC % Medical examinations Beijing iKang Jun’an Clinic Co., Ltd. (“iKang Beijing Jun’an”) November 28, 2013 PRC % Medical examinations & clinical services Beijing iKang Guobin Yayun Clinic Co., Ltd. (“iKang Beijing Yayun”) December 5, 2013 PRC % Medical examinations Changzhou iKang Guobin Clinic Co., Ltd. (“iKang Changzhou”) March 14, 2014 PRC % Medical examinations Beijing iKang Guobin Baishi Clinic Co., Ltd. (“iKang Beijing Baishi”) April 16, 2014 PRC % Medical examinations Chengdu Gaoxin iKang Guobin Chengnan Clinic Co., Ltd. (“Chengdu Gaoxin iKang West City ”) May 22, 2014 PRC % Medical examinations iKang Dental Hospital Management Co., Ltd. (“iKang Dental Hospital Management ”) August 13, 2014 PRC % Management of dental services Beijing iKang Guobin Wanzhishou Clinic Co., Ltd. (“iKang Beijing Wanzhishou ”) August 21, 2014 PRC % Medical examinations Shanghai Huajian Health Examination Management Co., Ltd. (“Shanghai Huajian Management”) July 1, 2014 PRC % Medical examinations Shanghai Huajian Clinic Co., Ltd.(“Shanghai Huajian”) July 1, 2014 PRC % Medical examinations Shanghai Jinxiu Huajian Clinic Co., Ltd.(“Shanghai Jinxiu Huajian”) July 1, 2014 PRC % Medical examinations Shanghai Jinshen Huajian Clinic Co., Ltd.(“Shanghai Jinshen Huajian”) July 1, 2014 PRC % Medical examinations Shenyang iKang Guobin Hospital(“iKang Shenyang Hospital”) November 14, 2014 PRC % Medical examinations Shenyang iKang Guobin Ningshan Hospital Co., Ltd. (“iKang Shenyang Ningshan Hospital”) November 19, 2014 PRC % Medical examinations Shenyang Golden iKang Guobin Hospital Co., Ltd. (“Gold iKang Shenyang Hospital”) December 19, 2014 PRC % Medical examinations Tianjin Hedong District iKang Guobin Dongrun Clinic Co., Ltd. (“iKang Tianjin Hedong Dongrun”) February 17, 2015 PRC % Medical examinations Tianjin Hexi District iKang Guobin Fenghui Clinic Co., Ltd. (“iKang Tianjin Hexi Fenghui”) February 17, 2015 PRC % Medical examinations Wuxi Woshi Hongtai Biotechnology Co., Ltd. (“Wuxi Woshi Hongtai”) March 3, 2015 PRC % Holding company Beijing Woshi Hongtai Investment Management Consultancy Co., Ltd. (“Beijing Woshi Hongtai”) March 3, 2015 PRC % Sales of healthcare services Beijing Zhenjing Clinic Co., Ltd.(“Beijing Zhenjing”) March 3, 2015 PRC % Medical examinations Shanghai Zhenjing Hospital Management Co., Ltd. (“Shanghai Zhenjing Hospital Management”) March 3, 2015 PRC % Sales of healthcare services Shanghai Zhenjing Clinic Co., Ltd. (“Shanghai Zhenjing”) March 3, 2015 PRC % Medical examinations Beijing iKang Guobin Shunping Clinic Co., Ltd. (“iKang Beijing Shunping”) August 04, 2015 PRC % Medical examinations Beijing iKang Guobin Baiyunlu Clinic Co., Ltd. (“iKang Beijing Baiyunlu”) October 14, 2015 PRC % Medical examinations Chongqing iKang Zhuoyue Clinic Co., Ltd. (“iKang Chongqing Zhuoyue”) November 10, 2015 PRC % Medical examinations Tianjin Hexi District iKang Guobin Clinic Co., Ltd. (“iKang Tianjin Hexi”) July 27, 2015 PRC % Medical examinations Tianjin iKang Guobin Yuecheng Clinic Co. Ltd. (“iKang Tianjin Yuecheng”) September 09, 2015 PRC % Medical examinations iKang Health Cloud(Beijing) Software Co.,Ltd. (“iKang Health Cloud”) May 07, 2015 PRC % Research & development China Physician Alliance Group, Limited. (“China Physician Alliance”) August 26, 2015 PRC % Sales of healthcare services Xi’an iKang Guobin Medical Examination Management Co., Ltd. (“Xi’an iKang”) December 17, 2015 PRC % Sales of healthcare services Xi’an Lianhu Yinglun Hospital Co., Ltd. (“Xi’an Lianhu Yinglun”) December 17, 2015 PRC % Medical examinations Xi’an Yanta Yinglun Clinic Co., Ltd. (“Xi’an Yanta Yinglun”) December 17, 2015 PRC % Medical examinations Xi’an Weiyang Yinglun Clinic Co., Ltd. (“Xi’an Weiyang Yinglun”) December 17, 2015 PRC % Medical examinations Yantai iKang Guobin Hongkang Health Management Co., Ltd. (“iKang Yantai Hongkang”) May 31, 2015 PRC % Sales of healthcare services Yantai iKang Guobin Hongkang Health Management Co., Ltd. Clinic (“iKang Yantai Hongkang Clinic”) May 31, 2015 PRC % Medical examinations Yantai iKang Guobin Hongkang Health Examination Management Co., Ltd. Clinic (“iKang Yantai Hongkang Examination Clinic”) May 31, 2015 PRC % Medical examinations Yantai iKang Guobin Hongkang Health Examination Management Co., Ltd. (“iKang Yantai Hongkang Examination”) May 31, 2015 PRC % Sales of healthcare services Guizhou iKang Guobin Health Technology Co., Ltd. (“Guizhou iKang”) January 22, 2016 PRC % Sales of healthcare services Guizhou Wishstar Health Examination Clinic Co., Ltd. (“Guizhou Wishstar”) January 22, 2016 PRC % Medical examinations Weifang Gaoxin iKang Guobin Clinic Co. Ltd. (“iKang Weifang Gaoxin”) January 13, 2016 PRC % Medical examinations Wuhu iKang Guobin Clinic Co. Ltd (“Wuhu iKang”) January 7, 2016 PRC % Medical examinations Chengdu Gaoxin iKang Dental Clinic Co., Ltd. (“iKang Chengdu Gaoxin”) July 3, 2015 PRC % Dental services Shandong iKang Guobin Medical Examination Management Co., Ltd. (“Shandong iKang”) May 14 2015 PRC % Sales of healthcare services Jinan iKang Zhuoyue Medical Examination Management Co, Ltd. (“iKang Jinan Zhuoyue”) August 05, 2015 PRC % Medical examinations Yinchuan iKang Guobin Ciming Clinic Co., Ltd. (“iKang Yinchuan Ciming”) May 31, 2015 PRC % Medical examinations Ningxia iKang Guobin Health Examination Investment Holding Co., Ltd. (“Ningxia iKang”) May 31, 2015 PRC % Sales of healthcare services Hangzhou iKang Guobin Jiangnan Avenue Clinic Co., Ltd. (“iKang Hangzhou Jiangnan Avenue”) November 16, 2015 PRC % Medical examinations Ningbo Haishu iKang Guobin Clinic Co., Ltd. (“iKang Ningbo Haishu”) July 07, 2015 PRC % Medical examinations Nanjing iKang Guobin Hedingqiao Clinic Co., Ltd. (“iKang Nanjing Hedingqiao”) November 25, 2015 PRC % Medical examinations Wuhan iKang Guobin Xiandai Sunny Clinic Co., Ltd. (“iKang Wuhan Xiandai Sunny”) January 01, 2016 PRC % Medical examinations Foshan iKang Guobin Clinic Co., Ltd. (“Foshan iKang”) October 24, 2015 PRC % Medical examinations Beijing Tianjian Sunny Health Science and Technology Co., Ltd. (“Beijing Tianjian Sunny”) May 25, 2015 PRC % Sales of healthcare services Beijing Tianjian Sunny Health Science and Technology Co., Ltd. Anhuaqiao Clinic (“Beijing Anhuaqiao”) May 25, 2015 PRC % Medical examinations Beijing Tianjian Sunny Health Science and Technology Co., Ltd. Fengtai Clinic (“Beijing Fengtai”) May 25, 2015 PRC % Medical examinations Sinopharm Sunny Health Science and Technology Co., Ltd. Konggang Clinic (“Beijing Konggang”) May 25, 2015 PRC % Sales of healthcare services Beijing iKang Guobin Sunny Jingchao Clinic Co., Ltd. (“iKang Beijing Jingchao”) May 25, 2015 PRC % Medical examinations Beijing iKang Guobin Sunny Jingchun Clinic Co., Ltd. (“iKang Beijing Jingchun”) May 25, 2015 PRC % Medical examinations Guangzhou Zhenxing Traditional Chinese Medical Clinic Co., Ltd. (“Guangzhou Zhenxing”) May 25, 2015 PRC % Medical examinations Beijing Tianzhikangjian Investment Management Co., Ltd. (“Beijing Tianzhikangjian”) May 25, 2015 PRC Changsha iKang Guobin Health Consultancy Co., Ltd. (“Changsha iKang”) May 25, 2015 PRC % Sales of healthcare services Changsha iKang Guobin Health Consultancy Co., Ltd. Sunny Clinic (“iKang Changsha Sunny Clinic”) May 25, 2015 PRC % Medical examinations Beijing iKang Zhuoyue Jingxi Clinic Co., Ltd. (“iKang Beijing Jingxi”) May 25, 2015 PRC % Medical examinations Yantai iKang Guobin Ciming Medical Examination Management Co., Ltd. (“Yantai Ciming”) July 31, 2015 PRC % Sales of healthcare services Yantai iKang Guobin Ciming Medical Examination Management Co., Ltd.Laishan Clinic (“Yantai Ciming Laishan Clinic”) July 31, 2015 PRC % Medical examinations Weifang Kuiwen iKang Guobin Ciming Clinic Co. Ltd. (“Weifang Kuiwen”) July 31, 2015 PRC % Medical examinations Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic (“Weihai Ciming Clinic”) July 31, 2015 PRC % Sales of healthcare services Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. (“Weihai Ciming”) July 31, 2015 PRC % Medical examinations Chengdu iKang Guobin Ommay Health Examination Hospital Co., Ltd. (“Chengdu Ommay”) April 01, 2015 PRC % Medical examinations Beijing iKang Guobin Headquarter Base Clinic Co., Ltd. (“Beijing Headquarter Base”) February 1, 2016 PRC % Medical examinations The VIE arrangements Before January 31, 2012, PRC regulations limited business entities with direct foreign ownership of more than 70% to provide certain healthcare services in the PRC. To comply with related PRC regulations, the Company conducted the majority of its businesses through Beijing iKang and Zhejiang iKang, subsidiaries of the Group, and iKang Holding, iKang Holding’s subsidiaries and iKang Hangzhou Xixi, which are VIEs and VIEs’ subsidiaries (“VIE entities”) of the Company. Beijing iKang and Zhejiang iKang entered into a series of contractual arrangements with the VIEs and their shareholders, and through those contractual arrangements, as described below, the Company obtained the control and the right to substantially all of economic benefits of the VIE entities. In July 2013, iKang acquired 100% of Yuanhua, including Yuanhua BVI, Yuanhua WFOE, a variable interest entity, Yuanhua Information and Yuanhua Clinic, which provide medical examination related services in China. Yuanhua WFOE entered into a series of contractual arrangements with Yuanhua Information and Mr. Haiqing Hu and Mr. Lei Zhao through which Yuanhua WFOE gained effective control over the operation of Yuanhua Information and is able to receive substantially all the economic benefits of Yuanhua Information. In December 2013, Beijing iKang entered into a series of contractual arrangements with Beijing Jiandatong and Mr. Haiqing Hu through which Beijing iKang gained effective control over the operation of Beijing Jiandatong and is able to receive substantially all the economic benefits of Beijing Jiandatong. Starting from January 31, 2012, foreign-invested enterprises incorporated in the PRC are not expressly prohibited from providing healthcare services in the PRC; however, in order to operate under a foreign-invested enterprise, the Group needs to reapply for the licenses or permits required for conducting such business from the Ministry of Health and Ministry of Commerce, because currently most licenses of the Group to conduct healthcare services are held by PRC entities. As of March 31, 2016, the Group has not yet applied for such licenses or permits. Therefore the Group still operates through its VIE entities. The VIE arrangements - continued Beijing iKang, Zhejiang iKang and Yuanhua WFOE have entered into the following contractual arrangements with iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong, Yuanhua Information and the shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information that enable the Company to (1) have power to direct the activities that most significantly affects the economic performance of the VIE entities, and (2) receive the economic benefits of the VIE entities that could be significant to the VIE entities. Accordingly, the Company is considered the primary beneficiary of the VIE entities and has consolidated the VIE entities’ financial results of operations, assets and liabilities in the Company’s consolidated financial statements. In making the conclusion that the Company is the primary beneficiary of the VIE entities, the Company believes the Company’s rights under the terms of the Exclusive Equity Option agreement provide it with a substantive kick out right. More specifically, the Company believes the terms of the Exclusive Equity Option agreement are valid, binding and enforceable under PRC laws and regulations currently in effect. The Company also believes that the minimum amount of consideration permitted by the applicable PRC law to exercise the option does not represent a financial barrier or disincentive for the Company to currently exercise its rights under the exclusive equity option agreement. The Company’s rights under the Exclusive Equity Option agreement give the Company the power to control the shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information and thus the power to direct the activities that most significantly impact the VIE entities economic performance. In addition, the Company’s rights under the Power of Attorney also reinforce the Company’s abilities to direct the activities that most significantly impact the VIE entities’ economic performance. The Company also believes that this ability to exercise control ensures that the VIE entities will continue to execute and renew the Exclusive Service agreement and pay service fees to the Company. By charging service fees in whatever amounts the Company deems fit, and by ensuring that the Exclusive Service agreements are executed and renewed indefinitely, the Company has the rights to receive substantially all of the economic benefits from the VIE entities. Agreements that provide the Company effective control over the VIE entities (1) Power of Attorney: Each registered shareholder of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information has executed a power of attorney agreement appointing Beijing iKang, Zhejiang iKang or Yuanhua WFOE to be the only and exclusive attorney, and irrevocably authorizing it to vote on each registered shareholder’s behalf on all of the matters concerning the VIE entities, that may require shareholders’ approval. The term of the power of attorney is perpetual and the contract can be terminated at the discretion of the wholly foreign owned enterprises (“WFOEs”). Agreements that provide the Company effective control over the VIE entities - continued (2) Exclusive Equity Option Agreement: Beijing iKang, Zhejiang iKang and Yuanhua WFOE have the exclusive right to purchase the equity interests of the VIE entities from the registered legal equity owners at the lowest consideration allowed by PRC regulations as far as PRC regulations permit a transfer of legal ownership to foreign ownership. The term of the exclusive purchase right agreement is ten years and will be renewed on the expiration date by WFOEs and can be terminated at the discretion of the WFOEs. (3) Spousal Consent Under the Spousal Consent letters , the spouse of each married registered shareholder of iKang Holding has signed a spousal consent letter, whereby the spouse agrees that (i) the equity interests of iKang Holding owned by such shareholder will be disposed of only in accordance with the applicable Exclusive Equity Option Agreement, Equity Interest Pledge Agreement, and other related agreements executed by the shareholder, (ii) such equity interests do not constitute communal property with such shareholder and (iii) the spouse irrevocably and unconditionally waives all rights and benefits with respect to such equity interests, including the right to sue in any court and under all applicable laws. Agreements that transfer economic benefits to the Company (1) Exclusive Services Agreement : Beijing iKang, Zhejiang iKang, Yuanhua WFOE and registered shareholders irrevocably agree that Beijing iKang, Zhejiang iKang and Yuanhua WFOE shall be the exclusive technology and consulting service provider to the VIE entities in return for a service fee as determined by Beijing iKang, Zhejiang iKang and Yuanhua WFOE up to the entire net profit of the VIE entities. The terms of the services agreement are ten years, respectively, and this agreement will be automatically renewed on applicable expiration dates, and the agreement can be terminated at the discretion of the WFOEs. (2) Equity Interest Pledge Agreement: Shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information have pledged all of their equity interests in VIE entities with Beijing iKang, Zhejiang iKang and Yuanhua WFOE and Beijing iKang, Zhejiang iKang and Yuanhua WFOE are entitled to the rights to sell the pledged equity interests if the VIE entities or the shareholders default in their obligations. The term of the pledge agreement is as long as the service agreement; and it can be terminated when the service agreement is terminated. Through these contractual agreements, the Company has the ability to effectively control the VIE entities and is also able to receive substantially all the economic benefits of the VIE entities. Risk in relation to the VIE structure The Company believes that WFOE’s contractual arrangements with the VIEs are in compliance with PRC law and are legally enforceable. The shareholders of iKang Holding are also shareholders of the Company and therefore have no current interest in seeking to act contrary to the contractual arrangements. However, uncertainties in the PRC legal system could limit the Company’s ability to enforce these contractual arrangements and if the shareholders of the VIEs were to reduce their interest in the Company, their interests may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIEs not to pay the service fees when required to do so. The Company’s ability to control the VIE entities also depends on the power of attorney Beijing iKang, Zhejiang iKang and Yuanhua WFOE have to vote on all matters requiring shareholder approval in the VIEs. As noted above, the Company believes this power of attorney is legally enforceable but may not be as effective as direct equity ownership. In addition, if the legal structure and contractual arrangements were found to be in violation of any existing PRC laws and regulations, the PRC government could: · revoke the Group’s business and operating licenses; · require the Group to discontinue or restrict operations; · restrict the Group’s right to collect revenues; · block the Group’s websites; · require the Group to restructure the operations in such a way as to compel the Group to establish a new enterprise, re-apply for the necessary licenses or relocate our businesses, staff and assets; · impose additional conditions or requirements with which the Group may not be able to comply; or · take other regulatory or enforcement actions against the Group that could be harmful to the Group’s business. The imposition of any of these penalties may result in a material and adverse effect on the Group’s ability to conduct the Group’s business. In addition, if the imposition of any of these penalties causes the Group to lose the rights to direct the activities of the VIE entities or the right to receive their economic benefits, the Group would no longer be able to consolidate the VIE entities. The Group does not believe that any penalties imposed or actions taken by the PRC Government would result in the liquidation of the Company, Beijing iKang, Zhejiang iKang, Yuanhua WFOE or the VIEs. The shareholders of the VIEs and the Company are as the following: (1) iKang Holding’s shareholders are Mr. Ligang Zhang and Mr. Boquan He, each of whom holds 50% of the equity interest in iKang Holding. (2) iKang Hangzhou Xixi’s shareholders are iKang Holding and Yalong Daoyi, which hold 80% and 20% of the equity interest in iKang Hangzhou Xixi, respectively. Yalong Daoyi is wholly-owned by iKang Holding. Therefore, iKang Holding owns the 100% equity interest in iKang Hangzhou Xixi. (3) Beijing Jiandatong’s shareholders is Mr. Haiqing Hu, who holds 80% of the equity interest in Beijing Jiandatong. (4) Yuanhua Information’s shareholders are Mr. Haiqing Hu and Mr. Lei Zhao, who hold 80% and 20% of the equity interest in Yuanhua Information, respectively. (5) Mr. Ligang Zhang and Mr. Boquan He are shareholders of the Company, who held 25.6% and 14.8% voting interest of the Company as of March 31, 2015, respectively. They own the equity interests in iKang Holding and iKang Hangzhou Xixi. Other than Mr. Ligang Zhang and Mr. Boquan He, none of the Company’s shareholders owns equity interests in iKang Holding and iKang Hangzhou Xixi. The two shareholders of iKang Holding are directors and shareholders of the Company. One of them is the Company’s CEO, and the managing director of the VIEs. Therefore they have no current interest in seeking to act contrary to the contractual arrangements. The interests of the VIEs’ shareholders may differ from the interests of the Company as a whole. The Company cannot assure that when conflicts of interest arise, the shareholders will act in the best interests of the Company or that conflicts of interests will be resolved in the Company’s favor. Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIEs’ may encounter in their capacity as the beneficial owners and director of the VIE entities, on the one hand, and as beneficial owners and directors or officer of the Company, on the other hand. The Company believes the shareholders of the VIEs will not act contrary to any of the contractual arrangements and the exclusive equity option agreement provides the Company with a mechanism to remove the shareholders as the beneficial shareholders of the VIEs should they act to the detriment of the Company. The Company relies on the VIEs’ shareholders, as directors and officer of the Company, to fulfill their fiduciary duties and abide by laws of the PRC and BVI and act in the best interest of the Company. If the Company cannot resolve any conflicts of interest or disputes between the Company and the VIEs’ shareholders, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings. The following financial statements amounts and balances of the VIE entities were included in the accompanying consolidated financial statements as of and for the years ended March 31(after inter-company elimination): As of March 31, 2015 2016 Cash and cash equivalents $ $ Accounts receivable and other current assets Total current assets Property and equipment, net Acquired intangible assets, net Other noncurrent assets Total non-current assets Total assets Deferred revenues Accounts payable and other current liabilities Total current liabilities Total non-current liabilities Total liabilities $ $ For the years ended March 31, 2014 2015 2016 Net revenues $ $ $ Net income $ $ $ For the years ended March 31, 2014 2015 2016 Net cash provided by operating activities $ $ $ Net cash used in investing activities $ ) $ ) $ ) Net cash provided by financing activities $ $ $ The VIE entities contributed an aggregate of 84.1%, 85.4% and 89.1% of the consolidated net revenues for the years ended March 31, 2014, 2015 and 2016, respectively. The Company’s operations not conducted through contractual arrangements with the VIE entities primarily consist of its high end health check services. As of the fiscal years ended March 31, 2015 and 2016, the VIE entities accounted for an aggregate of 58.0% and 82.2%, respectively, of the consolidated total assets, and 88.9% and 94.9%, respectively, of the consolidated total liabilities. The assets that were not associated with the VIE entities primarily consist of cash and cash equivalents, accounts receivable and prepaid expenses and other current assets. There are no terms in any arrangements, considering both explicit arrangements and implicit variable interests, that require the Company or its subsidiaries to provide financial support to the VIE entities. However, if the VIE entities ever need financial su

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Basis of consolidation The consolidated financial statements of the Group include the financial statements of iKang Guobin Healthcare Group Inc., its subsidiaries, its VIEs and its VIEs’ subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues, costs and expenses in the financial statements and accompanying notes. Significant accounting estimates reflected in the Group’s consolidated financial statements include revenue recognition, allowance for doubtful accounts, the useful lives and impairment of property and equipment, purchase price allocation relating to business acquisitions, the useful lives and impairment of intangible assets, impairment of goodwill, impairment of long-term investments, valuation allowance for deferred tax assets, share-based compensation and fair value of long-term available-for-sale investments, common shares, convertible redeemable preferred shares and forward contracts. Business Acquisitions Business combinations are recorded using the acquisition method of accounting. The purchase price of the acquisition is allocated to the tangible assets, liabilities, identifiable intangible assets acquired and non-controlling interest, if any, based on their estimated fair values as of the acquisition date. The excess of the purchase price over those fair values is recorded as goodwill. Acquisition-related expenses and restructuring costs are expensed as incurred. Where the consideration in an acquisition includes contingent consideration and the payment of which depends on the achievement of certain specified conditions post-acquisition, the contingent consideration is recognized and measured at its fair value at the acquisition date and if recorded as a liability, it is subsequently carried at fair value with changes in fair value reflected in earnings. Cash and cash equivalents Cash and cash equivalents consist of cash on hand and demand deposits, which are unrestricted as to withdrawal and use, and have maturities of three months or less when purchased. Restricted cash Restricted cash mainly consists of the cash deposit denominated in U.S. dollar in overseas accounts used to collateralize the locally borrowings in China to meet Group’s RMB funding needs, which is primarily to purchase property and equipment within China. Term deposits Term deposits consist of deposits placed with financial institutions with original maturity terms of greater than three months but less than one year. Accounts receivable and allowance for doubtful accounts Accounts receivable represents those receivables derived in the ordinary course of business. A general allowance for doubtful accounts is provided based on aging analyses of accounts receivable balances, historical bad debt rates, in addition to specific provisions established based on customers’ repayment patterns and customer credit worthiness. Financial instruments Financial instruments of the Group primarily consist of cash and cash equivalents, restricted cash, term deposits, accounts receivable, forward contracts, equity securities investments, amount due from related parties, accounts payable, amount due to related parties, short-term borrowing and long-term borrowing. The carrying values of cash and cash equivalents, restricted cash, term deposits, accounts receivable, accounts payable, amounts due from related parties, and short-term borrowings approximate their fair values due to short-term maturities. Effective interest method The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Interest expense is recognized on an effective interest basis. Fair value measurements Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. Authoritative literature provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows: · Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. · Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. · Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Group measures certain assets, including long-term investments and intangible assets, at fair value on a nonrecurring basis when they are deemed to be impaired. The fair values of intangible assets are determined based on valuation techniques using the best information available, and may include management judgments, future performance projections, etc. An impairment charge to the intangible assets is recorded when their carrying amounts may not be recoverable. Fair value of financial instruments is discussed in Note 19. Significant risks and uncertainties The Group operates in an industry with rapid changes in regulations, customer demand and competition and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations, or cash flows: advances and trends in healthcare industry standards, changes in certain strategic relationships or customer relationships, regulatory or other PRC related factors, risks associated with the Group’s ability to keep and increase the customer base, and risks surrounding pending litigations. Foreign currency risk The Renminbi (“RMB”) is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. Cash and cash equivalents of the Group included aggregate amounts of $30,172 and $98,577 at March 31, 2015 and 2016, respectively, which were denominated in RMB. Concentration of credit risk Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Group places their cash with financial institutions with high-credit ratings and quality. The Group conducts credit evaluations of customers and generally do not require collateral or other security from their customers. No customer accounted for 10% or more of total revenues for the years ended March 31, 2014, 2015 and 2016, respectively. No customer accounted for 10% or more of accounts receivable as of March 31, 2015 and 2016, respectively. Inventories Inventories are medical consumable supplies and are stated at the lower of cost or market value. Inventories are written down for obsolescence to net realizable value based upon estimates of future demand and expiration date of inventories. The Group did not record a write-down of inventories for the years ended March 31, 2014, 2015 and 2016, respectively. Property and equipment, net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives: Computer equipment and application software 5 years Furniture and fixture 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term Construction in progress represents unfinished leasehold improvement and installment of equipment for new clinics. Construction in progress will be transferred to leasehold improvement or property and equipment when it is finished. Depreciation is recorded at the time when assets are ready for the intended use. Intangible assets, net Intangible assets, other than goodwill, resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by management based on the fair value of assets acquired. Identifiable intangible assets are carried at cost less accumulated amortization. Amortization of customer relationship is computed using the estimated attrition pattern of the acquired customers, and amortization of other finite-lived intangible assets is computed using the straight-line method over the following estimated average useful lives, which are as follows: Weighted average (years) Range (years) Customer relationship 5.5 2.1~10.0 Non-compete agreement 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating license 2.9 0.3~5.0 Favorable lease contract 7.1 2.8~9.8 The weighted average estimated average useful life of the intangible assets with determinable lives is 5.3 years. Intangible assets-indefinite lives If an intangible asset is determined to have an indefinite life, it should not be amortized until its useful life is determined to be no longer indefinite. An intangible asset that is not subject to amortization is tested for impairment at least annually or if events or changes in circumstances indicate that the asset might be impaired. Such impairment test consists of the fair values of assets with their carrying value amounts and an impairment loss is recognized if and when the carrying amounts exceed the fair values. The estimates of fair values of intangible assets not subject to amortization are determined using various discounted cash flow valuation methodologies. Significant assumptions are inherent in this process, including estimates of discount rates. Impairment of long-lived assets and intangible assets with definite life Long-lived assets, such as property and equipment and definite-lived intangible assets are stated at cost less accumulated depreciation or amortization. Depreciation and amortization is computed principally using the straight-line method. The Group evaluates the recoverability of long-lived assets, including identifiable intangible assets, with determinable useful lives whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. The Group measures the carrying amount of long-lived assets against the estimated undiscounted future cash flows associated with it. Impairment exists when the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated. Impairment loss is calculated as the amount by which the carrying value of the asset exceeds its fair value. Fair value is estimated based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Group to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. Goodwill Goodwill represents the excess of the fair value of consideration paid over the fair value of identifiable net assets acquired in business combinations. Goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but tested for impairment annually or more frequently if events and circumstances indicate that they might be impaired. Goodwill is tested for impairment at the reporting unit level on an annual basis (March 31 for the Group) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the stock prices, business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. In the evaluation of the goodwill for impairment, the Group may first assess qualitative factors to determine whether it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, goodwill is then tested following a two-step process. The first step compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired and the second step will not be required. If the carrying amount of a reporting unit exceeds its fair value, the second step compares the implied fair value of goodwill to the carrying value of a reporting unit’s goodwill. The implied fair value of goodwill is determined in a manner similar to accounting for a business combination with the allocation of the assessed fair value determined in the first step to the assets and liabilities of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to the assets and liabilities is the implied fair value of goodwill. An impairment loss is recognized for any excess in the carrying value of goodwill over the implied fair value of goodwill. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimation of fair value of each reporting unit using a discounted cash flow methodology also requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the Group’s business, estimation of the useful life over which cash flows will occur, and determination of the Group’s weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for the reporting unit. The Group did not incur any impairment loss on goodwill for the years ended March 31, 2014, 2015 and 2016, respectively. Long-term investments The Group’s long-term investments consist of cost method investments, equity method investments and available-for-sale investments. Cost method investments For equity investments that are not considered as equity securities that have readily determinable fair values and over which the Group neither has significant influence nor control through investment in common stock or in-substance common stock, the cost method is used. Investments in limited partnerships over whose operating and financing policies the Group has virtually no influence and with investment less than 20 percent are accounted for using the cost method. Under the cost method, the Company carries the investment at cost and recognizes income to the extent of dividends received from the distribution of the equity investee’s post-acquisition profits. Equity method investments The Group applies the equity method to account for an equity investment, in common stock or in-substance common stock over which it has significant influence but does not own a majority equity interest or otherwise control. Significant influence is generally considered to exist when the Group has an ownership interest in the voting stock of the investee between 20% and 50%, and other factors, such as representation on the investee’s board of directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate. Under the equity method, the Group initially records its investment at cost and subsequently adjusts the carrying amount of the investment to recognize the Group’s proportionate share of each equity investee’s net income or loss into earnings after the date of investment. Available-for-sale investments For investments in investees’ stocks which are determined to be debt securities, the Group accounts for them as long-term available-for-sale investments when they are not classified as either trading or held-to-maturity investments. Available-for-sale investments are carried at their fair values and the unrealized gains or losses from the changes in fair values are included in accumulated other comprehensive income. The Group continually reviews its investments in equity investees to determine whether a decline in fair value below the carrying value is other than temporary. The primary factors the Group considers in its determination are the length of time that the fair value of the investment is below the Group’s carrying value; the financial condition, operating performance and the prospects of the equity investee; and other Group specific information such as recent financing rounds. If the decline in fair value is deemed to be other than temporary, the carrying value of the equity investee is written down to fair value. The Group estimated the fair value of these investee companies based on discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. Revenue recognition Revenue is stated net of business tax. The Group’s PRC subsidiaries and VIE entities are subject to a 5% business tax and related surcharges on the revenues earned from providing services and selling products in the PRC. Certain contracts under specific formalities are exempted from business tax in accordance with the PRC tax laws. The Group recognized $2,084, $2,156, and $2,692 business tax for the years ended March 31, 2014, 2015 and 2016, respectively. The Group recognizes revenues when persuasive evidence of an arrangement exists, service has been provided, the sales price is fixed or determinable, and collectability is reasonably assured. The Group offers medical examination and disease screening services and renders such services at the request of its customers. The Group recognizes revenues when the examination reports are issued and passed to the local couriers if hard copy reports are required by its customers, or when the examination reports are uploaded on line and can be viewed by the customers on line if hard copy reports are not required. The Group notifies its customers when their examination reports are delivered to the local couriers or ready to be viewed and downloaded on line. For individual customers, fees are collected before the performance of the services while corporate customers prepay a portion of service fees upon signing of the master contract, which is recognized as deferred revenue by the Group. All fees for services rendered are first charged against the corporate customer’s deferred revenues until it is entirely exhausted before the Group starts to invoice the corporate customers. The Group records accounts receivables from its corporate customers when the examination reports of the employees of corporate customers have been delivered or uploaded on line but the Group has not received remaining payments from the corporate customers. Sometimes the Group engages third-party providers to provide medical examination and disease screening services on behalf of the Group. The Group evaluates the services provided by third parties on behalf of the Group to determine whether to recognize the revenues on a gross or net basis. The determination is based upon an assessment as to whether the Group acts as a principal or agent when providing the services. All of the revenues involving third-party providers providing medical examination or disease screening services on behalf of the Group are currently accounted for on a gross basis since the Group is the primary obligor, has the latitude in establishing prices, discretion in third-party provider selection and the credit risks. The Group also provides packages of bundled services principally comprising combinations of medical examination, disease screening, health consultation and medical concierge services to its corporate customers, which normally expire within one year from the date of purchase and does not include right of return. The Group allocates revenues from the sale of bundled services to each component using the relative selling price of each component based on the Group’s best estimate. Revenue recognition criteria for components included in the bundled services is identical to as if the components are sold on a standalone basis. The Group recognizes revenue from dental services when the service is rendered and the service fee is collectable. Value added tax (“VAT”) On January 1, 2012, the PRC Ministry of Finance and the State Administration of Taxation officially launched a pilot value-added taxes (“VAT”) reform program (“Pilot Program”), applicable to business in selected industries. Such VAT Pilot Program were phased in Beijing, Jiangsu, Anhui, Fujian, Guangdong, Tianjin, Zhejiang, and Hubei between September and December 2012. Business in the Pilot Program would pay VAT instead of sales tax. Starting from August 1, 2013, the Pilot Program was expanded to cover all regions in the PRC. Cai Shui [2016] No. 36 specifies the industries and relevant requirements that can enjoy VAT exemption. In accordance with Cai Shui [2016] No. 36, the medical examination service is exempt from paying VAT, therefore, the Group’s medical examination service is not currently subject to VAT. Non-monetary exchange The Group occasionally exchanges medical examination services with advertising agencies for advertising credits. The amount of deferred revenues and prepaid expenses is based on the fair value of the medical examination services surrendered which approximates the price the Group offers to the individual customers and is more readily determinable. The amounts of revenues recognized for non-monetary transactions were $706, $571 and $1,767 for the years ended March 31, 2014, 2015 and 2016, respectively. Direct costs attributable to the revenues have been immaterial. Cost of revenues Cost of revenues consist of expenditures incurred in the generation of the Group’s revenues, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers. Research and development expenses Research and development expenses primarily consist of (i) salaries and benefits for research and development personnel, and (ii) office rental, general expenses and depreciation and amortization expenses associated with the research and development activities. The Group’s research and development activities primarily consist of the research and development of its information technology platform. Research and development expenses are expensed when incurred. Income taxes Current income taxes are provided for in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Net operating loss carry forwards and credits are applied using enacted statutory tax rates applicable to future years. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that a portion of or all of the deferred tax assets will not be realized. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. The impact of an uncertain income tax position on the income tax return is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Interest and penalties on income taxes will be classified as a component of the provisions for income taxes. The Group did not recognize any income tax due to uncertain tax position or incur any interest and penalties related to potential underpaid income tax expenses for the years ended March 31, 2014, 2015 or 2016, respectively. Share-based compensation Share-based payment transactions with employees, such as share options are measured based on the grant date fair value of the equity instrument. The Group recognizes the compensation costs net of an estimated forfeiture rate using the graded vesting attribution method over the requisite service period of the award, which is generally the vesting period of the award. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share compensation expense to be recognized in future periods. Share awards issued to non-employees, such as advisors, are measured at fair value at the earlier of the commitment date or the date the service is completed and recognized over the period the service is provided. Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period. The Group’s convertible redeemable preferred shares are participating securities as they participate in undistributed earnings on an as-if-converted basis. Accordingly, the Group uses the two-class method whereby undistributed net income is allocated on a pro rata basis to the common shares and preferred shares to the extent that each class may share in income for the period; whereas the undistributed net loss for the period is allocated to common shares only because preferred shares are not contractually obligated to share the loss. Diluted earnings per common share reflect the potential dilution that could occur if securities were exercised or converted into common shares. The Group had convertible redeemable preferred shares, and stock options, which could potentially dilute basic earnings per share. To calculate the number of shares for diluted income per share, the effect of the convertible redeemable preferred shares is computed using the as-if-converted method; the effect of the stock options is computed using the treasury stock method. Foreign currency translation The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”). The financial records of the Group’s subsidiaries and VIE entities located in the PRC are maintained in their local currencies, the RMB, which are also the functional currencies of these entities. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the statement of operations. The Group’s entities with functional currency of RMB translate their operating results and financial positions into the U.S. dollar, the Group’s reporting currency. Assets and liabilities are translated using the exchange rates in effect on the balance sheet date. Revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive income. Comprehensive income Comprehensive income includes net income, cumulative foreign currency translation adjustments, unrealized gain (loss) in available-for-sale investments and net of tax effect for years ended March 31, 2014, 2015 and 2016, and is reported in the statement of shareholder’s equity. Operating leases Leases where the rewards and risks of ownership of assets primarily remain with the lessor are accounted for as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease periods. Newly adopted accounting pronouncements In May 2014, the Financial Accounting Standards Board(“FASB”) issued Accounting Standards Update(“ASU”) 2014-09 which affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, Property, Plant, and Equipment, and intangible assets within the scope of Topic 350, Intangibles—Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early app

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Mar. 31, 2016
ACQUISITIONS
ACQUISITIONS	3. ACQUISITIONS (1) Acquisition of Shanghai Huajian Management The Group purchased 33% equity interest of Shanghai Huajian Management from an individual shareholder in January 2014 with a consideration of $6,376. Subsequently, the Group signed agreements with two other shareholders of Shanghai Huajian Management to acquire the remaining 37% and 30% of Shanghai Huajian Management for cash considerations of $7,484 and $5,382 in May and June 2014 respectively. The acquisition of the above remaining 67% equity interest of Shanghai Huajian Management was completed on July 1, 2014. Additionally, iKang granted 300,000 options at the exercise price of $16.18 per share (or equivalent to $8.09 per ADS) to one of the former shareholders of Shanghai Huajian Management on August 1, 2014 pursuant to an agreement entered into on December 30, 2013. The grant of the options was considered by management to be additional purchase consideration for Shanghai Huajian Management with a fair value of $7,202 , which was settled in the year ended March 31, 2016. On July 1, 2014, iKang obtained control of Shanghai Huajian Management. At the date of the acquisition, iKang’s existing 33% equity interest in Shanghai Huajian Management was remeasured to its fair value of $7,661, resulting in a gain of $883 recognized in the year ended March 31, 2015. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.5 years Trade name Indefinite Operating license 3.0 years Goodwill Deferred tax liability ) Total Total fair value of business acquired $ (1) Acquisition of Shanghai Huajian Management The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Shanghai Huajian Management have been included in the Group’s consolidated financial statements since the date of acquisition. Shanghai Huajian Management contributed net revenue of $10,772, and net loss of $676 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (2) Acquisition of iKang Shenyang Hospital On November 14, 2014, the Group acquired 100% equity interest of iKang Shenyang Hospital, formerly named Shenyang Ciming Hospital Co, Ltd., which provides medical examination services, with cash consideration of $1,636.Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful life Net tangible assets: Non-current assets $ Total Intangible assets acquired: Operating license 4.0 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Shenyang Hospital have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Shenyang Hospital contributed net revenue of $469, and net loss of $392 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (3) Acquisition of iKang Shenyang Ningshan Hospital On November 19, 2014, the Group acquired 100% equity interest of iKang Shenyang Ningshan Hospital, formerly named Shenyang Ciming Ningshan Hospital Co, Ltd., which provides medical examination services, with cash consideration of $1,628. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Non-current assets $ Total Intangible assets acquired: Favorable lease contract 2.8 years Operating license 5.0 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Shenyang Ningshan Hospital have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Shenyang Ningshan Hospital contributed net revenue of $144, and net loss of $124 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (4) Acquisition of Gold iKang Shenyang Hospital On December 19, 2014, the Group acquired 100% equity interest of Gold iKang Shenyang Hospital, formerly named Shenyang Golden Ciming Hospital Co, Ltd., which provides medical examination related services, with cash consideration of $6,447. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Non-current assets $ Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 2.5 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Gold iKang Shenyang Hospital have been included in the Group’s consolidated financial statements since the date of acquisition. Gold iKang Shenyang Hospital contributed net revenue of $44, and net loss of $475 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (5) Acquisition of iKang Tianjin Hedong Dongrun On February 17, 2015, the Group acquired 100% equity interest of iKang Tianjin Hedong Dongrun, formerly named Tianjin Hedong District Dongrun Clinic Co., Ltd., which provides medical examination services, with cash consideration of $3,032. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.4 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Tianjin Hedong Dongrun have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Tianjin Hedong Dongrun contributed net revenue of $30, and net loss of $47 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (6) Acquisition of iKang Tianjin Hexi Fenghui On February 17, 2015, the Group acquired 100% equity interest of iKang Tianjin Hexi Fenghui, formerly named Tianjin Hexi District Fenghui Clinic Co., Ltd., a company providing medical examination services, with cash consideration of $2,073. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.9 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Tianjin Hexi Fenghui have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Tianjin Hexi Fenghui contributed net revenue of $59, and net loss of $73 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (7) Acquisition of WA HK On March 3, 2015, the Group acquired 70% equity interest of WA HK, which provides high-end medical services and operates two medical centers in prime locations in Shanghai and Beijing, with cash consideration of $9,934. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 3.0 years Operating license 1.9-2.8 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of WA Health Care have been included in the Group’s consolidated financial statements since the date of acquisition. WA Health Care contributed net revenue of $494, and net loss of $203 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (8) Acquisition of Chengdu Ommay On April 16, 2015, the Group acquired 100% equity interest of Chengdu Ommay, formerly named as Ommay Health Management Co., Ltd., a middle to high-end private medical examination service center in Chengdu, with cash consideration of $4,033. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent appraiser and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.0 year Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Chengdu Ommay have been included in the Group’s consolidated financial statements since the date of acquisition. Chengdu Ommay contributed net revenue of $1,128 and net loss of $681 to the Group’s consolidated statements of operations in the year ended March 31, 2016. (9) Acquisition of Yinchuan Ciming On June 2, 2015, the Group acquired 70% of equity of Yinchuan Ciming, formerly named as Yinchuan Ciming Clinic Co., Ltd., which provides medical examination service,with cash consideration of $4,840. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Non-current assets $ Total Intangible assets acquired: Customer relationship 5.0 years Operating license 2.0 years Goodwill Deferred tax liability ) Total Non-controlling interests ) Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Yinchuan Ciming have been included in the Group’s consolidated financial statements since the date of acquisition. Yinchuan Ciming contributed net revenue of $3,746, and net income of $803 to the Group’s consolidated statements of operations in the year ended March 31, 2016. (10) Acquisition of Beijing Tianzhikangjian On May 18, 2015, The Group acquired 100% equity interest of Beijing Tianzhikangjian with cash consideration of $21,497. Beijing Tianzhikangjian held 82.85% equity interest in Beijing Tianjian Sunny Healthcare Technology Co., Ltd. (“Tianjian Sunny”), which is a prominent medical examination center chain in China. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 4.5 years Operating license 1.7-4.6 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Beijing Tianzhikangjian have been included in the Group’s consolidated financial statements since the date of acquisition. Beijing Tianzhikangjian contributed net revenue of $7,420 and net loss of $2,886 to the Group’s consolidated statements of operations in the year ended March 31, 2016. (11) Acquisition of iKang Yantai Hongkang and iKang Yantai Hongkang Management (“Yantai Hongkang”) On May 29, 2015, the Group acquired 100% equity interest in Yantai Hongkang, formerly named as Yantai Hongkang Health Management Co., Ltd. and Yantai Hongkang Health Examination Management Co., Ltd., which owns medical examination service centers in Yantai, PRC, with cash consideration of $7,422. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 3.8 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Yantai Hongkang have been included in the Group’s consolidated financial statements since the date of acquisition. Yantai Hongkang contributed net revenue of $3,272 and net loss of $66 to the Group’s consolidated statements of operations in the year ended March 31, 2016. (12) Acquisition of Yantai Ciming, Weifang Kuiwen and Weihai (“Shandong Ciming Clinics”) On August 14, 2015, the Group acquired 70% equity interest of Shandong Ciming Clinics, formerly named Yantai Ciming Medical Examination Management Co.,Ltd, Weifang Kuiwen Ciming Clinic Co.Ltd. and Weihai Ciming Medical Examination Management Co., Ltd., which operates medical examination service centers in three major cities in Shandong province, with cash consideration of $7,260. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful life Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.3-4.4 years Goodwill Deferred tax liability ) Total Non-controlling interests ) Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Shandong Ciming Clinics have been included in the Group’s consolidated financial statements since the date of acquisition. Shandong Ciming Clinics contributed net revenue of $3,711 and net loss of $1,330 to the Group’s consolidated statements of operations in the year ended March 31, 2016. (13) Acquisition of Wuhan Xiandai Sunny On January 1, 2016, the Group acquired 100% equity interest in Wuhan Xiandai Sunny, formerly named Wuhan Xiandai Sunny Clinic Co., Ltd., which providing medical health examination service in Wuhan, with cash consideration of $4,786. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.9 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Wuhan Xiandai Sunny have been included in the Group’s consolidated financial statements since the date of acquisition. Wuhan Xiandai Sunny contributed net revenue of $120, and net loss of $173 to the Group’s consolidated statements of operations in the year ended March 31, 2016. (14) Acquisition of Xi’an iKang On December 17, 2015, the Group acquired 70% equity interest of Xi’an iKang, which has 100% ownership in three medical centers under the brand name of Xi’an Inlung, formerly named Xi’an Lianhu Inlung Medical Center, Xi’an Weiyang Inlung Medical Center and Xi’an Yanta Inlung Medical Center, with a total cash consideration of $6,721, including contingent consideration of $2,846 which is primarily based on the performance of Xi’an iKang for the period from April 1, 2016 to March 31, 2017. The fair value of the contingent consideration on the acquisition date was $2,846 determined by the Group with the assistance of American Appraisal China Limited, an independent appraiser. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 3.6 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Xi’an iKang have been included in the Group’s consolidated financial statements since the date of acquisition. Xi’an iKang contributed net revenue of $267 and net loss of $663 to the Group’s consolidated statements of operations in the year ended March 31, 2016. (15) Acquisition of Guizhou Wishstar On January 22, 2016, the Group acquired 60% equity interest of Guizhou Wishstar, which provides medical examination service, with cash consideration of $8,170. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Total Intangible assets acquired: Customer relationship 5.0 years Operating license 2.0 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Guizhou Winstar have been included in the Group’s consolidated financial statements since the date of acquisition. Guizhou Winstar contributed net revenue of nil, and net income of $10 to the Group’s consolidated statements of operations in the year ended March 31, 2016. (16) Pro forma information The following unaudited pro forma information summarizes the results of operations of the Group for the years ended March 31, 2014 and 2015 assuming that the acquisitions of Yuanhua, Nanjing Aoyang, Zhejiang Ailikang, MediFast, Shanghai Huajian Management, iKang Shenyang Hospital, iKang Shenyang Ningshan Hospital, Gold iKang Shenyang Hospital, iKang Tianjin Hedong Dongrun, iKang Tianjin Hexi Fenghui and WA HK occurred as of April 1, 2013. The following pro forma financial information is not necessarily indicative of the results that would have occurred had the acquisitions been completed at the beginning of the periods indicated, nor is it indicative of future operating results: Years ended March 31, 2014 2015 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc. $ $ The following unaudited pro forma information summarizes the results of operations of the Group for the years ended March 31, 2015 and 2016 assuming that the acquisitions of Chengdu Ommay, Yinchuan Ciming, Beijing Tianzhikangjian, Yantai Hongkang, Shandong Ciming, Wuhan Xiandai Sunny, Xi’an iKang, Guizhou Winstar occurred as of April 1, 2014. The following pro forma financial information is not necessarily indicative of the results that would have occurred had the acquisitions been completed at the beginning of the periods indicated, nor is it indicative of future operating results: Years ended March 31, 2015 2016 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc. $ $ (17) Acquisition of Assets On September 9, 2015, the Group acquired the operating license of Tianjin Nankai Clinic with a cash consideration of $435.

ACCOUNTS RECEIVABLE, NET

ACCOUNTS RECEIVABLE, NET	12 Months Ended
	Mar. 31, 2016
ACCOUNTS RECEIVABLE, NET
ACCOUNTS RECEIVABLE, NET	4. ACCOUNTS RECEIVABLE, NET Accounts receivable consists of the following: As of March 31, 2015 2016 Accounts receivable $ $ Less: allowance for doubtful accounts Accounts receivable, net $ $ Movement of allowance for doubtful accounts is as follows: As of March 31, 2014 2015 2016 Balance at beginning of year $ $ $ Charge to expenses Write off ) ) ) Exchange difference ) Balance at end of year $ $ $ The Group decides to write off a receivable and the corresponding provision when it determines when events indicate that there is remote chance that an account receivable can be collected, such as liquidation of a customer or termination of business cooperation.

INVENTORIES

INVENTORIES	12 Months Ended
	Mar. 31, 2016
INVENTORIES
INVENTORIES	5. INVENTORIES Inventories consist of the following: As of March 31, 2015 2016 Medical consumable supplies $ $

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Mar. 31, 2016
PREPAID EXPENSES AND OTHER CURRENT ASSETS
PREPAID EXPENSES AND OTHER CURRENT ASSETS	6. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consist of the following: As of March 31, 2015 2016 Advance payments for acquisitions $ $ Advance to suppliers Staff advance Prepaid rental expenses Prepaid expenses (1) Advance payments for investment — Other receivable Interest income receivable $ $ (1) Prepaid expenses mainly consist of amounts paid for professional fees and advertisement fees for which relating services have not been provided.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Mar. 31, 2016
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET	(1) 7. PROPERTY AND EQUIPMENT, NET Property and equipment, net consists of the following: As of March 31, 2015 2016 Medical equipment $ $ Leasehold improvements Computer equipment and application software Furniture and fixtures Motor vehicles Construction in progress Less: accumulated depreciation and amortization Property and equipment, net $ $ Depreciation expenses charged to the consolidated statement of operations for the years ended March 31, 2014, 2015 and 2016 were $8,874, $14,691 and $19,625, respectively.

LONG-TERM INVESTMENTS

LONG-TERM INVESTMENTS	12 Months Ended
	Mar. 31, 2016
LONG-TERM INVESTMENTS
LONG-TERM INVESTMENTS	8. LONG-TERM INVESTMENTS The Group’s long-term investments consist of cost method investments, equity method investments and available-for-sale investments. As of March 31, 2015 2016 Cost method investments (1) $ $ Equity method investments (2) — Available-for-sale investments (3) — $ $ (1) Cost method investments Pursuant to a co-operation agreement with shareholder of Xi’an Puhui Physical Examination Co., Ltd. (“Xi’an Puhui”) in November 2015, the Group invested 23.1% equity interest of Xi’an Puhui, which operates fifteen medical clinics in Xi’an, Zhengzhou and other six cities, with a cash consideration of approximately $32,090. The transaction was closed in December 2015. The Group has no representative on Xi’an Puhui’s board of directors and does not have the ability to exercise significant influence over the operating and financial policies of Xi’an Puhui. The Group used cost method to account for this investment. In May 2015, the Group invested 1.8% equity interests of American Well Corporation (“AW”), a Delaware company with a cash consideration of approximately $13,500. The Group used cost-method to account for the investment as the Group has no representative on AW’s board of directors and does not have the ability to exercise significant influence over the operating and financial policies of AW. In September 2015, the Group purchased preferred shares of Elysium Health, Inc., a US medical services supplement company with cash consideration of $2,000, for 8.7% equity ownership on an as converted basis. The Group has no representative on Elysium Health’s board of directors and does not have the ability to exercise significant influence over the operating and financial policies of Elysium Health. In March 2016, the Group invested 4.0% equity interests of Shanghai Yimi Information Technology Co., Ltd., a company providing consulting and training service in medical industry, with a cash consideration of approximately $993. The Group has no representative on its board of directors and does not have the ability to exercise significant influence over the operating and financial policies of this investment. (2) Equity method investments In September 2015, the Group invested 21.8% equity interest of Shenzhen Topsky Jianxin Technology Co., Ltd. (“Topsky”) with a cash consideration of approximately $10,372. The transaction was closed in October 2015. The Group has two out of five representations on Topsky’s board of directors and has the ability to exercise significant influence over the operating and financial policies of Topsky. The Group accounted for this investment as equity method investment and recognized $335 loss for the year ended March 31, 2016. In December 2015, a share purchase agreement was signed by the Group and Worldcare International Inc., a worldwide medical institution providing innovative advisory services for various hospitals and medical organizations, pursuant to which the Group agreed to invest $4,032 to acquire 20% equity interest. The transaction has been closed in January 2016. The Group accounted for this investment as equity method investment because the Group has the ability to exercise significant influence but does not control over the investees and recognized its share of loss of $43 loss for the year ended March 31, 2016. In February 2016, the Group completed a strategic investment in New China Life Insurance Health Investment Management Co., Ltd. (“NCI Health”), which was established by New China Life Insurance Co., Ltd. on December 13, 2012 and operates sixteen medical centers in 16 cities in China, with a total cash consideration of $119,363. After the investment, the Group holds 45% equity interest in NCI Health. The Group has the ability to exercise significant influence but does not have control over the investee and used the equity method to account for the investment. The Group recognized its share of loss of $1,354 for the year ended March 31, 2016. In addition, the Group purchased 40% equity interest of Beijing Minzhong Clinic Co., Ltd. (“Beijing MZ”) with a total cash consideration of $12,407. The transaction was closed in March 2016. The Group summarizes the condensed financial information of the Group’s equity method investments as a group below in accordance with Rule 4-08 of Regulation S-X. The summarized financial information of the equity method investments were as follows: As of March 31, 2015 2016 Current assets $ — $ Non-current assets — Current liabilities — Non-current liabilities — — For the years ended March 31, 2014 2015 2016 Total revenues $ — $ — $ Gross profits — — Loss from operations — — ) Net loss — — ) (3) Available-for-sale investments In June 2015, the Group acquired 20% equity interest in Shanghai Shenmin Medical Technology Company Limited, for a cash consideration of US$1,897, which is a medical technology company incorporated under the laws of the PRC. The investment was classified as available-for-sale investment since it can be redeemed at the option of the Group once the redeemable events occurred and measured subsequently at fair value which was subsequently disposed in July 2016. There was no unrecognized gain or loss recognized for the year ended March 31, 2016. In June 2015, the Group invested $5,000 in China Medonline Inc. (“HDF”), a company engaging in providing on-line medical services, for 1% equity ownership interests on an as converted basis. The investment was classified as available-for-sale investment since it can be redeemed at the option of the Group once the redeemable events occurred, and measured subsequently at fair value. $186 unrecognized gain was recorded for the year ended March 31, 2016.

ACQUIRED INTANGIBLE ASSETS, NET

ACQUIRED INTANGIBLE ASSETS, NET	12 Months Ended
	Mar. 31, 2016
ACQUIRED INTANGIBLE ASSETS, NET
ACQUIRED INTANGIBLE ASSETS, NET	9. ACQUIRED INTANGIBLE ASSETS, NET The gross carrying amount, accumulated amortization, impairment and net carrying amount of the intangible assets are as follows: As of March 31, 2015 2016 Acquired intangible assets not subject to amortization Trade-name $ $ Acquired intangible assets subject to amortization Customer relationship Operating licenses Favorable lease contracts Contract backlog Non-compete agreement Less: accumulated amortization Customer relationship Operating licenses Favorable lease contracts Contract backlog Non-compete agreement Less: impairment Intangible assets, net $ $ Amortization expenses for the years ended March 31, 2014, 2015 and 2016 were $1,885, $5,221 and $10,769, respectively. Amortization expenses for the years ending March 31, 2017, 2018, 2019, 2020, 2021 and thereafter would be $10,346, $7,151, $4,600, $2,616, $617 and $680, respectively. No impairment loss was recognized on acquired intangible assets during the years ended March 31, 2014, 2015 and 2016, respectively.

GOODWILL

GOODWILL	12 Months Ended
	Mar. 31, 2016
GOODWILL
GOODWILL	10. GOODWILL The changes in carrying amounts of goodwill for the years ended March 31, 2015 and 2016 were as follows: As of March 31, 2015 2016 Gross amount: Beginning balance $ $ Additions for the year by acquisitions of Beijing Tianzhikangjian — Yantai Hongkang — Yinchuan Ciming — Chengdu Ommay — Shangdong Ciming — Xi’an iKang — Wuhan Xiandai Sunny — Guizhou Winstar — Shanghai Huajian Management — iKang Shenyang Hospital — iKang Shenyang Ningshan Hospital — Gold iKang Shenyang Hospital — iKang Tianjin Hedong Dongrun — iKang Tianjin Hexi Fenghui — WA HK — Exchange difference ) Ending balance Accumulated impairment loss: Beginning balance Exchange difference ) Ending balance Goodwill $ $

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	12 Months Ended
	Mar. 31, 2016
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	11. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following: As of March 31, 2015 2016 Acquisitions consideration payable (1) $ $ Accrued payroll and welfare Accrued rental expense Other payables Collection received on behalf of and payable to the former shareholders of business acquired — Other taxes payable Interest expense payable Accrued social insurance Accrued outsourcing cost Dividend payable (2) — $ $ (1) Acquisitions consideration payable consists of remaining payables to sellers of the acquired business for the years ended March 31, 2015 and 2016, which were as follows: As of March 31, 2015 2016 Beijing MZ $ — $ Xi’an iKang — Beijing Tianzhikangjian — Yantai Hongkang — Yinchuan Ciming — Wuhan Xiandai Sunny — Shandong Ciming — iKang Shanghai Jianwei — Nanjing Aoyang Yuanhua — Zhejiang Ailikang — Shanghai Huajian Management — Suzhou Aoyang iKang Tianjin Hedong Dongrun iKang Tianjin Hexi Fenghui Gold iKang Shenyang Hospital WA Health Care — $ $ (2) As of March 31, 2015, the balance represents the dividend payable for non-controlling interest shareholders of MediFast which was paid in the year ended March 31, 2016.

SHORT-TERM BORROWINGS

SHORT-TERM BORROWINGS	12 Months Ended
	Mar. 31, 2016
SHORT TERM BORROWINGS
SHORT TERM BORROWINGS	12. SHORT-TERM BORROWINGS As of March 31, 2015 2016 Bank borrowings $ $ $ $ In April 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $16,004 with Bank of East Asia, to meet the property and equipment need of the Group. In May 2014, iKang Online borrowed 2 one-year loans in a total of $4,843 under such framework agreement. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Bayley & Jackson (Hong Kong) and collateralized by restricted cash of $5,500. As of March 31, 2015, the above amount of short-term borrowing remained outstanding, which was repaid in May 2015. In May 2014, iKang Holding signed a 2-year loan framework agreement with an amount no more than $8,060 with China Merchants Bank, to meet the working capital and property and equipment needs of the Group. In May 2014, iKang Holding borrowed one-year loans of total $4,290 under such framework agreement, among which $155 and $1,084 were repaid in June and August 2014, respectively. In June 2014, iKang Holding borrowed a one-year loan of $1,437. The annual interest rate is the interest rate announced by the People’s Bank of China plus 20% of the benchmark interest rate. As of March 31, 2015, the above amount of short-term borrowing remained outstanding, which was repaid in May 2015 and June 2015. In June 2014, iKang Online borrowed a one-year loan of $14,561 with Xiamen International Bank, to repay the loans from BEA which was due in June 2014 and to pay the remaining balance of the consideration to purchase 35% equity interest in iKang Shanghai Xikang Road. The annual interest rate is 2.585%. The loan was collateralized by restricted cash in an amount of $15,002. As of March 31, 2015, the above amount of short-term borrowing remained outstanding, which was repaid in June 2015. In June 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $32,099 with Xiamen International Bank, to satisfy the daily operating need of the Group. In July 2014, iKang Online borrowed three one-year loans in a total of $17,537 according to the framework agreement. The annual interest rate is 2.585%. The loans were collateralized by restricted cash in an amount of $18,067. As of March 31, 2015, the above amount of short-term borrowing remained outstanding, which was repaid in May 2015 and July 2015. In August 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $32,509 with Xiamen International Bank, to satisfy the daily operating need of the Group. In September, iKang Online borrowed a one-year loan of $15,383 according to the framework agreement. The annual interest rate is 2.585%. The loan was collateralized by restricted cash in an amount of $15,848. As of March 31, 2015, the above amount of short-term borrowing remained outstanding, which was repaid in May 2015 and September 2015. In June 2015, iKang Online signed a one-year loan framework agreement with an amount no more than $77,543 with Xiamen International Bank, to satisfy the daily operating need of the Group. The annual interest rate is 2.22%. In June 2015, iKang Online borrowed a one-year loan of $13,958 according to the framework agreement. In July 2015, iKang Online borrowed a one-year loan of $3,040 and $3,018 according to the framework agreement respectively. In August 2015, iKang Online borrowed a one-year loan of $10,861 according to the framework agreement. The loans were collateralized by restricted cash in an amount of $31,690. As of March 31, 2016, the above amount of short-term borrowing remained outstanding. In July 2015, iKang Holding signed a 10-month loan framework agreement with China Merchants Bank to satisfy the daily operating need of the Shanghai clinics. The annual interest rate is 7.20%. In July 2015, iKang Holding borrowed a 10-months loan of $7,754 according to the framework agreement. As of March 31, 2016, the above amount of short-term borrowing remained outstanding. In September 2015, iKang Holding borrowed a 1-year loan of $2,326 from Bank of China to satisfy the daily operating need of the Shanghai clinics. The annual interest rate is 4.60%. As of March 31, 2016, the above amount of short-term borrowing remained outstanding. In October 2015, iKang Holding borrowed a 1-year loan of $3,102 from Bank of China to satisfy the daily operating need of the Shanghai clinics. The annual interest rate is 4.60%. As of March 31, 2016, the above amount of short-term borrowing remained outstanding. In November 2015, iKang Online signed a 1-year loan framework agreement with China Minsheng Bank, to satisfy the daily operating need of the Group. The annual interest rate is 4.35%. In November 2015, iKang Online borrowed a one-year loan of $3,722 according to the framework agreement. In November 2015, iKang Online borrowed a one-year loan of $1,551 according to the framework agreement. In December 2015, iKang Online borrowed a one-year loan of $2,481 according to the framework agreement. As of March 31, 2016, the above amount of short-term borrowing remained outstanding. In December 2015, iKang Holding borrowed a 1-year loan of $1,551 from Bank of China to satisfy the daily operating need of the Shanghai clinics. The annual interest rate is 4.35%. As of March 31, 2016, the above amount of short-term borrowing remained outstanding Interest expense incurred for the years ended March 31, 2014, 2015 and 2016 was $827, $2,466 and $1,734, respectively. The weighted average effective interest rate for the year ended March 31, 2014, 2015 and 2016 was 7.0%, 5.6% and 3.3%, respectively. The carrying values of short-term borrowings approximate their fair values due to short-term maturities. As the Group has considerable cash and cash equivalents denominated in U.S. dollars in overseas accounts, the Group from time to time enters into “Pledge Overseas and Borrow Locally” transactions with banks to meet its RMB funding needs, which is primarily to purchase property and equipment with cash within China. The parties to the transaction are typically one of the Group’s domestic entities, one of the Group’s overseas subsidiaries, and a bank which offers services for both bank accounts onshore and offshore. The principal terms of the arrangement include the interest, the term of the loan which is typically one year, and the requirement of collateral in the form of a fixed deposit. Under this type of transaction, the Group receives RMB locally, and has a pledged asset in the form of a fixed deposit denominated in U.S. dollars or other currencies with an overseas bank account. The pledged deposit is recognized by an entity within the Group that is domiciled outside of the PRC, while a PRC entity within the Group borrows RMB. Banks which offer both overseas and PRC bank account services provide this type of arrangement to accommodate PRC companies which are in need of RMB in a timelier manner. The Group pays interest on the loan as well as certain transaction fees while it earns interest income from the fixed deposit in the overseas account at a rate similar to comparable investments. The Group’s domestic entity repays the RMB loan at the scheduled repayment dates. The restricted cash balance is not released proportionally to loan repayments. Beginning in February 2015, the Group started to utilize a new government policy in China for the Group’s currency conversion needs so that the Company can gradually convert and reserve RMB balances to support its future expansion. As a result, the Group may gradually reduce its “Pledge Overseas Borrow Locally” transactions in the future.

LONG-TERM BORROWINGS

LONG-TERM BORROWINGS	12 Months Ended
	Mar. 31, 2016
LONG TERM BORROWINGS
LONG TERM BORROWINGS	13. LONG-TERM BORROWINGS As of March 31, 2015 2016 Bank borrowings (1) $ — $ Long-term loans (2) — $ $ — $ (1) In December 2015, iKang Holding signed a 2-year loan framework agreement with China Merchants Bank to satisfy the daily operating need of the Shanghai clinics. The annual interest rate is 4.75%. In December 2015, iKang Holding borrowed a 2-year loan of $12,345 according to the framework agreement. Upon the fact that the nominal annual interest rate is equivalent to the required rate of return asked by the China Merchants Bank, the fair value of this outstanding long term borrowing as of March 31, 2016 was equal to the principal. Interest expense incurred for the years ended March 31, 2016 was $145. The effective interest rate for the year ended March 31, 2016 was 4.75%. (2) In December 2015, a subsidiary of the Group entered into a series of agreements to issue certain long-term loans with principal amount totaling $217,122 (equivalent to RMB 1,400,000) to four third-party investors (“bond holders”) with terms vary from eighteen months to twenty-four months. According to the agreements, the Group agreed, by putting their best effort, to coordinate with its buyer group relating to its privatization process, to facilitate the long-term loans be converted into certain equity interest of the future listing vehicle at the then best price. The interest rate is 5% but subject to adjustment based on the privatization proceeding. If the Group successfully completes the privatization before the maturity date of the long-term loans, and the bond holders decide to convert into the future listing vehicle’s shares, no interest will be charged; however, if the bond holders decide not to convert, the interest rate will be 5%. Furthermore, if the privatization is not completed before the maturity date of the long-term loans, or the Group fails to put their best effort to facilitate the bond holders convert the loan into shares, the interest rate will increase by 5%~20%. It’s most probable, per management’s estimate, that the Group will complete the privatization and successfully arrange the terms to facilitate the bond holders’ conversion, and accordingly 5% interest rate is applied to calculate the interest expenses for the year ended March 31, 2016. Interest expense incurred for the years ended March 31, 2015 and 2016 was nil and $2,869, respectively. The effective interest rate for the year ended March 31, 2016 was 5%.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2016
INCOME TAXES
INCOME TAXES	14. INCOME TAXES Cayman Islands The Company is a tax-exempted company incorporated in the Cayman Islands and is not subject to tax on income or capital gains. British Virgin Islands (“BVI”) The iKang Guobin and iKang Zhejiang BVI are exempted from income tax in BVI, where they are incorporated. Hong Kong Bayley & Jackson (Hong Kong), Yuanhua HK, MediFast and WA Health Care are subject to Hong Kong Profits Tax at 16.5% on its activities conducted in Hong Kong. PRC Since January 1, 2008, the Company’s PRC subsidiaries, iKang Holding and its subsidiaries are subject to the 25% standard enterprise income tax (“EIT”). According to “Catalogue of Industries Encouraged to Develop in the Western Region”, iKang Chengdu Waishuangnan, iKang Chengdu Jinjiang, Chengdu Gaoxin iKang West City, Chengdu Ommay and iKang Chongqing were recognised as encouraged entities by relevant PRC government authorities in October 2014 and entitled to a preferential tax rate of 15% from October 1, 2014. iKang Shenzhen Nanshan, iKang Shenzhen Luohu and iKang Shenzhen Futian are subject to income tax rate of 35% due to regulations set by local governments. Enterprises that qualify as the “newly established software enterprise” (“NESE”) are exempt from EIT for two years beginning the enterprise’s first profitable year followed by a tax rate of 12.5% for the succeeding three years. iKang Health Cloud enjoyed the EIT tax benefit that began from June 2015. Under the EIT Law and its implementation rules which became effective on January 1, 2008, dividends generated after January 1, 2008 and payable by a foreign-invested enterprise in PRC to its foreign investors who are non-resident enterprises are subject to a 10% withholding tax, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with PRC that provides for a different withholding arrangement. Under the taxation arrangement between the PRC and Hong Kong, a qualified Hong Kong tax resident which is the “beneficial owner” and directly holds 25% or more of the equity interest in a PRC-resident enterprise is entitled to a reduced withholding tax rate of 5%. The BVI, where the Company is incorporated, does not have a tax treaty with PRC. Since January 1, 2008, the relevant tax authorities of the Group’s subsidiaries have not conducted a tax examination on the Group’s PRC entities. In accordance with relevant PRC tax administration laws, tax years from 2010 to 2015 of the Group’s PRC subsidiaries and VIE entities, remain subject to tax audits as of March 31, 2016, at the tax authority’s discretion. Aggregate undistributed earnings of the Company’s subsidiaries located in the PRC that are available for distribution to the Company are approximately $11,833 as of March 31, 2016. The undistributed earnings of the Company’s subsidiaries located in the PRC are considered to be indefinitely reinvested, because the Group does not have any present plan to pay any cash dividends on its common shares in the foreseeable future and intends to retain most of its available funds and any future earnings for use in the operation and expansion of its business. Accordingly, no deferred tax liability has been accrued for the Chinese dividend withholding taxes that would be payable upon the distribution of those amounts to the Company as of March 31, 2016. Aggregate undistributed earnings of the Company’s VIEs and its VIEs’ subsidiaries located in the PRC that are available for distribution to the Company were approximately $121,846 as of March 31, 2016. A deferred tax liability should be recorded for taxable temporary differences attributable to the excess of financial reporting amounts over tax basis amount in domestic subsidiaries However, recognition is not required in situations where the tax law provides a means by which the reported amount of that investment can be recovered tax-free and the enterprise expects that it will ultimately use that means. The Company has not recorded any such deferred tax liability attributable to the undistributed earnings of its financial interest in VIEs because it believes such excess earnings can be distributed in a manner that would not be subject to income tax. Uncertainties exist with respect to how the current income tax law in the PRC applies to the Group’s overall operations, and more specifically, with regard to tax residency status. The EIT Law includes a provision specifying that legal entities organized outside of the PRC will be considered residents for Chinese Income tax purposes if the place of effective management or control is within the PRC. The implementation rules to the EIT Law provide that non-resident legal entities will be considered China residents if substantial and overall management and control over the manufacturing and business operations, personnel, accounting, properties, etc., occurs within the PRC. Despite the present uncertainties resulting from the limited PRC tax guidance on the issue, the Group does not believe that the legal entities organized outside of the PRC within the Group should be treated as residents for EIT law purposes. If the PRC tax authorities subsequently determine that the Company and its subsidiaries registered outside the PRC should be deemed resident enterprises, the Company and its subsidiaries registered outside the PRC will be subject to the PRC income taxes, at a rate of 25%. The current and deferred portions of income tax expenses included in the consolidated statements of operations, which were attributable to the Group’s PRC subsidiaries and VIE entities, are as follows: Years ended March 31, 2014 2015 2016 Current tax expenses $ $ $ Deferred tax benefits ) ) ) Income tax expenses $ $ $ The principal components of the deferred income tax assets and liabilities are as follows: As of March 31, 2015 2016 Current deferred tax assets: Accrued expenses $ $ Accrued payroll Allowance for doubtful accounts Less: Valuation allowance ) ) Current deferred tax assets $ $ Non-current deferred tax assets: Depreciation and amortization $ $ Impairment of long-lived assets Net operating tax loss carry-forwards Less: Valuation allowance ) ) Non-current deferred tax assets $ $ As of March 31, 2015 2016 Non-current deferred tax liabilities: Intangible assets $ $ Non-current deferred tax liabilities $ $ The Group considers the following factors, among other matters, when determining whether some portion or all of the deferred tax assets will more likely than not be realized: the nature, frequency and severity of recent losses, forecasts of future profitability, the duration of statutory carryforward periods, the Group’s experience with tax attributes expiring unused and tax planning alternatives. The Group’s ability to realize deferred tax assets depends on its ability to generate sufficient taxable income within the carryforward periods provided for in the tax law. As of March 31, 2016, the Group’s PRC subsidiaries, VIEs and VIEs’ subsidiaries had a tax loss carry-forward amounted to $38,560 and would expire on various dates between March 31, 2016 and March 31, 2021. The Group does not file combined or consolidated tax returns, therefore, losses from individual subsidiaries or the VIE entities may not be used to offset other subsidiaries’ or VIE entities’ earnings within the Group. Valuation allowance is considered on each individual subsidiary and legal entity basis. Valuation allowances have been established in respect of certain deferred tax assets as it is considered more likely than not that the relevant deferred tax assets will not be realized in the foreseeable future. Reconciliation between the expense of income taxes computed by applying the PRC tax rate to income before income taxes and the actual provision for income taxes is as follows: For the year ended March 31, 2014 2015 2016 Income before provision for income taxes and (loss)/gain from equity method investments $ $ $ PRC statutory tax rate % % % Income tax at statutory tax rate Change in valuation allowance ) Expenses not deductible for tax purposes Effect of income tax rate difference for entities under individual income tax rate of 35% Loss utilized for entities under individual income tax rate of 35% ) ) — Effect of income tax rate differences in other jurisdictions Tax holidays and preferential tax rates — ) ) Income tax expenses $ $ $ The Group did not identify significant unrecognized tax benefits for the years ended March 31, 2014, 2015 and 2016, respectively. The Group did not incur any interest and penalties related to potential underpaid income tax expenses and also believed that uncertainty in income taxes did not have a significant impact on the unrecognized tax benefits within next twelve months.

COMMON SHARE

COMMON SHARE	12 Months Ended
	Mar. 31, 2016
COMMON SHARE
COMMON SHARE	15. COMMON SHARE Before the completion of the IPO in April 2014, the Class A and Class B common shares were owned by Mr. Ligang Zhang, his spouse and other shareholders. Immediately prior to the completion of the IPO, Class B common shares were automatically converted into Class A common shares on a one-for-one basis and 805,100 of the Group’s outstanding Class A common shares held by Time Intelligent Finance Limited were redesignated into Class C common shares. According to the Company’s Amended and Restated Articles of Association which became effective upon the completion of the IPO, the Company currently has two classes of authorized ordinary shares, Class A common shares and Class C common shares. All Class C common shares are held by Time Intelligent Finance Limited and beneficially owned by Mr. Ligang Zhang’s family trust. The rights of the holders of Class A and Class C common shares are identical, except with respect to voting and conversion rights. Each Class A common share is entitled to one vote per share, while each Class C common share is entitled to 15 votes per share and is convertible at any time into one Class A common share. Holders of Class A and Class C common shares shall at all times vote together as one class on all matters subject to a shareholders’ vote. On April 9, 2014, the Company completed its IPO in NASDAQ and a concurrent private placement. The Company issued 5,215,794 Class A ordinary shares, consisting of (i) 3,787,223 Class A common shares offered through IPO, and (ii) 1,428,571 Class A common shares issued in connection with the concurrent private placement. All of the Company’s preferred shares were automatically converted into 20,781,515 Class A common shares. On May 9, 2014, the Company issued an additional 514,556 Class A common shares to the investment bankers for excising the Green Shoe option. On December 2, 2015, the Board of Directors of the Group adopted a rights agreement, commonly referred to as a “poison pill,” and authorized the issuance of one Right for each outstanding Class A Common Share and Class C Common Share (the “Rights Plan”). The Rights Plan is intended to deter hostile or coercive attempts to acquire the Company. The Rights Plan enables shareholders to acquire shares of the Company’s common shares, at a substantial discount to the public market price should any person or group acquire more than 10% of the Company’s common shares. The Rights Plan will expire no later than December 2, 2016 unless renewed by the Board. No common shares were issued under the Rights Plan.

CONVERTIBLE REDEEMABLE PREFERRE

CONVERTIBLE REDEEMABLE PREFERRED SHARES	12 Months Ended
	Mar. 31, 2016
CONVERTIBLE REDEEMABLE PREFERRED SHARES
CONVERTIBLE REDEEMABLE PREFERRED SHARES	16. CONVERTIBLE REDEEMABLE PREFERRED SHARES On March 31, 2013, there were 1,094,668 Series A convertible redeemable participating preferred shares (“Series A shares”), 686,368 Series B convertible redeemable participating preferred shares (“Series B shares”), 794,250 Series C1 convertible redeemable participating preferred shares (“Series C1 shares”), 126,286 convertible redeemable participating preferred shares (“Series C2 shares”), 1,024,318 Series C3 convertible redeemable participating preferred shares (“Series C3 shares”) (Series C1 shares, Series C2 shares and Series C3 shares are collectively referred to as “Series C shares”), 3,538,864 Series D1 convertible redeemable participating preferred shares (“Series D1 shares”), 2,307,536 Series D2 convertible redeemable participating preferred shares (“Series D2 shares”) (Series D1 shares and Series D2 shares are collectively referred to as “Series D shares”), 4,289,457 Series E convertible redeemable participating preferred shares (“Series E shares”) and 4,654,697 Series F shares outstanding. On August 28, 2013, the Company issued 1,953,499 Series F shares, which are under the same terms of Series F shares issued on March 28, 2013 to a group of investors for a consideration of $25,181. On October 16, 2013, a total number of 596,484 Class A common shares and Series D1 and D2 preferred shares held by certain existing shareholders were sold to a third party investor pursuant to the share purchase agreements dated September 12, 2013. The existing shares were sold for $12.0309 per share, which was the same as the selling price of existing shares to new investors in March 2013. The 596,484 sold shares were redesignated as 596,484 Series F shares immediately after the completion of the sale and purchase of the shares. The price agreed and paid by the purchaser of Series F shares was $14.1792 per share, which was determined by the Company and agreed by the purchaser based on the estimated equity value of the Company on the date of the share purchase agreement. Total sold price of $7,176 was paid by the purchaser to the sellers in October 2013. The difference of selling price and purchase price of the shares totaling $1,281 was paid by the purchaser to the Company in October 2013. The Company credited for the $1,281 to the series F shares. On April 9, 2014, 1,094,668 Series A shares, 686,368 Series B shares, 794,250 Series C1 shares, 126,286 Series C2 shares, 1,024,318 Series C3 shares, 3,488,864 Series D1 shares, 2,072,624 Series D2 shares, 4,289,457 Series E shares and 7,204,680 Series F shares preferred shares had been automatically converted into Class A common shares after the closing of IPO. The Series A, B, C, D, E and F shares are collectively referred to as the preferred shares. Key terms of the preferred shares are summarized as follows: Redemption The original redemption price of the Series A, B, C, D and E shares equaled the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date until original maturity on April 22, 2012. The Company recognized entire changes in the redemption value and adjusted the carrying value of the preferred shares to equal the redemption value immediately when the preferred shares were issued. As a result, $26,353 of redemption premium of the preferred shares was recorded as a deemed dividend upon issuance of those preferred shares. Series E shares which were originally redeemable upon or at any time after (i) November 28, 2011, if no qualified IPO or a company sale had occurred by such date, or (ii) February 28, 2011, in the event that any shareholder refused to participate in a company sale. Pursuant to a supplemental agreement entered into between the Company and the holders of Series E shares dated on July 14, 2011, Series E shares would be redeemable after April 22, 2012, hence additional redemption premium of $2,312 related to the period from the original redemption due date of July 14, 2011 to April 22, 2012 was charged as deemed dividend for the year ended March 31, 2012. After issuance of Series F shares and at the election of Series F shareholders, each Series F share shall be eligible to be redeemed if any of the following events occurs: (1) by March 28, 2017, the Restructuring has been completed but a Qualified IPO has not been consummated; “Restructuring” means the transfer of all interests in the medical centers, clients, employees, contractors and all other assets held by the PRC Entities (other than direct or indirect wholly-owned subsidiaries of the Company) as of Series F shares issuance date and any such additional interests in medical centers, clients, employees, contractors and other acquired by the PRC Entities thereafter to a direct or indirect wholly owned subsidiary of the Company. (2) Other than as approved by the Group’s Board of Directors (including the affirmative votes of Series F share directors), the loss of control or the inability to consolidate over any subsidiaries or VIE entities of the Group that account for three percent (3%) or more of the then consolidated revenues or hold three percent (3%) or more of the then consolidated assets; (3) the Restructuring is not completed by the expiry of 18 months from the earlier of (i) the effective date of a Change of Law or (ii) the date of such announcement or promulgation of a Change of Law; “Change of Law” means any change of applicable Laws that would have a material adverse effect on the validity of, or on the rights (as a whole) granted under, the VIE arrangements. (4) the Restructuring is not completed within two years from the date of a Restricted Venue Resolution, or “Restricted Venue Resolution” means the resolution passed by the majority of the Group’s Board of Directors to proceed with an IPO upon the occurrence of Change of Law; (5) by March 28, 2017, the Restructuring has not been completed and a Qualified IPO has not been consummated. In the case of (1) to (4) above, the redemption price of the Series F shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date. In the case of (5) above, the redemption price of the Series F shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 12% per year compounded annually from the original preferred share issue date. Upon the issuance of Series F shares, redemption of preferred shares other than Series F and E shares, shall require no less than five affirmative votes out of nine votes of the board directors, including the both affirmative votes of Series F shares directors. Series E shares can only be redeemed at the election of Series E preferred shareholders for cash at their redemption price when Series F shares are redeemed. Series B, C1, C2 and D1 shares are redeemable upon the second anniversary of the Series F issuance date and thereafter. Series A shares are redeemable at the election of the relevant classes of preferred shareholders for cash at their redemption price when Series F, E, B, C1, C2 and D1 shares are redeemed. Series C3 and D2 shares can only be redeemed when series F, E, B, C1, C2, D1 and A shares are redeemed at the election of the preferred shareholders. Upon the issuance of Series F shares, the redemption price of the Series A, B, C, D and E shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date until March 28, 2017. The Company recognized changes in the redemption value and adjusted the carrying value of the preferred shares to equal the entire redemption value immediately when the preferred shares were issued, as a result, $74,075 and $17,763 of redemption premium of the preferred shares was recorded as a deemed dividend for the years ended March 31, 2013 and 2014, respectively. Voting rights Preferred shareholders are entitled to the number of votes equal to the number of common shares into which such preferred shares could be converted at the record date. Dividends Whenever a dividend is declared by the Board of Directors of the Group, the preferred shares holders shall receive, in preference to any dividend on any common shares a non-cumulative dividend in an amount equal to 6% annually of the preferred shares’ original purchase price, as adjusted for stock splits, stock dividends, etc., and shall also participate on an as converted basis with respect to any dividends payable to the common shares. The sequence of dividend participating right of all series of preferred shares was as follows: (1) Series F (2) Series E (3) Series B, C1, C2 and D1 (4) Series A (5) Series C3 and D2 Conversion Each preferred share shall be convertible, at the option of the holder thereof, at any time after the preferred shares’ original date of issuance, into such number common shares as determined by dividing the preferred share original issue price by preferred share conversion price. The initial conversion ratio was one for one. The conversion price has a standard anti-dilution adjustment term for items such as stock splits and recapitalization. It also has a down-round provision, under which when the Company issues any additional shares at a price per share that is lower than the conversion price per share then in effect, the conversion price per share is adjusted down. There have been no such adjustments to the conversion price. Each preferred share would automatically be converted into ordinary shares at the then effective conversion price, upon the closing of a Qualified IPO. “Qualified IPO” means (a) an IPO on the New York Stock Exchange, NASDAQ Stock Market, Main Board of The Stock Exchange of Hong Kong Limited, Shanghai Stock Exchange, Shenzhen Stock Exchange or other stock exchange approved by the Majority Preferred F Holders in writing, with: (i) if the IPO occurs on or before the first anniversary of the First Closing Date, a minimum pre-offering valuation of the Company of at least $555 million (representing for each Series F Preferred Share an annual compounded return, calculated from the First Closing Date, of no less than 50% on the Series F Original Purchase Price (as adjusted for stock dividends, stock splits, consolidation and the like)); (ii) if the IPO occurs after the first anniversary, but on or before the second anniversary of the First Closing Date, a minimum pre-offering valuation of the Company of at least $675 million (representing for each Series F Preferred Share an annual compounded return, calculated from the First Closing Date, of no less than 35% on the Series F Original Purchase Price (as adjusted for stock dividends, stock splits, consolidation and the like)); (iii) if the IPO occurs after the second anniversary, but on or before the third anniversary of the First Closing Date, a minimum pre-offering valuation of the Company of at least $723 million (representing for each Series F Preferred Share an annual compounded return, calculated from the First Closing Date, of no less than 25% on the Series F Original Purchase Price (as adjusted for stock dividends, stock splits, consolidation and the like)); or (iv) if the IPO occurs after the third anniversary of the First Closing Date, a minimum pre-offering valuation of the Company of at least $740 million, or (b) any other public offering as otherwise approved by the Majority Preferred F Holders and the holders representing at least seventy-five percent (75%) of the then outstanding Preferred Shares (voting together as a single class on an as-converted basis). Liquidation preference Upon occurrence of a liquidation event, an amount shall be paid with respect to each preferred share equal to 100% of the original purchase price, plus any declared but unpaid dividends, adjusted for any share dividends, combinations, splits, recapitalizations and the like. If, after liquidation, distribution, or winding up, the assets of the Company are insufficient to make payment in full to all preferred shareholders, then such assets shall be distributed among the preferred shareholders ratably in proportion to the full amounts to which they would otherwise be respectively entitled thereon. The sequence of liquidation right of all series of preferred shares is as follows: (1) Series F shares (2) Series E shares (3) Series B, C1, C2 and D1 shares (4) Series A shares (5) Series C3 and D2 shares The preferred shares were accounted for as mezzanine equity.

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	12 Months Ended
	Mar. 31, 2016
NET INCOME (LOSS) PER SHARE
NET INCOME (LOSS) PER SHARE	17. NET INCOME (LOSS) PER SHARE The Group has determined that its convertible redeemable preferred shares are participating securities as the preferred shares participate in undistributed earnings on an as-if-converted basis. The holders of the preferred shares are entitled to receive dividends on a pro rata basis, as if their shares had been converted into common shares. Accordingly, the Group uses the two-class method of computing net income per share, for common and preferred shares according to participation rights in undistributed earnings. The calculation of net income (loss) per share is as follows: For the years ended March 31, 2014 2015 2016 Net income attributable to iKang Guobin Healthcare Group, Inc. $ $ $ Deemed dividend to Series A shares — — Deemed dividend to Series B shares — — Deemed dividend to Series C shares — — Deemed dividend to Series D shares — Deemed dividend to Series E shares — — Deemed dividend to Series F shares — Undistributed earnings allocated to Series A shares — Undistributed earnings allocated to Series B shares — Undistributed earnings allocated to Series C shares — Undistributed earnings allocated to Series D shares — Undistributed earnings allocated to Series E shares — Undistributed earnings allocated to Series F shares — For the years ended March 31, 2014 2015 2016 Net (loss) income attributed to common and preferred shareholders for computing net income per common share- basic and diluted (1) $ ) $ $ Numerator: Series A shares- Deemed dividend — — Undistributed earnings allocation — — Series B shares- Deemed dividend — — Undistributed earnings allocation — — Series C shares- Deemed dividend — — Undistributed earnings allocation — Series D shares- Deemed dividend — Undistributed earnings allocation — — Series E shares- Deemed dividend — — Undistributed earnings allocation — — Series F shares- Deemed dividend — Undistributed earnings allocation — — Net (loss) income attributed to common shareholders for computing net income per common share- basic and diluted (1) ) — For the years ended March 31, 2014 2015 2016 Denominator: Weighted average common shares outstanding used in computing diluted net income per common share-basic (2) Weighted average shares outstanding used in computing net income per common shares-diluted (2) Weighted average shares used in computing basic net income per shares Series A shares — Series B shares — Series C shares — Series D shares — Series E shares — Series F shares — Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-basic $ ) $ $ Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-diluted $ ) $ $ Net income per Series A shares $ $ — Net income per Series B shares $ $ — Net income per Series C shares $ $ — Net income per Series D shares $ $ — Net income per Series E shares $ $ — Net income per Series F shares $ $ — For the year ended March 31, 2014, 1,094,668, 686,368, 1,944,954, 5,717,326, 4,289,457, 6,075,702 and 988,507 common shares resulting from the assumed conversion of the Series A shares, Series B shares, Series C shares, Series D shares, Series E shares, Series F shares and options, respectively, were excluded as their effect was anti-dilutive. For the years ended March 31, 2015 and March 31, 2016, no shares or options were excluded. Notes: (1) The Class A, Class B and Class C common shares enjoy the same dividend participating right, therefore earnings per share of each class was not separately presented. (2) The calculation of the weighted average number of common shares for the purpose of diluted net income (loss) per share has considered the effect of certain potentially dilutive securities.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Mar. 31, 2016
SHARE-BASED COMPENSATION.
SHARE-BASED COMPENSATION	SHARE-BASED 18. SHARE-BASED COMPENSATION The Group’s Board of Directors has approved and the Company has granted various tranches of options to its management and consultants since its inception. Option grants for the years ended March 31, 2014, 2015 and 2016 are as the following: On September 12, 2013, the Company granted 200,000 options with exercise price of $6.00 to its director, which has a vesting period of 3.55 years and can be exercised only when the Company’s common stocks become publicly traded or upon a Company Sale. On February 27, 2014, the Company granted additional 356,300 options with exercise price of $5.13 per share and 72,700 options with exercise price of $6.00 to its certain directors and employees, which have vesting periods of 1.35 and 1.91 years respectively and can be exercised only when the Company’s common stocks become publicly traded or upon a Company Sale. On August 1, 2014, the Company granted 300,000 options with exercise price of $ 16.18 per share to one of the former shareholder of Shanghai Huajian Management, which is vested and exercisable on the grant date. On October 28, 2014, the Company granted additional 8,600 options with exercise price of $6.00 per share and 17,200 options with exercise price of $5.13 to certain of its directors and employees, which have a vesting period of 2 years. On February 27, 2015, the Company granted additional 4,000 options with exercise price of $5.13 to one of its former employees, which has a vesting period of 2 years. The following table summarizes information regarding options granted: For the years ended March 31, 2014 2015 2016 Weighted Weighted Weighted Weighted Weighted Weighted average average average average average average exercise fair value exercise fair value exercise fair value Number of price per per option Number of price per per option Number of price per per option options option at grant date options option at grant date options option at grant date Outstanding on April 1 of year $ $ $ $ $ $ Granted — — — Exercised — — — ) ) Forfeited ) ) ) Outstanding on March 31 of year $ $ $ $ $ $ There were 696,991 vested options, and 192,183 options expected to vest as of March 31, 2016. For options expected to vest, the weighted-average exercise price is $5.52 and aggregate intrinsic value is $1,555 as of March 31, 2016. The following table summarizes information with respect to share options outstanding as of March 31, 2016: Option outstanding Option exercisable Weighted Weighted Aggregate Weighted Aggregate average average intrinsic average intrinsic remaining Exercise values as of Exercise values as of Number contractual price per March 31, Number price per March 31, Range of exercise price outstanding life in years option 2016 exercisable option 2016 $0.01 $ $ $ $ $1.00-$2.00 $ $ $5.13 $ $ $6.00 $ $ $ $ The fair value of each option granted was estimated on the date of grant using the binomial tree pricing model with the following assumptions used for grants during the applicable periods: Risk-free interest rate of return Contractual term Volatility Dividend yield Exercise price December 31, 2010 % 10 years % — 5.13 June 8, 2011 % 2.39 years % — 0.01 February 17, 2012 % 10 years % — 5.13 March 18, 2013 % 10 years % — 5.13~6.00 September 12, 2013 % 10 years % — 6.00 February 27, 2014 % 10 years % — 5.13~6.00 August 1, 2014 % 10 years % — 16.18 October 28, 2014 % 10 years % — 5.13~6.00 February 27, 2015 % 10 years % — 5.13 (1) Risk-free interest rate Risk-free interest rate was estimated based on the yield to maturity of China international government bonds with a maturity period close to the expected term of the options. (2) Contractual term The Company used the original contractual term. (3) Volatility The volatility of the underlying common shares during the life of the options was estimated based on the historical stock price volatility of comparable listed companies over a period comparable to the expected term of the options. (4) Dividend yield The dividend yield was estimated by the Group based on its expected dividend policy over the expected term of the options. (5) Exercise price The exercise price of the options was determined by the Group’s Board of Directors. (6) Fair value of underlying common shares The estimated fair value of the common shares underlying the options as of the respective grant dates was determined based on a retrospective valuation, which used management’s best estimate for projected cash flows as of each valuation date. After the closing of the IPO, the fair value of common shares is determined as the closing sales price of the shares as quoted on the principal exchange or system. The Group recorded share-based compensation of $930, $9,153 and $1,949 during the years ended March 31, 2014, 2015 and 2016, respectively, based on the fair value on the grant dates over the requisite service period of award according to the vesting schedule for employee share option. As of March 31, 2016, total unrecognized compensation expense relating to unvested share options was $3,429, which will be recognized over 2 years. The weighted-average remaining contractual term of options outstanding is 6.60 years.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Mar. 31, 2016
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	19. FAIR VALUE MEASUREMENTS (1) Measured on a recurring basis The Group measured its financial assets including foreign currency forward contracts at fair value on a recurring basis as of March 31, 2015 and 2016. The Group purchased foreign currency forward contracts to protect against the adverse effect that exchange rate fluctuation may have on foreign currency denominated financing activities. Foreign currency forward contracts are marked to market based on the prevailing forward exchange rate quoted by the contracted bank (level 2 inputs). Assets and liabilities resulted from foreign currency forward contracts are recorded at its fair value. Details of the outstanding foreign currency forward contracts as of March 31, 2015 and 2016 were as follows: As of March 31, 2015 2016 Balance at beginning of year $ $ — Loss from forward contracts ) — Settled ) — Balance at end of year $ — $ — The following table summarizes the fair value of the Group’s financial assets and liabilities measured on a recurring basis as of March 31, 2015 and 2016: As of March 31, 2015 As of March 31, 2016 Fair Value Measurements at the Reporting Date Using Fair Value Measurements at the Reporting Date Using Quoted prices in Significant Quoted prices in Significant active markets other Significant active markets other Significant for identical observable unobservable for identical observable unobservable instruments inputs inputs Total instruments inputs inputs Total (level 1) (level 2) (level 3) balance (level 1) (level 2) (level 3) balance Long-term investments Available-for-sale investments — — — — — Long-term loans — — — — — — Long-term bank borrowings — — — — — — Contingent consideration — — — — — — Total $ — $ — $ — $ — $ $ — $ $ (2) Measured at fair value on a non-recurring basis Goodwill, acquired intangible assets, long-lived assets, equity method investments and cost method investments are measured at fair value on a non-recurring basis and they are recorded at fair value only when impairment is recognized. The Group measured the fair value of acquired intangible assets, equity method investment and cost method investment using income approach based on which to recognize the impairment loss in respective years. These assets are considered at level 3 assets because the Group used unobservable inputs to determine their fair values. The Group estimated the fair value of these investee companies and acquired intangible assets based on discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. The Group did not recognize any impairment loss related to goodwill, acquired intangible assets, equity method investment and cost method investment for the years ended March 31, 2014, 2015 and 2016.

RELATED PARTY BALANCES AND TRAN

RELATED PARTY BALANCES AND TRANSACTIONS	12 Months Ended
	Mar. 31, 2016
RELATED PARTY BALANCES AND TRANSACTIONS
RELATED PARTY BALANCES AND TRANSACTIONS	20. RELATED PARTY BALANCES AND TRANSACTIONS As of March 31, 2015 2016 Amount due from a related party $ — $ Amount due from a related party represents non-interest bearing loans provided by the Group in February 2016 to two companies owned by the non-controlling shareholder of one of the Group's subsidiaries, totaling $4,653.

NONCONTROLLING INTEREST

NONCONTROLLING INTEREST	12 Months Ended
	Mar. 31, 2016
NONCONTROLLING INTEREST
NONCONTROLLING INTEREST	21. NONCONTROLLING INTEREST iKang iKang iKang Shenzhen Shanghai Zhejiang WA Shanghai Shanghai Fujian Hospital Jianwei Beijing iKang Beijing Yinchuan Shandong Xi’an Physician Guizhou Wuhu BVI HK Gubei Lujiazui iKang Management Management Jiandatong MediFast Changzhou Tianzhikangjian Ciming Ciming iKang alliance winstar iKang Total Balance at March 31, 2013 $ $ — $ $ $ $ $ — $ — $ — $ — $ — $ — $ — $ — $ — $ — $ — $ Addition of non-controlling interest in connection with establishment of Beijing Jiandatong — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with acquisition of MediFast — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with establishment of iKang Changzhou — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holder of Shanghai Wangzu Guobin Medical Center Co., Ltd — — ) — — — — — — — — — — — — — — ) Share of profit (loss) — ) ) ) — — — — — — — Purchase of non-controlling interest — — — ) — — — — — — — — — — — — — ) Other comprehensive income ) — ) ) ) ) ) ) ) — — — — — — — ) Balance at March 31, 2014 $ $ — $ $ — $ $ $ $ $ $ $ — $ — $ — $ — $ — $ — $ — $ Capital contribution of non-controlling interest holder of Beijing Jiandatong — — — — — — — — — — — — — — — — Capital contribution of non-controlling interest holder of Shanghai Jianwei — — — — — — — — — — — — — — — — Capital contribution of non-controlling interest Addition of non-controlling interest in connection with acquisition of WA HK — — — — — — — — — — — — — — — — Capital contribution of non-controlling interest holder of WA HK — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holder of MediFast — — — — — — — — ) — — — — — — — — ) Share of profit (loss) ) — ) ) ) ) — — — — — — — Other comprehensive income — — — — — — — — — — — — — Balance at March 31, 2015 $ $ $ $ — $ $ ) $ $ $ $ $ — $ — $ — $ — $ — $ — $ — $ Additional purchase of non-controlling interest — — ) — — — — — — — ) — — — — — — ) Addition of non-controlling interest in connection with acquisitions — — — — — — — — — — — — Addition of non-controlling interest in connection with capital injection — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with new establishments — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holders — — ) — — — — — ) — — — — — — — — ) Share of profit (loss) ) — ) ) ) ) ) ) ) ) ) Other comprehensive income — ) — — ) — ) — ) ) ) ) ) Balance at March 31, 2016 $ $ $ — $ — $ $ ) $ ) $ $ $ $ $ $ $ $ $ $ $

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Mar. 31, 2016
SEGMENT INFORMATION
SEGMENT INFORMATION	22. SEGMENT INFORMATION The Group’s chief operating decision maker has been identified as the Chief Executive Officer who reviews results of operations by business lines when making decisions about allocating resources and assessing performance of the Group. The Group has two operating segments: medical examinations and other medical services and dental services. The Group does not allocate any assets to its operating segments as management does not believe that allocating these assets is useful in evaluating these segments’ performance. Accordingly, the Group has not made disclosure of total assets by reportable segments. For the years ended March 31, 2014 2015 2016 Net revenues: Medical examinations and other medical services $ $ $ Dental services — Total net revenues Cost of revenues: Medical examinations and other medical services Dental services — Total cost of revenues Gross profit: Medical examinations and other medical services Dental services — Total gross profit Operating expenses: Selling and marketing expenses General and administrative expenses Research and development expenses Total operating expenses Income from operations $ $ $ The revenue and cost of revenues in relation to the operating segment of dental services for the year ended March 31, 2014 were not presented as they were immaterial. Components of net revenues are presented in the following table: For the years ended March 31, 2014 2015 2016 Medical examinations $ $ $ Disease screening Other services Medical examinations and other medical services Dental services — Total $ $ $ Substantially all of the Group’s revenues for the years ended March 31, 2014, 2015 and 2016 were generated from the PRC entities. Substantially all of the Group’s long-lived assets are located in the PRC as of March 31, 2014, 2015 and 2016.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2016
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	23. COMMITMENTS AND CONTINGENCIES Commitments (1) Operating lease as lessee The Group leases its clinics and offices under non-cancelable operating lease agreements. These leases expire through 2036 and are renewable upon negotiation. Rental expenses under operating leases for the years ended March 31, 2014, 2015 and 2016 were $28,129, $37,733 and $51,719, respectively. Future minimum lease payments under such leases as of March 31, 2016 were as follows: 2017 $ 2018 2019 2020 2021 After 2021 $ (2) Future minimum principal payments related to the Company’s long-term borrowings as of March 31, 2016 are as follows (see Note 13): 2017 $ — 2018 2019 — 2020 — 2021 — After 2021 — $ Contingent liabilities The Group is subject to governmental supervision and regulations by the relevant PRC regulatory authorities including the Ministry of Health, the Ministry of Industry and Information Technology, and other relevant government authorities. Each of the Group’s medical centers is required to obtain a business license, a medical institution establishment approval, a medical institution practicing license and a radiation-related diagnosis and treatment license. If the Group fails to obtain such licenses or to amend the medical institution practicing licenses for the forgoing medical centers or other competent PRC regulatory authorities consider that the Group is operating the relevant businesses in an illegal manner, the Group may be ordered to shut down the relevant medical centers or cease the relevant services or suffer fines or penalties. The Group has been named in a number of lawsuits arising in its ordinary course of business. In the case where the management can reasonably estimate the outcome of the lawsuits taking into account of the legal advices, provision would be made for the probable losses. Where the management cannot reasonably estimate the outcome of the lawsuits or believe the probability of loss is remote, no provision is made.

EMPLOYEE BENEFIT PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Mar. 31, 2016
EMPLOYEE BENEFIT PLAN
EMPLOYEE BENEFIT PLAN	24. EMPLOYEE BENEFIT PLAN Full time employees of the Group in the PRC participate in a government-mandated defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to employees. The Group accrues for these benefits based on relevant percentages of the employees’ salaries. The total provisions for such employee benefits were $7,249, $10,417 and $16,342 for the years ended March 31, 2014, 2015 and 2016, respectively.

STATUTORY RESERVE AND RESTRICTE

STATUTORY RESERVE AND RESTRICTED NET ASSETS	12 Months Ended
	Mar. 31, 2016
STATUTORY RESERVE AND RESTRICTED NET ASSETS
STATUTORY RESERVE AND RESTRICTED NET ASSETS	25. STATUTORY RESERVE AND RESTRICTED NET ASSETS In accordance with the Regulations on Enterprises with Foreign Investment of China and their articles of association, the Group’s subsidiaries and VIE entities located in the PRC, being foreign invested enterprises established in the PRC, are required to provide for certain statutory reserves. These statutory reserve funds include one or more of the following: (i) a general reserve, (ii) an enterprise expansion fund or discretionary reserve fund, and (iii) a staff bonus and welfare fund. Subject to certain cumulative limits, the general reserve fund requires a minimum annual appropriation of 10% of after-tax profit (as determined under accounting principles generally accepted in China at each year-end); the other fund appropriations are at the subsidiaries’ or the affiliated PRC entities’ discretion. These statutory reserve funds can only be used for specific purposes of enterprise expansion, staff bonus and welfare, and are not distributable as cash dividends except in the event of liquidation of our subsidiaries, our affiliated PRC entities and their respective subsidiaries. The Group’s subsidiaries and VIE entities are required to allocate at least 10% of their after-tax profits to the general reserve until such reserve has reached 50% of their respective registered capital. As of March 31, 2016, none of the Group’s PRC subsidiaries and VIE entities had a general reserve that reached the 50% of their registered capital threshold except iKang Beijing Xuanwumen, iKang Beijing Yayun, iKang Guangzhou Huanshi East/Tianhe, iKang Chengdu Waishuangnan, iKang Chengdu Hongzhaobi, iKang Chongqing, iKang Fuzhou Gulou therefore they will continue to allocate at least 10% of their after tax profits to the general reserve fund. Appropriations to the enterprise expansion reserve and the staff welfare and bonus reserve are to be made at the discretion of the Board of Directors of each of the Group’s subsidiaries. The appropriation to these reserves by the Group’s PRC subsidiaries was $2,738, $3,394 and $3,130 for the years ended March 31, 2014, 2015 and 2016, respectively. As a result of these PRC laws and regulations and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Group. Amounts restricted include paid-in capital and the statutory reserves of the Group’s PRC subsidiaries and VIE entities. The aggregate amounts of capital and statutory reserves restricted which represented the amount of net assets of the relevant subsidiaries and VIE entities in the Group not available for distribution was $216,340 as of March 31, 2016. As the restricted net assets of the Group’s subsidiaries and VIE entities were over the 25% of the consolidated net assets of the Group as of March 31, 2016, parent-only financials are presented in Schedule I.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2016
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	26. SUBSEQUENT EVENTS On May 20, 2016 the Group completed the acquisition of 100% equity interest in Beijing Bohui Clinic Co. Ltd. (“Beijing Bohui”) and Beijing Zhongpu Bohui Clinic Co. Ltd. (“Zhongpu Bohui”) with cash consideration of $5,375. On June 6, 2016, the Group announced that its Board of Directors (the “Board”) received a preliminary non-binding proposal letter, dated June 6, 2016, from Shanghai Yunfeng Capital Management Ltd.(“Yunfeng Capital”), proposing a going-private transaction in which Yunfeng Capital would acquire all of the outstanding Class A common shares, Class C common shares and American depositary of the Company in an all-cash transaction for US$20.00 to US$25.00 per ADS or US$40.00 to US$50.00 per share. On June 7, 2016, the Group’s special committee, which was formed by the Board of the Group on September 10, 2015 and consists of independent directors, was notified that Mr. Lee Zhang, Company's CEO and certain of his affiliated entities determined to withdraw from the founder buyer group and withdraw their prior going private proposal made on August 31, 2015. On June 8, 2016, the special committee was also notified that Meinian Onehealth Healthcare (Group) Co., Ltd determined to withdraw from the Meinian buyer group and determined that it would not submit a binding offer for a going private transaction involving the Group.

ADDITIONAL INFORMATION-FINANCIA

ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	12 Months Ended
	Mar. 31, 2016
ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY
ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY CONDENSED BALANCE SHEETS (In thousands of US dollars, except share data and per share data, or otherwise noted) March 31, 2015 2016 ASSETS Current assets: Cash and cash equivalents $ $ Amounts due from related parties Prepaid expenses and other current assets Total current assets $ $ Investment in subsidiaries and VIE entities Rental deposit and other non-current assets TOTAL ASSETS $ $ LIABILITIES AND EQUITY: Current liabilities: Accrued expenses and other current liabilities $ $ Amount due to related parties Total current liabilities $ $ Equity: Class A common shares ($0.01 par value; 37,648,485 shares authorized as of March 31, 2015 and 2016, respectively, 33,556,439 issued and outstanding as of March 31, 2015 and 2016, respectively) Class C common shares ($0.01 par value; 2,000,000 shares authorized as of March 31, 2015 and 2016, respectively, 805,100 shares issued and outstanding as of March 31, 2015 and 2016, respectively) Additional paid-in capital Accumulated deficit ) ) Accumulated other comprehensive income/(loss) ) Total iKang Healthcare Group, Inc.’s equity TOTAL LIABILITIES AND EQUITY $ $ CONDENSED STATEMENTS OF OPERATIONS (In thousands of US dollars, except share data and per share data, or otherwise noted) Years ended March 31 2014 2015 2016 Operating expenses: Selling and marketing expenses $ — $ $ — General and administrative expenses Total operating expenses Loss from operations ) ) ) Interest income Interest expense ) — ) Equity in earnings of subsidiaries and VIE entities Income before provision for income tax expenses Income tax expenses — — — Net income $ $ $ CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (In thousands of US dollars, except share data and per share data, or otherwise noted) For the years ended March 31, 2014 2015 2016 Net income $ $ $ Other comprehensive income, net of tax Foreign currency translation adjustment ) ) Unrealized gain of available-for-sale securities, net of tax effect of nil for year ended March 31, 2014, 2015 and 2016 — — Comprehensive income attributable to iKang Healthcare Group, Inc. $ $ $ CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (In thousands of US dollars, except share data and per share data, or otherwise noted) Common Accumulated other Total Comprehensive Additional Accumulated comprehensive shareholders’ Shares Amount paid-in capital deficit income(loss) equity/(deficit) Balance at March 31, 2013 $ $ $ ) $ $ ) iKang Healthcare Group, Inc. one common share of $0.01 entered into a share swap agreement — — — — — Redesignation to Series F Series F convertible redeemable participating preferred shares ) ) ) — — ) Share-based compensation expenses — — — — Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd. — — — ) — ) Purchase of non-controlling interest of Shanghai iKang Guobin Blue Cross Clinic Co., Ltd — — ) — — ) Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium — — — ) — ) Net income — — — — Foreign currency translation adjustment — — — — ) ) Balance at March 31, 2014 $ $ $ ) $ $ ) Conversion of participating convertible redeemable preferred shares to common shares — — Share-based compensation expenses — — Issuance of common shares upon initial public offering, net of offering costs of $2,882 — — Issuance of common shares upon Green Shoe — — Issuance of common shares in connection with exercise of options — — Issuance of common shares in connection with share-based compensation arrangement(1) — — — Capital contribution of non-controlling interest holder of Shanghai iKang Jianwei Health Management Co., Ltd. — — ) — — ) Capital contribution of non-controlling interest holder of WA Centers HK Limited — — ) — — ) Net income — — — — Foreign currency translation adjustment — — — — Balance at March 31, 2015 $ $ $ ) $ $ Share-based compensation expenses — — — — Exercise of employee share options(1) — — — — Settlement of acquisition payable of Shanghai Huajian Management — — — Purchase of non-controlling interest of iKang Shanghai Gubei — — ) — — ) Net income — — — — Foreign currency translation adjustment — — — — ) ) Unrealized gain on available-for-sale investments — — — — Balance at March 31, 2016 $ $ $ ) $ ) $ (1) Shares were previously issued during the year ended March 31, 2015. CONDENSED STATEMENTS OF CASH FLOWS (In thousands of US dollars, except share data and per share data, or otherwise noted) For the years ended March 31, 2014 2015 2016 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ $ $ Adjustments to reconcile net income to net cash provided by operating activities: Investment income from subsidiaries ) ) ) Share based compensation expenses Changes in assets and liabilities: Prepaid expenses and other current assets ) ) Amount due from related parties ) ) ) Accrued expenses and other current liabilities ) ) Net cash generated from (used in) operating activities ) ) ) CASH FLOW FROM INVESTING ACTIVITIES: Loan provided to a related party ) — — Repayment of loan provided to a related party — — Payment for long-term investments — — ) Investment in subsidiaries — — ) Payment for loan receivable — ) ) Payments for business acquisitions ) ) — Net cash used in investing activities ) ) ) CASH FLOW FROM FINANCING ACTIVITIES: Proceeds from issuance of convertible redeemable preferred shares — — Proceeds from redesignation of Class A common shares — — Proceeds from redesignation of convertible redeemable preferred shares — — Payment for convertible preferred shares transaction professional fees ) — — Proceeds from issuance of common shares upon initial public offering — — Proceeds from issuance of common shares upon Green Shoe — — Payment of initial public offering expenses — ) — Proceeds from exercise of share options — Payment for business acquisitions — ) — Repayment of convertible loan ) — — Net cash provided by financing activities Net increase/ (decrease) in cash and cash equivalents ) ) CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR CASH AND CASH EQUIVALENTS AT END OF THE YEAR $ $ $ CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY NOTES TO THE FINANCIAL STATEMENTS 1. BASIS FOR PREPARATION The condensed financial information of the Parent Company has been prepared using the same accounting policies as set out in the Group’s consolidated financial statement except that the Parent Company used the equity method to account for investments in its subsidiaries and VIE entities. The condensed financial information is provided since the restricted net assets of the Group’s subsidiaries and VIE entities were over the 25% of the consolidated net assets of the Group as of March 31, 2016. 2. INVESTMENTS IN SUBSIDIARIES The Parent Company, its subsidiaries and VIE entities were included in the consolidated financial statements where inter-company balances and transactions were eliminated upon consolidation. For the purpose of the Parent Company’s stand-alone financial information, its investments in subsidiaries and VIE entities are reported using the equity method of accounting. The Parent Company’s share of income from its subsidiaries and VIE entities were reported as share of income of subsidiaries and VIE entities in the accompanying Parent Company’s financial information.

SUMMARY OF SIGNIFICANT ACCOUN38

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation	Basis of presentation The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Basis of consolidation	Basis of consolidation The consolidated financial statements of the Group include the financial statements of iKang Guobin Healthcare Group Inc., its subsidiaries, its VIEs and its VIEs’ subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues, costs and expenses in the financial statements and accompanying notes. Significant accounting estimates reflected in the Group’s consolidated financial statements include revenue recognition, allowance for doubtful accounts, the useful lives and impairment of property and equipment, purchase price allocation relating to business acquisitions, the useful lives and impairment of intangible assets, impairment of goodwill, impairment of long-term investments valuation allowance for deferred tax assets, share-based compensation and fair value of long-term available-for-sale investments, common shares, convertible redeemable preferred shares and forward contracts.
Business Acquisitions	Business Acquisitions Business combinations are recorded using the acquisition method of accounting. The purchase price of the acquisition is allocated to the tangible assets, liabilities, identifiable intangible assets acquired and non-controlling interest, if any, based on their estimated fair values as of the acquisition date. The excess of the purchase price over those fair values is recorded as goodwill. Acquisition-related expenses and restructuring costs are expensed as incurred. Where the consideration in an acquisition includes contingent consideration and the payment of which depends on the achievement of certain specified conditions post-acquisition, the contingent consideration is recognized and measured at its fair value at the acquisition date and if recorded as a liability, it is subsequently carried at fair value with changes in fair value reflected in earnings.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of cash on hand and demand deposits, which are unrestricted as to withdrawal and use, and have maturities of three months or less when purchased.
Restricted cash	Restricted cash Restricted cash mainly consists of the cash deposit denominated in U.S. dollar in overseas accounts used to collateralize the locally borrowings in China to meet Group’s RMB funding needs, which is primarily to purchase property and equipment within China.
Term deposits	Term deposits Term deposits consist of deposits placed with financial institutions with original maturity terms of greater than three months but less than one year.
Accounts receivable and allowance for doubtful accounts	Accounts receivable and allowance for doubtful accounts Accounts receivable represents those receivables derived in the ordinary course of business. A general allowance for doubtful accounts is provided based on aging analyses of accounts receivable balances, historical bad debt rates, in addition to specific provisions established based on customers’ repayment patterns and customer credit worthiness.
Financial instruments	Financial instruments Financial instruments of the Group primarily consist of cash and cash equivalents, restricted cash, term deposits, accounts receivable, forward contracts, equity securities investments, amount due from related parties, accounts payable, amount due to related parties, short-term borrowing and long-term borrowing. The carrying values of cash and cash equivalents, restricted cash, term deposits, accounts receivable, accounts payable, amounts due from related parties, and short-term borrowings approximate their fair values due to short-term maturities.
Effective interest method	Effective interest method The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Interest expense is recognized on an effective interest basis.
Fair value measurements	Fair value measurements Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. Authoritative literature provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows: · Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. · Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. · Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Group measures certain assets, including long-term investments and intangible assets, at fair value on a nonrecurring basis when they are deemed to be impaired. The fair values of intangible assets are determined based on valuation techniques using the best information available, and may include management judgments, future performance projections, etc. An impairment charge to the intangible assets is recorded when their carrying amounts may not be recoverable. Fair value of financial instruments is discussed in Note 19.
Significant risks and uncertainties	Significant risks and uncertainties The Group operates in an industry with rapid changes in regulations, customer demand and competition and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations, or cash flows: advances and trends in healthcare industry standards, changes in certain strategic relationships or customer relationships, regulatory or other PRC related factors, risks associated with the Group’s ability to keep and increase the customer base, and risks surrounding pending litigations.
Foreign currency risk	Foreign currency risk The Renminbi (“RMB”) is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. Cash and cash equivalents of the Group included aggregate amounts of $30,172 and $98,577 at March 31, 2015 and 2016, respectively, which were denominated in RMB.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Group places their cash with financial institutions with high-credit ratings and quality. The Group conducts credit evaluations of customers and generally do not require collateral or other security from their customers. No customer accounted for 10% or more of total revenues for the years ended March 31, 2014, 2015 and 2016, respectively. No customer accounted for 10% or more of accounts receivable as of March 31, 2015 and 2016, respectively.
Inventories	Inventories Inventories are medical consumable supplies and are stated at the lower of cost or market value. Inventories are written down for obsolescence to net realizable value based upon estimates of future demand and expiration date of inventories. The Group did not record a write-down of inventories for the years ended March 31, 2014, 2015 and 2016, respectively.
Property and equipment, net	Property and equipment, net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives: Computer equipment and application software 5 years Furniture and fixture 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term Construction in progress represents unfinished leasehold improvement and installment of equipment for new clinics. Construction in progress will be transferred to leasehold improvement or property and equipment when it is finished. Depreciation is recorded at the time when assets are ready for the intended use.
Intangible assets, net	Intangible assets, net Intangible assets, other than goodwill, resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by management based on the fair value of assets acquired. Identifiable intangible assets are carried at cost less accumulated amortization. Amortization of customer relationship is computed using the estimated attrition pattern of the acquired customers, and amortization of other finite-lived intangible assets is computed using the straight-line method over the following estimated average useful lives, which are as follows: Weighted average (years) Range (years) Customer relationship 5.5 2.1~10.0 Non-compete agreement 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating license 2.9 0.3~5.0 Favorable lease contract 7.1 2.8~9.8 The weighted average estimated average useful life of the intangible assets with determinable lives is 5.3 years.
Intangible assets-indefinite lives	Intangible assets-indefinite lives If an intangible asset is determined to have an indefinite life, it should not be amortized until its useful life is determined to be no longer indefinite. An intangible asset that is not subject to amortization is tested for impairment at least annually or if events or changes in circumstances indicate that the asset might be impaired. Such impairment test consists of the fair values of assets with their carrying value amounts and an impairment loss is recognized if and when the carrying amounts exceed the fair values. The estimates of fair values of intangible assets not subject to amortization are determined using various discounted cash flow valuation methodologies. Significant assumptions are inherent in this process, including estimates of discount rates.
Impairment of long-lived assets and intangible assets with definite life	Impairment of long-lived assets and intangible assets with definite life Long-lived assets, such as property and equipment and definite-lived intangible assets are stated at cost less accumulated depreciation or amortization. Depreciation and amortization is computed principally using the straight-line method. The Group evaluates the recoverability of long-lived assets, including identifiable intangible assets, with determinable useful lives whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. The Group measures the carrying amount of long-lived assets against the estimated undiscounted future cash flows associated with it. Impairment exists when the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated. Impairment loss is calculated as the amount by which the carrying value of the asset exceeds its fair value. Fair value is estimated based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Group to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts.
Goodwill	Goodwill Goodwill represents the excess of the fair value of consideration paid over the fair value of identifiable net assets acquired in business combinations. Goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but tested for impairment annually or more frequently if events and circumstances indicate that they might be impaired. Goodwill is tested for impairment at the reporting unit level on an annual basis (March 31 for the Group) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the stock prices, business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. In the evaluation of the goodwill for impairment, the Group may first assess qualitative factors to determine whether it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, goodwill is then tested following a two-step process. The first step compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired and the second step will not be required. If the carrying amount of a reporting unit exceeds its fair value, the second step compares the implied fair value of goodwill to the carrying value of a reporting unit’s goodwill. The implied fair value of goodwill is determined in a manner similar to accounting for a business combination with the allocation of the assessed fair value determined in the first step to the assets and liabilities of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to the assets and liabilities is the implied fair value of goodwill. An impairment loss is recognized for any excess in the carrying value of goodwill over the implied fair value of goodwill. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimation of fair value of each reporting unit using a discounted cash flow methodology also requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the Group’s business, estimation of the useful life over which cash flows will occur, and determination of the Group’s weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for the reporting unit. The Group did not incur any impairment loss on goodwill for the years ended March 31, 2014, 2015 and 2016, respectively.
Long-term investments	Long-term investments The Group’s long-term investments consist of cost method investments, equity method investments and available-for-sale investments. Cost method investments For equity investments that are not considered as equity securities that have readily determinable fair values and over which the Group neither has significant influence nor control through investment in common stock or in-substance common stock, the cost method is used. Investments in limited partnerships over whose operating and financing policies the Group has virtually no influence and with investment less than 20 percent are accounted for using the cost method. Under the cost method, the Company carries the investment at cost and recognizes income to the extent of dividends received from the distribution of the equity investee’s post-acquisition profits. Equity method investments The Group applies the equity method to account for an equity investment, in common stock or in-substance common stock over which it has significant influence but does not own a majority equity interest or otherwise control. Significant influence is generally considered to exist when the Group has an ownership interest in the voting stock of the investee between 20% and 50%, and other factors, such as representation on the investee’s board of directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate. Under the equity method, the Group initially records its investment at cost and subsequently adjusts the carrying amount of the investment to recognize the Group’s proportionate share of each equity investee’s net income or loss into earnings after the date of investment. Available-for-sale investments For investments in investees’ stocks which are determined to be debt securities, the Group accounts for them as long-term available-for-sale investments when they are not classified as either trading or held-to-maturity investments. Available-for-sale investments are carried at their fair values and the unrealized gains or losses from the changes in fair values are included in accumulated other comprehensive income. The Group continually reviews its investments in equity investees to determine whether a decline in fair value below the carrying value is other than temporary. The primary factors the Group considers in its determination are the length of time that the fair value of the investment is below the Group’s carrying value; the financial condition, operating performance and the prospects of the equity investee; and other Group specific information such as recent financing rounds. If the decline in fair value is deemed to be other than temporary, the carrying value of the equity investee is written down to fair value. The Group estimated the fair value of these investee companies based on discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital.
Revenue recognition	Revenue recognition Revenue is stated net of business tax. The Group’s PRC subsidiaries and VIE entities are subject to a 5% business tax and related surcharges on the revenues earned from providing services and selling products in the PRC. Certain contracts under specific formalities are exempted from business tax in accordance with the PRC tax laws. The Group recognized $2,084, $2,156, and $2,692 business tax for the years ended March 31, 2014, 2015 and 2016, respectively. The Group recognizes revenues when persuasive evidence of an arrangement exists, service has been provided, the sales price is fixed or determinable, and collectability is reasonably assured. The Group offers medical examination and disease screening services and renders such services at the request of its customers. The Group recognizes revenues when the examination reports are issued and passed to the local couriers if hard copy reports are required by its customers, or when the examination reports are uploaded on line and can be viewed by the customers on line if hard copy reports are not required. The Group notifies its customers when their examination reports are delivered to the local couriers or ready to be viewed and downloaded on line. For individual customers, fees are collected before the performance of the services while corporate customers prepay a portion of service fees upon signing of the master contract, which is recognized as deferred revenue by the Group. All fees for services rendered are first charged against the corporate customer’s deferred revenues until it is entirely exhausted before the Group starts to invoice the corporate customers. The Group records accounts receivables from its corporate customers when the examination reports of the employees of corporate customers have been delivered or uploaded on line but the Group has not received remaining payments from the corporate customers. Sometimes the Group engages third-party providers to provide medical examination and disease screening services on behalf of the Group. The Group evaluates the services provided by third parties on behalf of the Group to determine whether to recognize the revenues on a gross or net basis. The determination is based upon an assessment as to whether the Group acts as a principal or agent when providing the services. All of the revenues involving third-party providers providing medical examination or disease screening services on behalf of the Group are currently accounted for on a gross basis since the Group is the primary obligor, has the latitude in establishing prices, discretion in third-party provider selection and the credit risks. The Group also provides packages of bundled services principally comprising combinations of medical examination, disease screening, health consultation and medical concierge services to its corporate customers, which normally expire within one year from the date of purchase and does not include right of return. The Group allocates revenues from the sale of bundled services to each component using the relative selling price of each component based on the Group’s best estimate. Revenue recognition criteria for components included in the bundled services is identical to as if the components are sold on a standalone basis. The Group recognizes revenue from dental services when the service is rendered and the service fee is collectable.
Value added tax ("VAT")	Value added tax (“VAT”) On January 1, 2012, the PRC Ministry of Finance and the State Administration of Taxation officially launched a pilot value-added taxes (“VAT”) reform program (“Pilot Program”), applicable to business in selected industries. Such VAT Pilot Program were phased in Beijing, Jiangsu, Anhui, Fujian, Guangdong, Tianjin, Zhejiang, and Hubei between September and December 2012. Business in the Pilot Program would pay VAT instead of sales tax. Starting from August 1, 2013, the Pilot Program was expanded to cover all regions in the PRC. Cai Shui [2016] No. 36 specifies the industries and relevant requirements that can enjoy VAT exemption. In accordance with Cai Shui [2016] No. 36, the medical examination service is exempt from paying VAT, therefore, the Group’s medical examination service is not currently subject to VAT.
Non-monetary exchange	Non-monetary exchange The Group occasionally exchanges medical examination services with advertising agencies for advertising credits. The amount of deferred revenues and prepaid expenses is based on the fair value of the medical examination services surrendered which approximates the price the Group offers to the individual customers and is more readily determinable. The amounts of revenues recognized for non-monetary transactions were $706, $571 and $1,767 for the years ended March 31, 2014, 2015 and 2016, respectively. Direct costs attributable to the revenues have been immaterial.
Cost of revenues	Cost of revenues Cost of revenues consist of expenditures incurred in the generation of the Group’s revenues, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers.
Research and development expenses	Research and development expenses Research and development expenses primarily consist of (i) salaries and benefits for research and development personnel, and (ii) office rental, general expenses and depreciation and amortization expenses associated with the research and development activities. The Group’s research and development activities primarily consist of the research and development of its information technology platform. Research and development expenses are expensed when incurred.
Income taxes	Income taxes Current income taxes are provided for in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Net operating loss carry forwards and credits are applied using enacted statutory tax rates applicable to future years. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that a portion of or all of the deferred tax assets will not be realized. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. The impact of an uncertain income tax position on the income tax return is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Interest and penalties on income taxes will be classified as a component of the provisions for income taxes. The Group did not recognize any income tax due to uncertain tax position or incur any interest and penalties related to potential underpaid income tax expenses for the years ended March 31, 2014, 2015 or 2016, respectively.
Share-based compensation	Share-based compensation Share-based payment transactions with employees, such as share options are measured based on the grant date fair value of the equity instrument. The Group recognizes the compensation costs net of an estimated forfeiture rate using the graded vesting attribution method over the requisite service period of the award, which is generally the vesting period of the award. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share compensation expense to be recognized in future periods. Share awards issued to non-employees, such as advisors, are measured at fair value at the earlier of the commitment date or the date the service is completed and recognized over the period the service is provided.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period. The Group’s convertible redeemable preferred shares are participating securities as they participate in undistributed earnings on an as-if-converted basis. Accordingly, the Group uses the two-class method whereby undistributed net income is allocated on a pro rata basis to the common shares and preferred shares to the extent that each class may share in income for the period; whereas the undistributed net loss for the period is allocated to common shares only because preferred shares are not contractually obligated to share the loss. Diluted earnings per common share reflect the potential dilution that could occur if securities were exercised or converted into common shares. The Group had convertible redeemable preferred shares, and stock options, which could potentially dilute basic earnings per share. To calculate the number of shares for diluted income per share, the effect of the convertible redeemable preferred shares is computed using the as-if-converted method; the effect of the stock options is computed using the treasury stock method.
Foreign currency translation	Foreign currency translation The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”). The financial records of the Group’s subsidiaries and VIE entities located in the PRC are maintained in their local currencies, the RMB, which are also the functional currencies of these entities. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the statement of operations. The Group’s entities with functional currency of RMB translate their operating results and financial positions into the U.S. dollar, the Group’s reporting currency. Assets and liabilities are translated using the exchange rates in effect on the balance sheet date. Revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive income.
Comprehensive income	Comprehensive income Comprehensive income includes net income, cumulative foreign currency translation adjustments, unrealized gain (loss) in available-for-sale investments and net of tax effect for years ended March 31, 2014, 2015 and 2016, and is reported in the statement of shareholder’s equity.
Operating leases	Operating leases Leases where the rewards and risks of ownership of assets primarily remain with the lessor are accounted for as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease periods.
Newly adopted accounting pronouncements	Newly adopted accounting pronouncements In May 2014, the Financial Accounting Standards Board(“FASB”) issued Accounting Standards Update(“ASU”) 2014-09 which affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, Property, Plant, and Equipment, and intangible assets within the scope of Topic 350, Intangibles—Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early application will be permitted. An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented and the entity may elect any of the following practical expedients:  For completed contracts, an entity need not restate contracts that begin and end within the same annual reporting period.  For completed contracts that have variable consideration, an entity may use the transaction price at the date the contract was completed rather than estimating variable consideration amounts in the comparative reporting periods.  For all reporting periods presented before the date of initial application, an entity need not disclose the amount of the transaction price allocated to remaining performance obligations and an explanation of when the entity expects to recognize that amount as revenue 2. Retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. If an entity elects this transition method it also should provide the additional disclosures in reporting periods that include the date of initial application of:  The amount by which each financial statement line item is affected in the current reporting period by the application of this ASU as compared to the guidance that was in effect before the change.  An explanation of the reasons for significant changes. The Group is in the process of evaluating the impact of this pronouncement to its consolidated financial statements. In June 2014, the FASB issued ASU 2014-12, which requires that a performance target that affects vesting and that could be achieved after the requisite service period is treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation—Stock Compensation, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. Entities may apply the amendments in this ASU either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this ASU as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Group does not expect the adoption of this guidance will have a significant effect on its consolidated financial statements. In August 2015, the FASB issued a new pronouncement, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date. The amendments in this ASU defer the effective date of ASU 2014-09 by one year. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance for all entities. Public business entities should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Group is currently evaluating the impact on its consolidated financial statements of adopting this guidance. In September, 2015, the FASB issued a new pronouncement, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. To simplify the accounting for adjustments made to provisional amounts recognized in a business combination, the amendments eliminate the requirement to retrospectively account for those adjustments. Under this ASU, an acquirer must recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The ASU also requires acquirers to present separately on the face of the income statement, or disclose in the notes, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The ASU must be applied prospectively to adjustments to provisional amounts that occur after the effective date. Early adoption is permitted for financial statements that have not been issued. The Group does not expect the adoption of this guidance will have a significant effect on its consolidated financial statements. In November, 2015, the FASB issued a new pronouncement ASU 2015-17 which changes how deferred taxes are classified on organizations’ balance sheets. The ASU eliminates the current requirement for organizations to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, organizations will be required to classify all deferred tax assets and liabilities as noncurrent. The amendments apply to all organizations that present a classified balance sheet. For public companies, the amendments are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. This ASU may be applied prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Group does not expect the adoption of this guidance will have a significant effect on the Group’s consolidated financial statements. In January, 2016, the FASB issued a new pronouncement ASU 2016-01 which is intended to improve the recognition and measurement of financial instruments. The ASU affects public and private companies, not-for-profit organizations, and employee benefit plans that hold financial assets or owe financial liabilities. The new guidance makes targeted improvements to existing U.S. GAAP by:  Requiring equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income;  Requiring public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes;  Requiring separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (i.e., securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements;  Eliminating the requirement to disclose the fair value of financial instruments measured at amortized cost for organizations that are not public business entities;  Eliminating the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; and  Requiring a reporting organization to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk (also referred to as “own credit”) when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. The new guidance is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The new guidance permits early adoption of the own credit provision. Adoption of the amendment must be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption, except for amendments related to equity instruments that do not have readily determinable fair values which should be applied prospectively. The Group does not expect the adoption of this guidance will have a significant effect on the Group’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The guidance supersedes existing guidance on accounting for leases with the main difference being that operating leases are to be recorded in the statement of financial position as right-of-use assets and lease liabilities, initially measured at the present value of the lease payments. For operating leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. For public business entities, the guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application of the guidance is permitted. In transition, entities are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The Group is in the process of evaluating the impact that this guidance will have on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-08, which amends the principal-versus-agent implementation guidance and illustrations in the Board’s new revenue standard (ASC 606). The amendments in this update clarify the implementation guidance on principal versus agent considerations. When another party, along with the reporting entity, is involved in providing goods or services to a customer, an entity is required to determine whether the nature of its promise is to provide that good or service to the customer (as a principal) or to arrange for the good or service to be provided to the customer by the other party (as an agent). The guidance is effective for interim and annual periods beginning after December 15, 2017. The Group is in the process of evaluating the impact of adoption of this guidance on the consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718). The new guidance simplifies certain aspects related to income taxes, statement of cash flows, and forfeitures when accounting for share-based payment transactions. This new guidance will be effective for the Company for the first reporting period beginning after December 15, 2016, with earlier adoption permitted. Certain of the amendments related to timing of the recognition of tax benefits and tax withholding requirements should be applied using a modified retrospective transition method. Amendments related to the presentation of the statement of cash flows should be applied retrospectively. All other provisions may be applied on a prospective or modified retrospective basis. For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early application will be permitted. The Group is in the process of evaluating the impacts of the adoption of this ASU.

ORGANIZATION AND PRINCIPAL AC39

ORGANIZATION AND PRINCIPAL ACTIVITIES (Tables)	12 Months Ended
	Mar. 31, 2016
ORGANIZATION AND PRINCIPAL ACTIVITIES
Schedule of details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries	As of March 31, 2016, details of the Group’s subsidiaries, VIEs and the VIEs’ subsidiaries were as follows: Percentage of Later date of beneficial interest incorporation/ Place of by iKang Names acquisition incorporation Healthcare Group, Inc. Principal activities Subsidiaries: iKang Guobin Healthcare Group, Inc.(“iKang Guobin”) December 24, 2003 BVI % Holding company ShanghaiMed iKang, Inc. (“Beijing iKang”) February 27, 2004 PRC % Sales of healthcare service Shanghai iKang Co., Ltd. (“Shanghai iKang”) December 27, 2004 PRC % Sales of healthcare service iKang Zhejiang, Inc. (“iKang Zhejiang BVI”) April 5, 2006 BVI % Holding company iKang HealthManagement (Zhejiang) Co., Ltd. (“Zhejiang iKang”) July 11, 2006 PRC % Sales of healthcare service Bayley & Jackson (China) Medical Services Limited (“Bayley & Jackson (Hong Kong)”) October 10, 2006 Hong Kong % Holding company Beijing Bayley & Jackson Clinic Co., Ltd. (“iKang Beijing Ritan”) October 10, 2006 PRC % Medical examinations & clinical services Yuanhua Healthcare Limited (HongKong) (“Yuanhua HK”) July 31, 2013 Hong Kong % Holding company MediFast (Hong Kong) Limited (“MediFast”) January 14, 2014 Hong Kong % Medical examinations & clinical services Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. (“Yuanhua WFOE”) July 31, 2013 PRC % Sales of healthcare service WA Cen ters HK Limited (“WA HK ”) March 3, 2015 Hong Kong % Holding company iKang Health Cloud Technology Limited (“iKang Cloud HK”) January 5, 2015 Hong Kong % Holding company iKang(Shanghai) Financing Lease Co., Ltd. (“iKang(Shanghai) Financing Lease”) December 19, 2014 PRC % Lease services VIEs: iKang Healthcare Technology Group Co., Ltd. (formerly named as “Shanghai iKang Guobin Holding Co., Ltd.”) (“iKang Holding”) April 27, 2007 PRC % Holding company Hangzhou iKang Guobin Clinic Co., Ltd. (“iKang Hangzhou Xixi”) September 26, 2010 PRC % Medical examinations Shanghai Yuanhua Information Technology Co., Ltd. (“Yuanhua Information”) July 31, 2013 PRC % Holding company Jiandatong Health Technology (Beijing) Co., Ltd. (“Beijing Jiandatong”) April 1, 2013 PRC % Sales of healthcare service VIEs’ subsidiaries: iKang Guobin Healthcare Group Co., Ltd. (formerly named as “Beijing iKang Online Technology Co., Ltd.”) (“iKang Online”) September 13, 2004 PRC % Sales of healthcare service Beiijng iKang Medical Examination Application Technology Co., Ltd. February 3, 2005 PRC % Sales of healthcare service Shenzhen iKang Co., Ltd. (“Shenzhen iKang”) July 12, 2006 PRC % Sales of healthcare service Shanghai Yalong Daoyi Services Co., Ltd. (“Yalong Daoyi”) December 20, 2006 PRC % Sales of healthcare service Guangzhou iKang Guobin Health Examination Co., Ltd. (“iKang Guangzhou Huanshi East/Tianhe”) April 27, 2007 PRC % Medical examinations Shanghai Guobin Medical Center Co., Ltd. (“iKang Shanghai Xikang Road”) April 27, 2007 PRC % Medical examinations & clinical services Shanghai Wangzu Guobin Medical Center Co., Ltd. (“iKang Shanghai Gubei”) April 27, 2007 PRC % Medical examinations Shanghai iKang Guobin Mingmen Clinic Co., Ltd. (“iKang Shanghai Pudong Avenue”) April 27, 2007 PRC % Medical examinations Shenzhen iKang Guobin Hospital Management Co., Ltd. (“Shenzhen Hospital Management”) September 10, 2007 PRC % Holding company Shenzhen iKang Guobin Puji Clinic Co., Ltd. (formerly named as “Shenzhen Puji Clinic”) (“iKang Shenzhen Nanshan”) September 10, 2007 PRC % Medical examinations & clinical services Beijing iKang Guobin Lidu Clinic Co., Ltd. (“iKang Beijing Lidu”) December 3, 2007 PRC % Medical examinations Nanjing iKang Guobin Xinjie Clinic Co., Ltd. January 10, 2008 PRC % Medical examinations Shenzhen iKang Guobin Clinic Co., Ltd. (formerly named as “Shenzhen iKang Guobin Clinic”) (“iKang Shenzhen Luohu”) March 25, 2008 PRC % Medical examinations Beijing iKang Guobin Jianwai Clinic Co., Ltd. (“iKang Beijing Jianguomen”) September 9, 2008 PRC % Medical examinations Beijing iKang Guobin Zhongguan Clinic Co., Ltd. (“iKang Beijing Zhongguancun”) September 19, 2008 PRC % Medical examinations Beijing iKang Guobin Zhengqingyuan Clinic Co., Ltd. (“iKang Beijing Kunming Lake”) December 1, 2008 PRC % Medical examinations Beijing iKang Guobin Jiuxianqiao Clinic Co., Ltd. (“iKang Beijing Yansha East”) December 1, 2008 PRC % Medical examinations Shanghai iKang Guobin Renren Clinic Co., Ltd. (“iKang Shanghai Yangpu”) December 9, 2008 PRC % Medical examinations Chengdu iKang Guobin Health Examination Hospital Co., Ltd. (“iKang Chengdu Waishuangnan”) January 15, 2009 PRC % Medical examinations Shanghai iKang Guobin Blue Cross Clinic Co., Ltd. (“iKang Shanghai Lujiazui”) January 28, 2010 PRC % Medical examinations Shanghai Wenzhong Clinic Co., Ltd. (“Shanghai Wenzhong”) February 12, 2010 PRC % Medical examinations Beijing iKang Guobin Clinic Co., Ltd. (“iKang Beijing Xuanwumen”) August 5, 2010 PRC % Medical examinations Nanjing iKang Guobin Clinic Co., Ltd. (“iKang Nanjing Gulou”) January 19, 2011 PRC % Medical examinations Shenzhen Xinglin Clinic Co., Ltd. (formerly named as “Shenzhen Xinglin Clinic”) (“iKang Shenzhen Futian”) January 25, 2011 PRC % Medical examinations Fujian iKang Guobin Health Management Co., Ltd. (“Fujian iKang”) April 1, 2011 PRC % Sales of healthcare service Fuzhou iKang Guobin Clinic Co., Ltd. (“iKang Fuzhou Gulou”) November 14, 2011 PRC % Medical examinations Beijing iKang Guobin Xinei Clinic Co., Ltd. (“iKang Beijing Xinei”) January 30, 2012 PRC % Medical examinations Shanghai iKang Guobin Fukang Clinic Co., Ltd. (“Yan’an West Road”) January 18, 2012 PRC % Medical examinations Shanghai iKang Guobin Zhonghuan Yipin Clinic Co., Ltd. (formerly named as “Shanghai Zhonghuan Yipin Clinic Co., Ltd.”) (“iKang Shanghai Zhonghuan”) January 21, 2012 PRC % Medical examinations Shanghai iKang Guobin Yipin Clinic Co., Ltd. (formerly named as “Shanghai Yipin Clinic Co., Ltd.”) (“iKang Shanghai Jing’an”) January 21, 2012 PRC % Medical examinations Shanghai iKang Guobin Waizhitan Clinic Co., Ltd. (“iKang Shanghai Yan’an East Road”) May 29, 2012 PRC % Medical examinations Shanghai iKang Guobin Jianwei Clinic Co., Ltd. (formerly named as “Shanghai Jianzhiwei Clinic Co., Ltd.”) (“iKang Shanghai Jianzhiwei”) August 17, 2012 PRC % Medical examinations Hangzhou iKang Guobin Wenhui Clinic Co., Ltd. (“iKang Hangzhou Wenhui”) September 3, 2012 PRC % Medical examinations Tianjin Heping Aibin Clinic Co., Ltd. (“iKang Tianjin Heping”) October 15, 2012 PRC % Medical examinations Suzhou iKang Guobin Clinic Co., Ltd. (formerly named as “Suzhou Aibin Clinic, Co., Ltd.”) (“iKang Suzhou”) November 13, 2012 PRC % Medical examinations Suzhou Zhuoyue Clinic Co., Ltd. (“Suzhou Zhuoyue”) October 15, 2014 PRC % Medical examinations Changchun iKang Guobin Jiachang General Clinic Co., Ltd. (“iKang Changchun”) November 5, 2012 PRC % Medical examinations Chengdu Jinjiang iKang Guobin Hongzhaobi Health Co., Ltd. (“iKang Chengdu Hongzhaobi”) December 21, 2012 PRC % Examination General Clinic Medical examinations Chongqing Aibin Clinic Co., Ltd. (“iKang Chongqing”) December 18, 2012 PRC % Medical examinations Guangzhou Wokang Medical Clinic (“iKang Guangzhou Wokang”) December 3, 2012 PRC % Medical examinations Shenzhen iKang Guobin Kefa Clinic Co., Ltd. (formerly named as “Shenzhen iKang Guobin Kefa Clinic”) (“Shenzhen Kefa”) March 26, 2013 PRC % Medical examinations Shanghai iKang Jianwei Health Management Co., Ltd. (“Shanghai Jianwei Management”) September 6, 2013 PRC % Sales of healthcare services Shanghai Yuanhua Clinic Co., Ltd. (“Yuanhua Clinic”) July 31, 2013 PRC % Medical examinations Nanjing iKang Jun’an TCM Clinic Co., Ltd. (“iKang Nanjing Jun’an”) September 1, 2013 PRC % Medical examinations Nanjing Aibin Health Information Consultancy Co., Ltd. (“Nanjing Aoyang Shunkang”) September 1, 2013 PRC % Sales of healthcare service Jiangyin iKang Guobin Clinic Co., Ltd. (“iKang Jiangyin”) December 16, 2013 PRC % Medical examinations Zhejiang Huzhou Ailikang Investment Management Co., Ltd. (“Zhejiang Ailikang”) December 31, 2013 PRC % Sales of healthcare services Hangzhou iKang Jun’an Clinic Co., Ltd. (formerly named as “Hangzhou Aibo Huagang Clinic Co. Ltd.”) (“Hangzhou Aibo”) December 31, 2013 PRC % Medical examinations Beijing iKang Jun’an Clinic Co., Ltd. (“iKang Beijing Jun’an”) November 28, 2013 PRC % Medical examinations & clinical services Beijing iKang Guobin Yayun Clinic Co., Ltd. (“iKang Beijing Yayun”) December 5, 2013 PRC % Medical examinations Changzhou iKang Guobin Clinic Co., Ltd. (“iKang Changzhou”) March 14, 2014 PRC % Medical examinations Beijing iKang Guobin Baishi Clinic Co., Ltd. (“iKang Beijing Baishi”) April 16, 2014 PRC % Medical examinations Chengdu Gaoxin iKang Guobin Chengnan Clinic Co., Ltd. (“Chengdu Gaoxin iKang West City ”) May 22, 2014 PRC % Medical examinations iKang Dental Hospital Management Co., Ltd. (“iKang Dental Hospital Management ”) August 13, 2014 PRC % Management of dental services Beijing iKang Guobin Wanzhishou Clinic Co., Ltd. (“iKang Beijing Wanzhishou ”) August 21, 2014 PRC % Medical examinations Shanghai Huajian Health Examination Management Co., Ltd. (“Shanghai Huajian Management”) July 1, 2014 PRC % Medical examinations Shanghai Huajian Clinic Co., Ltd.(“Shanghai Huajian”) July 1, 2014 PRC % Medical examinations Shanghai Jinxiu Huajian Clinic Co., Ltd.(“Shanghai Jinxiu Huajian”) July 1, 2014 PRC % Medical examinations Shanghai Jinshen Huajian Clinic Co., Ltd.(“Shanghai Jinshen Huajian”) July 1, 2014 PRC % Medical examinations Shenyang iKang Guobin Hospital(“iKang Shenyang Hospital”) November 14, 2014 PRC % Medical examinations Shenyang iKang Guobin Ningshan Hospital Co., Ltd. (“iKang Shenyang Ningshan Hospital”) November 19, 2014 PRC % Medical examinations Shenyang Golden iKang Guobin Hospital Co., Ltd. (“Gold iKang Shenyang Hospital”) December 19, 2014 PRC % Medical examinations Tianjin Hedong District iKang Guobin Dongrun Clinic Co., Ltd. (“iKang Tianjin Hedong Dongrun”) February 17, 2015 PRC % Medical examinations Tianjin Hexi District iKang Guobin Fenghui Clinic Co., Ltd. (“iKang Tianjin Hexi Fenghui”) February 17, 2015 PRC % Medical examinations Wuxi Woshi Hongtai Biotechnology Co., Ltd. (“Wuxi Woshi Hongtai”) March 3, 2015 PRC % Holding company Beijing Woshi Hongtai Investment Management Consultancy Co., Ltd. (“Beijing Woshi Hongtai”) March 3, 2015 PRC % Sales of healthcare services Beijing Zhenjing Clinic Co., Ltd.(“Beijing Zhenjing”) March 3, 2015 PRC % Medical examinations Shanghai Zhenjing Hospital Management Co., Ltd. (“Shanghai Zhenjing Hospital Management”) March 3, 2015 PRC % Sales of healthcare services Shanghai Zhenjing Clinic Co., Ltd. (“Shanghai Zhenjing”) March 3, 2015 PRC % Medical examinations Beijing iKang Guobin Shunping Clinic Co., Ltd. (“iKang Beijing Shunping”) August 04, 2015 PRC % Medical examinations Beijing iKang Guobin Baiyunlu Clinic Co., Ltd. (“iKang Beijing Baiyunlu”) October 14, 2015 PRC % Medical examinations Chongqing iKang Zhuoyue Clinic Co., Ltd. (“iKang Chongqing Zhuoyue”) November 10, 2015 PRC % Medical examinations Tianjin Hexi District iKang Guobin Clinic Co., Ltd. (“iKang Tianjin Hexi”) July 27, 2015 PRC % Medical examinations Tianjin iKang Guobin Yuecheng Clinic Co. Ltd. (“iKang Tianjin Yuecheng”) September 09, 2015 PRC % Medical examinations iKang Health Cloud(Beijing) Software Co.,Ltd. (“iKang Health Cloud”) May 07, 2015 PRC % Research & development China Physician Alliance Group, Limited. (“China Physician Alliance”) August 26, 2015 PRC % Sales of healthcare services Xi’an iKang Guobin Medical Examination Management Co., Ltd. (“Xi’an iKang”) December 17, 2015 PRC % Sales of healthcare services Xi’an Lianhu Yinglun Hospital Co., Ltd. (“Xi’an Lianhu Yinglun”) December 17, 2015 PRC % Medical examinations Xi’an Yanta Yinglun Clinic Co., Ltd. (“Xi’an Yanta Yinglun”) December 17, 2015 PRC % Medical examinations Xi’an Weiyang Yinglun Clinic Co., Ltd. (“Xi’an Weiyang Yinglun”) December 17, 2015 PRC % Medical examinations Yantai iKang Guobin Hongkang Health Management Co., Ltd. (“iKang Yantai Hongkang”) May 31, 2015 PRC % Sales of healthcare services Yantai iKang Guobin Hongkang Health Management Co., Ltd. Clinic (“iKang Yantai Hongkang Clinic”) May 31, 2015 PRC % Medical examinations Yantai iKang Guobin Hongkang Health Examination Management Co., Ltd. Clinic (“iKang Yantai Hongkang Examination Clinic”) May 31, 2015 PRC % Medical examinations Yantai iKang Guobin Hongkang Health Examination Management Co., Ltd. (“iKang Yantai Hongkang Examination”) May 31, 2015 PRC % Sales of healthcare services Guizhou iKang Guobin Health Technology Co., Ltd. (“Guizhou iKang”) January 22, 2016 PRC % Sales of healthcare services Guizhou Wishstar Health Examination Clinic Co., Ltd. (“Guizhou Wishstar”) January 22, 2016 PRC % Medical examinations Weifang Gaoxin iKang Guobin Clinic Co. Ltd. (“iKang Weifang Gaoxin”) January 13, 2016 PRC % Medical examinations Wuhu iKang Guobin Clinic Co. Ltd (“Wuhu iKang”) January 7, 2016 PRC % Medical examinations Chengdu Gaoxin iKang Dental Clinic Co., Ltd. (“iKang Chengdu Gaoxin”) July 3, 2015 PRC % Dental services Shandong iKang Guobin Medical Examination Management Co., Ltd. (“Shandong iKang”) May 14 2015 PRC % Sales of healthcare services Jinan iKang Zhuoyue Medical Examination Management Co, Ltd. (“iKang Jinan Zhuoyue”) August 05, 2015 PRC % Medical examinations Yinchuan iKang Guobin Ciming Clinic Co., Ltd. (“iKang Yinchuan Ciming”) May 31, 2015 PRC % Medical examinations Ningxia iKang Guobin Health Examination Investment Holding Co., Ltd. (“Ningxia iKang”) May 31, 2015 PRC % Sales of healthcare services Hangzhou iKang Guobin Jiangnan Avenue Clinic Co., Ltd. (“iKang Hangzhou Jiangnan Avenue”) November 16, 2015 PRC % Medical examinations Ningbo Haishu iKang Guobin Clinic Co., Ltd. (“iKang Ningbo Haishu”) July 07, 2015 PRC % Medical examinations Nanjing iKang Guobin Hedingqiao Clinic Co., Ltd. (“iKang Nanjing Hedingqiao”) November 25, 2015 PRC % Medical examinations Wuhan iKang Guobin Xiandai Sunny Clinic Co., Ltd. (“iKang Wuhan Xiandai Sunny”) January 01, 2016 PRC % Medical examinations Foshan iKang Guobin Clinic Co., Ltd. (“Foshan iKang”) October 24, 2015 PRC % Medical examinations Beijing Tianjian Sunny Health Science and Technology Co., Ltd. (“Beijing Tianjian Sunny”) May 25, 2015 PRC % Sales of healthcare services Beijing Tianjian Sunny Health Science and Technology Co., Ltd. Anhuaqiao Clinic (“Beijing Anhuaqiao”) May 25, 2015 PRC % Medical examinations Beijing Tianjian Sunny Health Science and Technology Co., Ltd. Fengtai Clinic (“Beijing Fengtai”) May 25, 2015 PRC % Medical examinations Sinopharm Sunny Health Science and Technology Co., Ltd. Konggang Clinic (“Beijing Konggang”) May 25, 2015 PRC % Sales of healthcare services Beijing iKang Guobin Sunny Jingchao Clinic Co., Ltd. (“iKang Beijing Jingchao”) May 25, 2015 PRC % Medical examinations Beijing iKang Guobin Sunny Jingchun Clinic Co., Ltd. (“iKang Beijing Jingchun”) May 25, 2015 PRC % Medical examinations Guangzhou Zhenxing Traditional Chinese Medical Clinic Co., Ltd. (“Guangzhou Zhenxing”) May 25, 2015 PRC % Medical examinations Beijing Tianzhikangjian Investment Management Co., Ltd. (“Beijing Tianzhikangjian”) May 25, 2015 PRC Changsha iKang Guobin Health Consultancy Co., Ltd. (“Changsha iKang”) May 25, 2015 PRC % Sales of healthcare services Changsha iKang Guobin Health Consultancy Co., Ltd. Sunny Clinic (“iKang Changsha Sunny Clinic”) May 25, 2015 PRC % Medical examinations Beijing iKang Zhuoyue Jingxi Clinic Co., Ltd. (“iKang Beijing Jingxi”) May 25, 2015 PRC % Medical examinations Yantai iKang Guobin Ciming Medical Examination Management Co., Ltd. (“Yantai Ciming”) July 31, 2015 PRC % Sales of healthcare services Yantai iKang Guobin Ciming Medical Examination Management Co., Ltd.Laishan Clinic (“Yantai Ciming Laishan Clinic”) July 31, 2015 PRC % Medical examinations Weifang Kuiwen iKang Guobin Ciming Clinic Co. Ltd. (“Weifang Kuiwen”) July 31, 2015 PRC % Medical examinations Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic (“Weihai Ciming Clinic”) July 31, 2015 PRC % Sales of healthcare services Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. (“Weihai Ciming”) July 31, 2015 PRC % Medical examinations Chengdu iKang Guobin Ommay Health Examination Hospital Co., Ltd. (“Chengdu Ommay”) April 01, 2015 PRC % Medical examinations Beijing iKang Guobin Headquarter Base Clinic Co., Ltd. (“Beijing Headquarter Base”) February 1, 2016 PRC % Medical examinations
Schedule of financial statements amounts and balances of the VIE entities, included in the accompanying consolidated financial statements (after inter-company elimination)	As of March 31, 2015 2016 Cash and cash equivalents $ $ Accounts receivable and other current assets Total current assets Property and equipment, net Acquired intangible assets, net Other noncurrent assets Total non-current assets Total assets Deferred revenues Accounts payable and other current liabilities Total current liabilities Total non-current liabilities Total liabilities $ $ For the years ended March 31, 2014 2015 2016 Net revenues $ $ $ Net income $ $ $ For the years ended March 31, 2014 2015 2016 Net cash provided by operating activities $ $ $ Net cash used in investing activities $ ) $ ) $ ) Net cash provided by financing activities $ $ $

SUMMARY OF SIGNIFICANT ACCOUN40

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of estimated useful lives of property and equipment	Computer equipment and application software 5 years Furniture and fixture 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term
Schedule of estimated average useful lives of finite-lived intangible assets	Weighted average (years) Range (years) Customer relationship 5.5 2.1~10.0 Non-compete agreement 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating license 2.9 0.3~5.0 Favorable lease contract 7.1 2.8~9.8

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	12 Months Ended
	Mar. 31, 2016
Shanghai Huajian Management
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.5 years Trade name Indefinite Operating license 3.0 years Goodwill Deferred tax liability ) Total Total fair value of business acquired $
iKang Shenyang Hospital
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful life Net tangible assets: Non-current assets $ Total Intangible assets acquired: Operating license 4.0 years Goodwill Deferred tax liability ) Total Total consideration $
iKang Shenyang Ningshan Hospital
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Non-current assets $ Total Intangible assets acquired: Favorable lease contract 2.8 years Operating license 5.0 years Goodwill Deferred tax liability ) Total Total consideration $
Gold iKang Shenyang Hospital
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Non-current assets $ Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 2.5 years Goodwill Deferred tax liability ) Total Total consideration $
iKang Tianjin Hedong Dongrun
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.4 years Goodwill Deferred tax liability ) Total Total consideration $
iKang Tianjin Hexi Fenghui
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.9 years Goodwill Deferred tax liability ) Total Total consideration $
WA HK
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 3.0 years Operating license 1.9-2.8 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $
Chengdu Ommay
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.0 year Goodwill Deferred tax liability ) Total Total consideration $
Yinchuan Ciming
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Non-current assets $ Total Intangible assets acquired: Customer relationship 5.0 years Operating license 2.0 years Goodwill Deferred tax liability ) Total Non-controlling interests ) Total consideration $
Beijing Tianzhikangjian
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 4.5 years Operating license 1.7-4.6 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $
Yantai Hongkang
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 3.8 years Goodwill Deferred tax liability ) Total Total consideration $
Shandong Ciming Clinics
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful life Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.3-4.4 years Goodwill Deferred tax liability ) Total Non-controlling interests ) Total consideration $
Wuhan Xiandai Sunny
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.9 years Goodwill Deferred tax liability ) Total Total consideration $
Xi'an iKang
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 3.6 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $
Guizhou Wishstar
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Total Intangible assets acquired: Customer relationship 5.0 years Operating license 2.0 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $
Acquisitions during the year ended Maech 31, 2015 and previous
Acquisitions
Summary of the unaudited pro forma information	Years ended March 31, 2014 2015 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc. $ $
Acquisitions during the year ended Maech 31, 2016
Acquisitions
Summary of the unaudited pro forma information	Years ended March 31, 2015 2016 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc. $ $

ACCOUNTS RECEIVABLE, NET (Table

ACCOUNTS RECEIVABLE, NET (Tables)	12 Months Ended
	Mar. 31, 2016
ACCOUNTS RECEIVABLE, NET
Schedule of accounts receivable	As of March 31, 2015 2016 Accounts receivable $ $ Less: allowance for doubtful accounts Accounts receivable, net $ $
Schedule of movement of allowance for doubtful accounts	As of March 31, 2014 2015 2016 Balance at beginning of year $ $ $ Charge to expenses Write off ) ) ) Exchange difference ) Balance at end of year $ $ $

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Mar. 31, 2016
INVENTORIES
Schedule of inventories	As of March 31, 2015 2016 Medical consumable supplies $ $

PREPAID EXPENSES AND OTHER CU44

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Mar. 31, 2016
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Schedule of prepaid expenses and other current assets	As of March 31, 2015 2016 Advance payments for acquisitions $ $ Advance to suppliers Staff advance Prepaid rental expenses Prepaid expenses (1) Advance payments for investment — Other receivable Interest income receivable $ $ (1) Prepaid expenses mainly consist of amounts paid for professional fees and advertisement fees for which relating services have not been provided.

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Mar. 31, 2016
PROPERTY AND EQUIPMENT, NET
Schedule of property and equipment, net	As of March 31, 2015 2016 Medical equipment $ $ Leasehold improvements Computer equipment and application software Furniture and fixtures Motor vehicles Construction in progress Less: accumulated depreciation and amortization Property and equipment, net $ $

LONG-TERM INVESTMENTS (Tables)

LONG-TERM INVESTMENTS (Tables)	12 Months Ended
	Mar. 31, 2016
LONG-TERM INVESTMENTS
Schedule of long-term investments	As of March 31, 2015 2016 Cost method investments (1) $ $ Equity method investments (2) — Available-for-sale investments (3) — $ $
Summarized condensed financial information of the equity method investments	As of March 31, 2015 2016 Current assets $ — $ Non-current assets — Current liabilities — Non-current liabilities — — For the years ended March 31, 2014 2015 2016 Total revenues $ — $ — $ Gross profits — — Loss from operations — — ) Net loss — — )

ACQUIRED INTANGIBLE ASSETS, N47

ACQUIRED INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	Mar. 31, 2016
ACQUIRED INTANGIBLE ASSETS, NET
Schedule of gross carrying amount, accumulated amortization and net carrying amount of the intangible assets	As of March 31, 2015 2016 Acquired intangible assets not subject to amortization Trade-name $ $ Acquired intangible assets subject to amortization Customer relationship Operating licenses Favorable lease contracts Contract backlog Non-compete agreement Less: accumulated amortization Customer relationship Operating licenses Favorable lease contracts Contract backlog Non-compete agreement Less: impairment Intangible assets, net $ $

GOODWILL (Tables)

GOODWILL (Tables)	12 Months Ended
	Mar. 31, 2016
GOODWILL
Schedule of changes in carrying amounts of goodwill	As of March 31, 2015 2016 Gross amount: Beginning balance $ $ Additions for the year by acquisitions of Beijing Tianzhikangjian — Yantai Hongkang — Yinchuan Ciming — Chengdu Ommay — Shangdong Ciming — Xi’an iKang — Wuhan Xiandai Sunny — Guizhou Winstar — Shanghai Huajian Management — iKang Shenyang Hospital — iKang Shenyang Ningshan Hospital — Gold iKang Shenyang Hospital — iKang Tianjin Hedong Dongrun — iKang Tianjin Hexi Fenghui — WA HK — Exchange difference ) Ending balance Accumulated impairment loss: Beginning balance Exchange difference ) Ending balance Goodwill $ $

ACCRUED EXPENSES AND OTHER CU49

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Mar. 31, 2016
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Schedule of accrued expenses and other current liabilities	As of March 31, 2015 2016 Acquisitions consideration payable (1) $ $ Accrued payroll and welfare Accrued rental expense Other payables Collection received on behalf of and payable to the former shareholders of business acquired — Other taxes payable Interest expense payable Accrued social insurance Accrued outsourcing cost Dividend payable (2) — $ $ (1) Acquisitions consideration payable consists of remaining payables to sellers of the acquired business for the years ended March 31, 2015 and 2016, which were as follows: (2) As of March 31, 2015, the balance represents the dividend payable for non-controlling interest shareholders of MediFast which was paid in the year ended March 31, 2016.
Schedule of acquisitions consideration payable	As of March 31, 2015 2016 Beijing MZ $ — $ Xi’an iKang — Beijing Tianzhikangjian — Yantai Hongkang — Yinchuan Ciming — Wuhan Xiandai Sunny — Shandong Ciming — iKang Shanghai Jianwei — Nanjing Aoyang Yuanhua — Zhejiang Ailikang — Shanghai Huajian Management — Suzhou Aoyang iKang Tianjin Hedong Dongrun iKang Tianjin Hexi Fenghui Gold iKang Shenyang Hospital WA Health Care — $ $

SHORT TERM BORROWINGS (Tables)

SHORT TERM BORROWINGS (Tables)	12 Months Ended
	Mar. 31, 2016
SHORT TERM BORROWINGS
Schedule of short-term borrowings	As of March 31, 2015 2016 Bank borrowings $ $ $ $

LONG TERM BORROWINGS (Tables)

LONG TERM BORROWINGS (Tables)	12 Months Ended
	Mar. 31, 2016
LONG TERM BORROWINGS
Schedule of long term borrowings	As of March 31, 2015 2016 Bank borrowings (1) $ — $ Long-term loans (2) — $ $ — $ (1) In December 2015, iKang Holding signed a 2-year loan framework agreement with China Merchants Bank to satisfy the daily operating need of the Shanghai clinics. The annual interest rate is 4.75%. In December 2015, iKang Holding borrowed a 2-year loan of $12,345 according to the framework agreement. Upon the fact that the nominal annual interest rate is equivalent to the required rate of return asked by the China Merchants Bank, the fair value of this outstanding long term borrowing as of March 31, 2016 was equal to the principal. Interest expense incurred for the years ended March 31, 2016 was $145. The effective interest rate for the year ended March 31, 2016 was 4.75%. (2) In December 2015, a subsidiary of the Group entered into a series of agreements to issue certain long-term loans with principal amount totaling $217,122 (equivalent to RMB 1,400,000) to four third-party investors (“bond holders”) with terms vary from eighteen months to twenty-four months. According to the agreements, the Group agreed, by putting their best effort, to coordinate with its buyer group relating to its privatization process, to facilitate the long-term loans be converted into certain equity interest of the future listing vehicle at the then best price. The interest rate is 5% but subject to adjustment based on the privatization proceeding. If the Group successfully completes the privatization before the maturity date of the long-term loans, and the bond holders decide to convert into the future listing vehicle’s shares, no interest will be charged; however, if the bond holders decide not to convert, the interest rate will be 5%. Furthermore, if the privatization is not completed before the maturity date of the long-term loans, or the Group fails to put their best effort to facilitate the bond holders convert the loan into shares, the interest rate will increase by 5%~20%. It’s most probable, per management’s estimate, that the Group will complete the privatization and successfully arrange the terms to facilitate the bond holders’ conversion, and accordingly 5% interest rate is applied to calculate the interest expenses for the year ended March 31, 2016. Interest expense incurred for the years ended March 31, 2015 and 2016 was nil and $2,869, respectively. The effective interest rate for the year ended March 31, 2016 was 5%.

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2016
INCOME TAXES
Schedule of current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group's PRC subsidiaries and VIE entities	Years ended March 31, 2014 2015 2016 Current tax expenses $ $ $ Deferred tax benefits ) ) ) Income tax expenses $ $ $
Schedule of principal components of the deferred income tax assets and liabilities	As of March 31, 2015 2016 Current deferred tax assets: Accrued expenses $ $ Accrued payroll Allowance for doubtful accounts Less: Valuation allowance ) ) Current deferred tax assets $ $ Non-current deferred tax assets: Depreciation and amortization $ $ Impairment of long-lived assets Net operating tax loss carry-forwards Less: Valuation allowance ) ) Non-current deferred tax assets $ $ As of March 31, 2015 2016 Non-current deferred tax liabilities: Intangible assets $ $ Non-current deferred tax liabilities $ $
Schedule of reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes	For the year ended March 31, 2014 2015 2016 Income before provision for income taxes and (loss)/gain from equity method investments $ $ $ PRC statutory tax rate % % % Income tax at statutory tax rate Change in valuation allowance ) Expenses not deductible for tax purposes Effect of income tax rate difference for entities under individual income tax rate of 35% Loss utilized for entities under individual income tax rate of 35% ) ) — Effect of income tax rate differences in other jurisdictions Tax holidays and preferential tax rates — ) ) Income tax expenses $ $ $

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Mar. 31, 2016
NET INCOME (LOSS) PER SHARE
Schedule of calculation of net income (loss) per share	For the years ended March 31, 2014 2015 2016 Net income attributable to iKang Guobin Healthcare Group, Inc. $ $ $ Deemed dividend to Series A shares — — Deemed dividend to Series B shares — — Deemed dividend to Series C shares — — Deemed dividend to Series D shares — Deemed dividend to Series E shares — — Deemed dividend to Series F shares — Undistributed earnings allocated to Series A shares — Undistributed earnings allocated to Series B shares — Undistributed earnings allocated to Series C shares — Undistributed earnings allocated to Series D shares — Undistributed earnings allocated to Series E shares — Undistributed earnings allocated to Series F shares — For the years ended March 31, 2014 2015 2016 Net (loss) income attributed to common and preferred shareholders for computing net income per common share- basic and diluted (1) $ ) $ $ Numerator: Series A shares- Deemed dividend — — Undistributed earnings allocation — — Series B shares- Deemed dividend — — Undistributed earnings allocation — — Series C shares- Deemed dividend — — Undistributed earnings allocation — Series D shares- Deemed dividend — Undistributed earnings allocation — — Series E shares- Deemed dividend — — Undistributed earnings allocation — — Series F shares- Deemed dividend — Undistributed earnings allocation — — Net (loss) income attributed to common shareholders for computing net income per common share- basic and diluted (1) ) — For the years ended March 31, 2014 2015 2016 Denominator: Weighted average common shares outstanding used in computing diluted net income per common share-basic (2) Weighted average shares outstanding used in computing net income per common shares-diluted (2) Weighted average shares used in computing basic net income per shares Series A shares — Series B shares — Series C shares — Series D shares — Series E shares — Series F shares — Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-basic $ ) $ $ Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-diluted $ ) $ $ Net income per Series A shares $ $ — Net income per Series B shares $ $ — Net income per Series C shares $ $ — Net income per Series D shares $ $ — Net income per Series E shares $ $ — Net income per Series F shares $ $ — Notes: (1) The Class A, Class B and Class C common shares enjoy the same dividend participating right, therefore earnings per share of each class was not separately presented. (2) The calculation of the weighted average number of common shares for the purpose of diluted net income (loss) per share has considered the effect of certain potentially dilutive securities.

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Mar. 31, 2016
SHARE-BASED COMPENSATION.
Summary of information regarding options granted	For the years ended March 31, 2014 2015 2016 Weighted Weighted Weighted Weighted Weighted Weighted average average average average average average exercise fair value exercise fair value exercise fair value Number of price per per option Number of price per per option Number of price per per option options option at grant date options option at grant date options option at grant date Outstanding on April 1 of year $ $ $ $ $ $ Granted — — — Exercised — — — ) ) Forfeited ) ) ) Outstanding on March 31 of year $ $ $ $ $ $
Summary of information with respect to share options outstanding	Option outstanding Option exercisable Weighted Weighted Aggregate Weighted Aggregate average average intrinsic average intrinsic remaining Exercise values as of Exercise values as of Number contractual price per March 31, Number price per March 31, Range of exercise price outstanding life in years option 2016 exercisable option 2016 $0.01 $ $ $ $ $1.00-$2.00 $ $ $5.13 $ $ $6.00 $ $ $ $
Schedule of assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods	Risk-free interest rate of return Contractual term Volatility Dividend yield Exercise price December 31, 2010 % 10 years % — 5.13 June 8, 2011 % 2.39 years % — 0.01 February 17, 2012 % 10 years % — 5.13 March 18, 2013 % 10 years % — 5.13~6.00 September 12, 2013 % 10 years % — 6.00 February 27, 2014 % 10 years % — 5.13~6.00 August 1, 2014 % 10 years % — 16.18 October 28, 2014 % 10 years % — 5.13~6.00 February 27, 2015 % 10 years % — 5.13 (1) Risk-free interest rate Risk-free interest rate was estimated based on the yield to maturity of China international government bonds with a maturity period close to the expected term of the options. (2) Contractual term The Company used the original contractual term. (3) Volatility The volatility of the underlying common shares during the life of the options was estimated based on the historical stock price volatility of comparable listed companies over a period comparable to the expected term of the options. (4) Dividend yield The dividend yield was estimated by the Group based on its expected dividend policy over the expected term of the options. (5) Exercise price The exercise price of the options was determined by the Group’s Board of Directors. (6) Fair value of underlying common shares The estimated fair value of the common shares underlying the options as of the respective grant dates was determined based on a retrospective valuation, which used management’s best estimate for projected cash flows as of each valuation date.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Mar. 31, 2016
FAIR VALUE MEASUREMENTS
Schedule of outstanding foreign currency forward contracts	As of March 31, 2015 2016 Balance at beginning of year $ $ — Loss from forward contracts ) — Settled ) — Balance at end of year $ — $ —
Schedule of assets that are measured at fair value on a recurring basis	As of March 31, 2015 As of March 31, 2016 Fair Value Measurements at the Reporting Date Using Fair Value Measurements at the Reporting Date Using Quoted prices in Significant Quoted prices in Significant active markets other Significant active markets other Significant for identical observable unobservable for identical observable unobservable instruments inputs inputs Total instruments inputs inputs Total (level 1) (level 2) (level 3) balance (level 1) (level 2) (level 3) balance Long-term investments Available-for-sale investments — — — — — Long-term loans — — — — — — Long-term bank borrowings — — — — — — Contingent consideration — — — — — — Total $ — $ — $ — $ — $ $ — $ $

RELATED PARTY BALANCES AND TR56

RELATED PARTY BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Mar. 31, 2016
RELATED PARTY BALANCES AND TRANSACTIONS
Schedule of amounts due from related parties of the Group	As of March 31, 2015 2016 Amount due from a related party $ — $

NONCONTROLLING INTEREST (Tables

NONCONTROLLING INTEREST (Tables)	12 Months Ended
	Mar. 31, 2016
NONCONTROLLING INTEREST
Schedule of noncontrolling interest	iKang iKang iKang Shenzhen Shanghai Zhejiang WA Shanghai Shanghai Fujian Hospital Jianwei Beijing iKang Beijing Yinchuan Shandong Xi’an Physician Guizhou Wuhu BVI HK Gubei Lujiazui iKang Management Management Jiandatong MediFast Changzhou Tianzhikangjian Ciming Ciming iKang alliance winstar iKang Total Balance at March 31, 2013 $ $ — $ $ $ $ $ — $ — $ — $ — $ — $ — $ — $ — $ — $ — $ — $ Addition of non-controlling interest in connection with establishment of Beijing Jiandatong — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with acquisition of MediFast — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with establishment of iKang Changzhou — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holder of Shanghai Wangzu Guobin Medical Center Co., Ltd — — ) — — — — — — — — — — — — — — ) Share of profit (loss) — ) ) ) — — — — — — — Purchase of non-controlling interest — — — ) — — — — — — — — — — — — — ) Other comprehensive income ) — ) ) ) ) ) ) ) — — — — — — — ) Balance at March 31, 2014 $ $ — $ $ — $ $ $ $ $ $ $ — $ — $ — $ — $ — $ — $ — $ Capital contribution of non-controlling interest holder of Beijing Jiandatong — — — — — — — — — — — — — — — — Capital contribution of non-controlling interest holder of Shanghai Jianwei — — — — — — — — — — — — — — — — Capital contribution of non-controlling interest Addition of non-controlling interest in connection with acquisition of WA HK — — — — — — — — — — — — — — — — Capital contribution of non-controlling interest holder of WA HK — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holder of MediFast — — — — — — — — ) — — — — — — — — ) Share of profit (loss) ) — ) ) ) ) — — — — — — — Other comprehensive income — — — — — — — — — — — — — Balance at March 31, 2015 $ $ $ $ — $ $ ) $ $ $ $ $ — $ — $ — $ — $ — $ — $ — $ Additional purchase of non-controlling interest — — ) — — — — — — — ) — — — — — — ) Addition of non-controlling interest in connection with acquisitions — — — — — — — — — — — — Addition of non-controlling interest in connection with capital injection — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with new establishments — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holders — — ) — — — — — ) — — — — — — — — ) Share of profit (loss) ) — ) ) ) ) ) ) ) ) ) Other comprehensive income — ) — — ) — ) — ) ) ) ) ) Balance at March 31, 2016 $ $ $ — $ — $ $ ) $ ) $ $ $ $ $ $ $ $ $ $ $

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Mar. 31, 2016
SEGMENT INFORMATION
Schedule of reconciliation of gross profit by segment to consolidated income from operations	For the years ended March 31, 2014 2015 2016 Net revenues: Medical examinations and other medical services $ $ $ Dental services — Total net revenues Cost of revenues: Medical examinations and other medical services Dental services — Total cost of revenues Gross profit: Medical examinations and other medical services Dental services — Total gross profit Operating expenses: Selling and marketing expenses General and administrative expenses Research and development expenses Total operating expenses Income from operations $ $ $
Schedule of components of net revenues	For the years ended March 31, 2014 2015 2016 Medical examinations $ $ $ Disease screening Other services Medical examinations and other medical services Dental services — Total $ $ $

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Mar. 31, 2016
COMMITMENTS AND CONTINGENCIES
Schedule of future minimum lease payments	Future minimum lease payments under such leases as of March 31, 2016 were as follows: 2017 $ 2018 2019 2020 2021 After 2021 $
Schedule of future minimum principal payments related to long-term borrowings	Future minimum principal payments related to the Company’s long-term borrowings as of March 31, 2016 are as follows (see Note 13): 2017 $ — 2018 2019 — 2020 — 2021 — After 2021 — $

ORGANIZATION AND PRINCIPAL AC60

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details)	Mar. 01, 2014	Jan. 31, 2012	Mar. 31, 2016item	Jul. 31, 2013
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Ratio of shares swap with existing shareholders of iKang Guobin Healthcare Group, Inc.	1
Maximum percentage of direct foreign ownership allowed in business entities providing healthcare services in the PRC		70.00%
Yuanhua
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Interest acquired (as a percent)				100.00%
iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Number of shareholders who are directors and shareholders of the Company			2
Mr. Ligang Zhang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			25.60%
Mr. Ligang Zhang | iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			50.00%
Mr. Boquan He
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			14.80%
Mr. Boquan He | iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			50.00%
iKang Holding | iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Total equity interest held, including indirect ownership			100.00%
Yalong Daoyi | iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			20.00%
Mr. Haiqing Hu | Beijing Jiandatong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Mr. Haiqing Hu | Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Mr. Lei Zhao | Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			20.00%
Exclusive Equity Option Agreement
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Term of agreement			10 years
Exclusive Services Agreement
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Term of agreement			10 years
iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			73.00%
Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Beijing Jiandatong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			80.00%
iKang Online
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Technology
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shenzhen iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Yalong Daoyi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Guangzhou Huanshi East/Tianhe
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Xikang Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Gubei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Shanghai Pudong Avenue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shenzhen Hospital Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			66.00%
iKang Shenzhen Nanshan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			66.00%
iKang Beijing Lidu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Nanjing Xinjiekou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenzhen Luohu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Jianguomen
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Zhongguancun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Kunming Lake
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Yansha East
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Yangpu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chengdu Waishuangnan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Lujiazui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Wenzhong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			71.00%
iKang Beijing Xuanwumen
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Nanjing Gulou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenzhen Futian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Fujian iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			71.00%
iKang Fuzhou Gulou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			71.00%
iKang Beijing Xinei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Yan'an West Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Zhonghuan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Jing'an
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Yan'an East Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Jianzhiwei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Hangzhou Wenhui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Tianjin Heping
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Suzhou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Suzhou Zhuoyue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Changchun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chengdu Hongzhaobi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chongqing
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Guangzhou Wokang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenzhen Kefa
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Jianwei Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			90.00%
Yuanhua Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Nanjing Jun'an
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Nanjing Aoyang Shunkang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Jiangyin
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Zhejiang Ailikang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Hangzhou Aibo
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Jun'an
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Yayun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Changzhou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			62.50%
iKang Beijing Baishi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Chengdu Gaoxin iKang West City
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Dental Hospital Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Wanzhishou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Huajian Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Huajian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Jinxiu Huajian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Jinshen Huajian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenyang Hospital
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenyang Ningshan Hospital
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Gold iKang Shenyang Hospital
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Tianjin Hedong Dongrun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Tianjin Hexi Fenghui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Wuxi Woshi Hongtai
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Beijing Woshi Hongtai
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Beijing Zhenjing
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Shanghai Zhenjing Hospital Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Shanghai Zhenjing
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Beijing Shunping
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Baiyunlu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chongqing Zhuoyue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Ikang Tianjin Hexi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Tianjin Yuecheng
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Health Cloud
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
China Physician Alliance
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			82.00%
Xi'an iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Xi'an Lianhu Yinglun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Xi'an Yanta Yinglun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Xi'an Weiyang Yinglun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Yantai Hongkang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Yantai Hongkang Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Yantai Hongkang Examination Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Yantai Hongkang Examination
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Guizhou iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			60.00%
Guizhou Wishstar
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			60.00%
iKang Weifang Gaoxin
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Wuhu iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			60.00%
iKang Chengdu Gaoxin
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shandong iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Jinan Zhuoyue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Yinchuan Ciming
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Ningxia iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Hangzhou Jiangnan Avenue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Ningbo Haishu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Nanjing Hedingqiao
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Wuhan Xiandai Sunny
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Foshan iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Beijing Tianjian Sunny
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
Beijing Anhuaqiao
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
Beijing Fengtai
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
Beijing Konggang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
iKang Beijing Jingchao
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
iKang Beijing Jingchun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
Guangzhou Zhenxing
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
Changsha iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
iKang Changsha Sunny Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
iKang Beijing Jingxi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
Yantai Ciming
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Yantai Ciming Laishan Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Weifang Kuiwen
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Weihai Ciming Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Weihai Ciming
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Chengdu Ommay
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Beijing Headquarter Base
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Guobin
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Beijing iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Shanghai iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
iKang Zhejiang BVI
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			73.00%
Zhejiang iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			73.00%
Bayley & Jackson (Hong Kong)
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
iKang Beijing Ritan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Yuanhua HK (HongKong)
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
MediFast
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			80.00%
Yuanhua WFOE
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
WA HK
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			70.00%
ikang Cloud HK
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
(iKang Shanghai) Financing Lease
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%

ORGANIZATION AND PRINCIPAL AC61

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Financial statements amounts and balances of the VIE entities included in the accompanying consolidated financial statements
Cash and cash equivalents	$ 108,111	$ 97,336	$ 30,221	$ 63,154
Total current assets	305,703	278,665
Property and equipment, net	130,170	105,022
Acquired intangible assets, net	37,179	30,634
TOTAL ASSETS	803,641	499,001
Deferred revenues	61,881	38,457
Total current liabilities	199,000	163,147
TOTAL LIABILITIES	438,239	170,653
Net revenues	370,812	290,781	202,304
Net income	16,488	27,396	21,926
Net cash provided by operating activities	43,602	41,097	34,303
Net cash used in investing activities	(261,533)	(147,062)	(96,714)
Net cash provided by financing activities	$ 237,465	$ 173,570	$ 29,342
Net revenues from VIE entities as a percentage of consolidated net revenues	89.10%	85.40%	84.10%
Assets from VIE entities as a percentage of consolidated total assets	82.20%	58.00%
Liabilities from VIE entities as a percentage of consolidated total liabilities	94.90%	88.90%
VIE entities
Financial statements amounts and balances of the VIE entities included in the accompanying consolidated financial statements
Cash and cash equivalents	$ 92,231	$ 22,870
Accounts receivable and other current assets	128,400	94,658
Total current assets	220,631	117,528
Property and equipment, net	126,897	101,237
Acquired intangible assets, net	35,122	29,081
Other noncurrent assets	277,689	41,562
Total non-current assets	439,708	171,880
TOTAL ASSETS	660,339	289,408
Deferred revenues	52,210	31,786
Accounts payable and other current liabilities	124,754	113,250
Total current liabilities	176,964	145,036
Total non-current liabilities	238,889	6,670
TOTAL LIABILITIES	415,853	151,706
Net revenues	330,391	248,202	$ 170,226
Net income	12,614	35,643	20,948
Net cash provided by operating activities	92,294	76,495	16,927
Net cash used in investing activities	(239,274)	(91,833)	(29,649)
Net cash provided by financing activities	$ 216,341	$ 26,882	$ 10,740

SUMMARY OF SIGNIFICANT ACCOUN62

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Term deposits
Maturity terms of term deposits- minimum	3 months
Maturity terms of term deposits- maximum	1 year
Foreign currency risk
Aggregate amounts of cash and cash equivalent denominated in RMB	$ 108,111	$ 97,336	$ 30,221	$ 63,154
Foreign currency risk | China, Yuan Renminbi
Foreign currency risk
Aggregate amounts of cash and cash equivalent denominated in RMB	$ 98,577	$ 30,172

SUMMARY OF SIGNIFICANT ACCOUN63

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Mar. 31, 2016
Computer equipment and application software
Property and equipment, net
Estimated useful life	5 years
Furniture and fixtures
Property and equipment, net
Estimated useful life	5 years
Medical equipment
Property and equipment, net
Estimated useful life	10 years
Motor vehicles
Property and equipment, net
Estimated useful life	5 years

SUMMARY OF SIGNIFICANT ACCOUN64

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)	12 Months Ended
	Mar. 31, 2016
Weighted average
Intangible assets, net
Estimated useful lives	5 years 3 months 18 days
Customer relationship | Weighted average
Intangible assets, net
Estimated useful lives	5 years 6 months
Customer relationship | Minimum
Intangible assets, net
Estimated useful lives	2 years 1 month 6 days
Customer relationship | Maximum
Intangible assets, net
Estimated useful lives	10 years
Non-compete agreement | Weighted average
Intangible assets, net
Estimated useful lives	3 years
Non-compete agreement | Minimum
Intangible assets, net
Estimated useful lives	2 years
Non-compete agreement | Maximum
Intangible assets, net
Estimated useful lives	3 years
Contract backlog | Weighted average
Intangible assets, net
Estimated useful lives	8 months 12 days
Contract backlog | Minimum
Intangible assets, net
Estimated useful lives	4 months 24 days
Contract backlog | Maximum
Intangible assets, net
Estimated useful lives	10 months 24 days
Operating licenses | Weighted average
Intangible assets, net
Estimated useful lives	2 years 10 months 24 days
Operating licenses | Minimum
Intangible assets, net
Estimated useful lives	3 months 18 days
Operating licenses | Maximum
Intangible assets, net
Estimated useful lives	5 years
Favorable lease contracts | Weighted average
Intangible assets, net
Estimated useful lives	7 years 1 month 6 days
Favorable lease contracts | Minimum
Intangible assets, net
Estimated useful lives	2 years 9 months 18 days
Favorable lease contracts | Maximum
Intangible assets, net
Estimated useful lives	9 years 9 months 18 days

SUMMARY OF SIGNIFICANT ACCOUN65

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Maximum
Revenue recognition
Expiry period of components from date of purchase	1 year
PRC subsidiaries and VIE entities | PRC
Revenue recognition
Business tax on the revenues earned from providing services and selling products (as a percent)	5.00%
Business tax recognized	$ 2,692	$ 2,156	$ 2,084

SUMMARY OF SIGNIFICANT ACCOUN66

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 6) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Non-monetary exchange
Revenues recognized for non-monetary transactions	$ 1,767	$ 571	$ 706

ACQUISITIONS - General Informat

ACQUISITIONS - General Information (Details) $ / shares in Units, $ in Thousands

Jan. 22, 2016USD ($)

Jan. 01, 2016USD ($)

Dec. 17, 2015USD ($)clinic

Aug. 14, 2015USD ($)city

Jun. 02, 2015USD ($)

May 29, 2015USD ($)

May 18, 2015USD ($)

Apr. 16, 2015USD ($)shareholder

Mar. 03, 2015USD ($)clinic

Feb. 17, 2015USD ($)

Dec. 19, 2014USD ($)

Nov. 19, 2014USD ($)

Nov. 14, 2014USD ($)

Aug. 01, 2014$ / sharesshares

Jun. 30, 2014USD ($)

May 31, 2014USD ($)

Jan. 31, 2014USD ($)shareholder

Mar. 31, 2015USD ($)

Mar. 31, 2016USD ($)

Jul. 01, 2014

Acquisitions

Number of third party shareholders | shareholder

2

Equity interest previously held by counterparty (as a percent)

67.00%

Shanghai Huajian Management

Acquisitions

Equity interest acquired (as a percent)

33.00%

Consideration

$ 6,376

Cash consideration

$ 5,382

$ 7,484

Additional equity interest to be acquired (as a percent)

30.00%

37.00%

Number of options granted | shares

300,000

Exercise price for the option (in dollars per share) | $ / shares

$ 16.18

Fair value of the options granted

$ 7,202

Fair value remeasured for existing interest

$ 7,661

Fair value remeasurement gain

$ 883

iKang Shenyang Hospital

Acquisitions

Equity interest acquired (as a percent)

100.00%

Cash consideration

$ 1,636

Acquisition-related costs

$ 0

iKang Shenyang Ningshan Hospital

Acquisitions

Equity interest acquired (as a percent)

100.00%

Cash consideration

$ 1,628

Acquisition-related costs

$ 0

Gold iKang Shenyang Hospital

Acquisitions

Equity interest acquired (as a percent)

100.00%

Cash consideration

$ 6,447

Acquisition-related costs

$ 0

iKang Tianjin Hedong Dongrun

Acquisitions

Equity interest acquired (as a percent)

100.00%

Cash consideration

$ 3,032

Acquisition-related costs

$ 0

iKang Tianjin Hexi Fenghui

Acquisitions

Equity interest acquired (as a percent)

100.00%

Cash consideration

$ 2,073

Acquisition-related costs

$ 0

WA HK

Acquisitions

Equity interest acquired (as a percent)

70.00%

Cash consideration

$ 9,934

Number of medical centers | clinic

2

Acquisition-related costs

$ 0

Chengdu Ommay

Acquisitions

Equity interest acquired (as a percent)

100.00%

Cash consideration

$ 4,033

Number of third party shareholders | shareholder

4

Acquisition-related costs

$ 0

Yinchuan Ciming

Acquisitions

Equity interest acquired (as a percent)

70.00%

Cash consideration

$ 4,840

Acquisition-related costs

$ 0

Beijing Tianzhikangjian

Acquisitions

Equity interest acquired (as a percent)

100.00%

Cash consideration

$ 21,497

Acquisition-related costs

$ 0

Yantai Hongkang

Acquisitions

Cash consideration

$ 7,422

Acquisition-related costs

$ 0

Yantai Hongkang Tijian Co Ltd

Acquisitions

Equity interest acquired (as a percent)

100.00%

Shandong Ciming Clinics

Acquisitions

Equity interest acquired (as a percent)

70.00%

Number of cities in which acquiree's medical centers/clinics are located | city

3

Cash consideration

$ 7,260

Acquisition-related costs

$ 0

Wuhan Xiandai Sunny

Acquisitions

Equity interest acquired (as a percent)

100.00%

Cash consideration

$ 4,786

Acquisition-related costs

$ 0

Xi'an iKang

Acquisitions

Equity interest acquired (as a percent)

70.00%

Cash consideration

$ 6,721

Ownership percentage in medical centers (as a percent)

100.00%

Number of medical centers | clinic

3

Contingent consideration

$ 2,846

Acquisition-related costs

$ 0

Guizhou Wishstar

Acquisitions

Equity interest acquired (as a percent)

60.00%

Cash consideration

$ 8,170

Acquisition-related costs

$ 0

Tianjian Sunny | Beijing Tianzhikangjian

Acquisitions

Acquiree's interest in a subsidiary (as a percent)

82.85%

ADS | Shanghai Huajian Management

Acquisitions

Exercise price for the option (in dollars per share) | $ / shares

$ 8.09

ACQUISITIONS - Purchase Price A

ACQUISITIONS - Purchase Price Allocation (Details) - USD ($) $ in Thousands

Mar. 31, 2016

Jan. 22, 2016

Jan. 01, 2016

Dec. 17, 2015

Aug. 14, 2015

Jun. 02, 2015

May 29, 2015

May 18, 2015

Apr. 16, 2015

Mar. 31, 2015

Mar. 05, 2015

Feb. 17, 2015

Dec. 19, 2014

Nov. 19, 2014

Nov. 14, 2014

Jul. 01, 2014

Net tangible assets:

Goodwill

$ 108,839

$ 72,101

Shanghai Huajian Management

Net tangible assets:

Current assets

$ 4,738

Non-current assets

5,673

Current liabilities

(5,413)

Total

4,998

Goodwill

14,032

Deferred tax liability

(3,108)

Total

22,731

Total consideration

27,729

iKang Shenyang Hospital

Net tangible assets:

Non-current assets

$ 645

Total

645

Goodwill

982

Deferred tax liability

(101)

Total

991

Total consideration

1,636

iKang Shenyang Ningshan Hospital

Net tangible assets:

Non-current assets

$ 7

Total

7

Goodwill

1,124

Deferred tax liability

(166)

Total

1,621

Total consideration

1,628

Gold iKang Shenyang Hospital

Net tangible assets:

Non-current assets

$ 2,832

Current liabilities

(55)

Total

2,777

Goodwill

3,464

Deferred tax liability

(68)

Total

3,670

Total consideration

6,447

iKang Tianjin Hedong Dongrun

Net tangible assets:

Current assets

$ 141

Non-current assets

634

Current liabilities

(90)

Total

685

Goodwill

2,099

Deferred tax liability

(279)

Total

2,347

Total consideration

3,032

iKang Tianjin Hexi Fenghui

Net tangible assets:

Current assets

133

Non-current assets

356

Current liabilities

(3)

Total

486

Goodwill

1,228

Deferred tax liability

(120)

Total

1,587

Total consideration

2,073

WA HK

Net tangible assets:

Current assets

$ 1,413

Non-current assets

5,459

Current liabilities

(3,006)

Total

3,866

Goodwill

7,570

Deferred tax liability

(666)

Total

9,456

Non-controlling interest

(3,388)

Total consideration

9,934

Chengdu Ommay

Net tangible assets:

Current assets

$ 748

Non-current assets

499

Current liabilities

(734)

Total

513

Goodwill

2,853

Deferred tax liability

(285)

Total

3,520

Total consideration

4,033

Yinchuan Ciming

Net tangible assets:

Non-current assets

$ 927

Total

927

Goodwill

4,406

Deferred tax liability

(493)

Total

5,526

Non-controlling interest

(1,613)

Total consideration

4,840

Beijing Tianzhikangjian

Net tangible assets:

Current assets

$ 7,094

Non-current assets

6,382

Current liabilities

(4,751)

Total

8,725

Goodwill

15,542

Deferred tax liability

(1,092)

Total

17,822

Non-controlling interest

(5,050)

Total consideration

21,497

Yantai Hongkang

Net tangible assets:

Current assets

$ 592

Non-current assets

1,340

Current liabilities

(124)

Total

1,808

Goodwill

3,690

Deferred tax liability

(722)

Total

5,614

Total consideration

7,422

Shandong Ciming Clinics

Net tangible assets:

Current assets

$ 2,770

Non-current assets

4,099

Current liabilities

(1,544)

Total

5,325

Goodwill

2,361

Deferred tax liability

(748)

Total

4,351

Non-controlling interest

(2,416)

Total consideration

7,260

Wuhan Xiandai Sunny

Net tangible assets:

Current assets

$ 159

Non-current assets

793

Total

952

Goodwill

3,131

Deferred tax liability

(315)

Total

3,834

Total consideration

4,786

Xi'an iKang

Net tangible assets:

Current assets

$ 55

Non-current assets

2,510

Current liabilities

(171)

Total

2,394

Goodwill

7,415

Deferred tax liability

(1,014)

Total

10,415

Non-controlling interest

(3,242)

Total consideration

9,567

Guizhou Wishstar

Net tangible assets:

Current assets

$ 8,170

Non-current assets

2,888

Total

11,058

Goodwill

725

Deferred tax liability

(277)

Total

1,558

Non-controlling interest

(4,446)

Total consideration

8,170

Customer relationship | Shanghai Huajian Management

Net tangible assets:

Intangible assets acquired, finite

7,339

Customer relationship | Gold iKang Shenyang Hospital

Net tangible assets:

Intangible assets acquired, finite

210

Customer relationship | iKang Tianjin Hedong Dongrun

Net tangible assets:

Intangible assets acquired, finite

479

Customer relationship | iKang Tianjin Hexi Fenghui

Net tangible assets:

Intangible assets acquired, finite

415

Customer relationship | WA HK

Net tangible assets:

Intangible assets acquired, finite

2,472

Customer relationship | Chengdu Ommay

Net tangible assets:

Intangible assets acquired, finite

936

Customer relationship | Yinchuan Ciming

Net tangible assets:

Intangible assets acquired, finite

1,581

Customer relationship | Beijing Tianzhikangjian

Net tangible assets:

Intangible assets acquired, finite

3,001

Customer relationship | Yantai Hongkang

Net tangible assets:

Intangible assets acquired, finite

2,533

Customer relationship | Shandong Ciming Clinics

Net tangible assets:

Intangible assets acquired, finite

2,593

Customer relationship | Wuhan Xiandai Sunny

Net tangible assets:

Intangible assets acquired, finite

988

Customer relationship | Xi'an iKang

Net tangible assets:

Intangible assets acquired, finite

3,875

Customer relationship | Guizhou Wishstar

Net tangible assets:

Intangible assets acquired, finite

1,064

Favorable lease contracts | iKang Shenyang Ningshan Hospital

Net tangible assets:

Intangible assets acquired, finite

554

Operating licenses | Shanghai Huajian Management

Net tangible assets:

Intangible assets acquired, finite

97

Operating licenses | iKang Shenyang Hospital

Net tangible assets:

Intangible assets acquired, finite

$ 110

Operating licenses | iKang Shenyang Ningshan Hospital

Net tangible assets:

Intangible assets acquired, finite

$ 109

Operating licenses | Gold iKang Shenyang Hospital

Net tangible assets:

Intangible assets acquired, finite

$ 64

Operating licenses | iKang Tianjin Hedong Dongrun

Net tangible assets:

Intangible assets acquired, finite

48

Operating licenses | iKang Tianjin Hexi Fenghui

Net tangible assets:

Intangible assets acquired, finite

$ 64

Operating licenses | WA HK

Net tangible assets:

Intangible assets acquired, finite

$ 80

Operating licenses | Chengdu Ommay

Net tangible assets:

Intangible assets acquired, finite

$ 16

Operating licenses | Yinchuan Ciming

Net tangible assets:

Intangible assets acquired, finite

$ 32

Operating licenses | Beijing Tianzhikangjian

Net tangible assets:

Intangible assets acquired, finite

$ 371

Operating licenses | Yantai Hongkang

Net tangible assets:

Intangible assets acquired, finite

$ 113

Operating licenses | Shandong Ciming Clinics

Net tangible assets:

Intangible assets acquired, finite

$ 145

Operating licenses | Wuhan Xiandai Sunny

Net tangible assets:

Intangible assets acquired, finite

$ 30

Operating licenses | Xi'an iKang

Net tangible assets:

Intangible assets acquired, finite

$ 139

Operating licenses | Guizhou Wishstar

Net tangible assets:

Intangible assets acquired, finite

$ 46

Trade name | Shanghai Huajian Management

Net tangible assets:

Intangible assets acquired, indefinite

$ 4,371

ACQUISITIONS - Estimated Useful

ACQUISITIONS - Estimated Useful Lives (Details)

Jan. 22, 2016

Jan. 01, 2016

Dec. 17, 2015

Aug. 14, 2015

Jun. 02, 2015

May 29, 2015

May 18, 2015

Apr. 16, 2015

Mar. 05, 2015

Feb. 17, 2015

Dec. 19, 2014

Nov. 19, 2014

Nov. 14, 2014

Jul. 01, 2014

Mar. 31, 2016

Customer relationship | Shanghai Huajian Management

Acquisitions

Estimated useful lives

5 years 6 months

Customer relationship | Gold iKang Shenyang Hospital

Acquisitions

Estimated useful lives

5 years

Customer relationship | iKang Tianjin Hedong Dongrun

Acquisitions

Estimated useful lives

5 years

Customer relationship | iKang Tianjin Hexi Fenghui

Acquisitions

Estimated useful lives

5 years

Customer relationship | WA HK

Acquisitions

Estimated useful lives

3 years

Customer relationship | Chengdu Ommay

Acquisitions

Estimated useful lives

5 years

Customer relationship | Yinchuan Ciming

Acquisitions

Estimated useful lives

5 years

Customer relationship | Beijing Tianzhikangjian

Acquisitions

Estimated useful lives

4 years 6 months

Customer relationship | Yantai Hongkang

Acquisitions

Estimated useful lives

5 years

Customer relationship | Shandong Ciming Clinics

Acquisitions

Estimated useful lives

5 years

Customer relationship | Wuhan Xiandai Sunny

Acquisitions

Estimated useful lives

5 years

Customer relationship | Xi'an iKang

Acquisitions

Estimated useful lives

5 years

Customer relationship | Guizhou Wishstar

Acquisitions

Estimated useful lives

5 years

Favorable lease contracts | iKang Shenyang Ningshan Hospital

Acquisitions

Estimated useful lives

2 years 9 months 18 days

Operating licenses | Shanghai Huajian Management

Acquisitions

Estimated useful lives

3 years

Operating licenses | iKang Shenyang Hospital

Acquisitions

Estimated useful lives

4 years

Operating licenses | iKang Shenyang Ningshan Hospital

Acquisitions

Estimated useful lives

5 years

Operating licenses | Gold iKang Shenyang Hospital

Acquisitions

Estimated useful lives

2 years 6 months

Operating licenses | iKang Tianjin Hedong Dongrun

Acquisitions

Estimated useful lives

1 year 4 months 24 days

Operating licenses | iKang Tianjin Hexi Fenghui

Acquisitions

Estimated useful lives

1 year 10 months 24 days

Operating licenses | Chengdu Ommay

Acquisitions

Estimated useful lives

1 year

Operating licenses | Yinchuan Ciming

Acquisitions

Estimated useful lives

2 years

Operating licenses | Yantai Hongkang

Acquisitions

Estimated useful lives

3 years 9 months 18 days

Operating licenses | Wuhan Xiandai Sunny

Acquisitions

Estimated useful lives

1 year 10 months 24 days

Operating licenses | Xi'an iKang

Acquisitions

Estimated useful lives

3 years 7 months 6 days

Operating licenses | Guizhou Wishstar

Acquisitions

Estimated useful lives

2 years

Minimum | Customer relationship

Acquisitions

Estimated useful lives

2 years 1 month 6 days

Minimum | Favorable lease contracts

Acquisitions

Estimated useful lives

2 years 9 months 18 days

Minimum | Operating licenses

Acquisitions

Estimated useful lives

3 months 18 days

Minimum | Operating licenses | WA HK

Acquisitions

Estimated useful lives

1 year 10 months 24 days

Minimum | Operating licenses | Beijing Tianzhikangjian

Acquisitions

Estimated useful lives

1 year 8 months 12 days

Minimum | Operating licenses | Shandong Ciming Clinics

Acquisitions

Estimated useful lives

1 year 3 months 18 days

Maximum | Customer relationship

Acquisitions

Estimated useful lives

10 years

Maximum | Favorable lease contracts

Acquisitions

Estimated useful lives

9 years 9 months 18 days

Maximum | Operating licenses

Acquisitions

Estimated useful lives

5 years

Maximum | Operating licenses | WA HK

Acquisitions

Estimated useful lives

2 years 9 months 18 days

Maximum | Operating licenses | Beijing Tianzhikangjian

Acquisitions

Estimated useful lives

4 years 7 months 6 days

Maximum | Operating licenses | Shandong Ciming Clinics

Acquisitions

Estimated useful lives

4 years 4 months 24 days

ACQUISITIONS - Additional Infor

ACQUISITIONS - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Shanghai Huajian Management
Acquisitions
Net revenue		$ 10,772
Net income (loss)		(676)
iKang Shenyang Hospital
Acquisitions
Net revenue		469
Net income (loss)		(392)
iKang Shenyang Ningshan Hospital
Acquisitions
Net revenue		144
Net income (loss)		(124)
Gold iKang Shenyang Hospital
Acquisitions
Net revenue		44
Net income (loss)		(475)
iKang Tianjin Hedong Dongrun
Acquisitions
Net revenue		30
Net income (loss)		(47)
iKang Tianjin Hexi Fenghui
Acquisitions
Net revenue		59
Net income (loss)		(73)
WA HK
Acquisitions
Net revenue		494
Net income (loss)		$ (203)
Chengdu Ommay
Acquisitions
Net revenue	$ 1,128
Net income (loss)	(681)
Yinchuan Ciming
Acquisitions
Net revenue	3,746
Net income (loss)	803
Beijing Tianzhikangjian
Acquisitions
Net revenue	7,420
Net income (loss)	(2,886)
Yantai Hongkang
Acquisitions
Net revenue	3,272
Net income (loss)	(66)
Shandong Ciming Clinics
Acquisitions
Net revenue	3,711
Net income (loss)	(1,330)
Wuhan Xiandai Sunny
Acquisitions
Net revenue	120
Net income (loss)	(173)
Xi'an iKang
Acquisitions
Net revenue	267
Net income (loss)	(663)
Guizhou Wishstar
Acquisitions
Net revenue	0
Net income (loss)	$ 10

ACQUISITIONS - Pro Forma Inform

ACQUISITIONS - Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Acquisitions during the year ended Maech 31, 2015 and previous
Pro forma financial information
Pro forma net revenue		$ 305,493	$ 238,706
Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc		25,299	$ 18,387
Acquisitions during the year ended Maech 31, 2016
Pro forma financial information
Pro forma net revenue	$ 385,286	321,149
Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc	$ 14,319	$ 20,130

ACQUISITIONS - Acquisition of A

ACQUISITIONS - Acquisition of Assets (Details) - USD ($) $ in Thousands	Sep. 09, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Acquisitions
Cash consideration		$ 37,024	$ 39,767	$ 35,838
Operating license of Tianjian Nankai Clinic
Acquisitions
Cash consideration	$ 435

ACCOUNTS RECEIVABLE, NET (Detai

ACCOUNTS RECEIVABLE, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2016	Mar. 31, 2015
Accounts receivable
Accounts receivable				$ 88,492	$ 67,705
Less: allowance for doubtful accounts	$ 8,055	$ 4,330	$ 3,272	14,329	8,055
Accounts receivable, net				$ 74,163	$ 59,650
Movement of allowance for doubtful accounts
Balance at beginning of year	8,055	4,330	3,272
Charge to expenses	8,509	3,758	1,100
Write off	(1,822)	(42)	(97)
Exchange difference	(413)	9	55
Balance at end of year	$ 14,329	$ 8,055	$ 4,330

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
INVENTORIES
Medical consumable supplies	$ 4,015	$ 2,661
Medical consumable
INVENTORIES
Medical consumable supplies	$ 4,015	$ 2,661

PREPAID EXPENSES AND OTHER CU75

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Advance payments for acquisitions	$ 10,570	$ 22,215
Advance to suppliers	24,930	9,150
Staff advance	5,485	5,261
Prepaid rental expenses	7,788	3,724
Prepaid expenses	4,302	3,327
Advance payments for investment	4,000
Other receivable	5,557	316
Interest income receivable	27	38
Total	$ 62,659	$ 44,031

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Property and equipment, net
Less: accumulated depreciation and amortization	$ 69,630	$ 53,309
Property and equipment, net	130,170	105,022
Depreciation expenses	19,625	14,691	$ 8,874
Medical equipment
Property and equipment, net
Property and equipment, gross	100,514	77,095
Leasehold improvements
Property and equipment, net
Property and equipment, gross	67,542	55,242
Computer equipment and application software
Property and equipment, net
Property and equipment, gross	15,740	11,734
Furniture and fixtures
Property and equipment, net
Property and equipment, gross	10,557	8,380
Motor vehicles
Property and equipment, net
Property and equipment, gross	1,389	944
Construction in progress
Property and equipment, net
Property and equipment, gross	$ 4,058	$ 4,936

LONG-TERM INVESTMENTS (Details)

LONG-TERM INVESTMENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
LONG-TERM INVESTMENTS
Cost method investments	$ 48,583	$ 129
Equity method investments	144,442
Available-for-sale investments	7,083
Total	$ 200,108	$ 129

LONG-TERM INVESTMENTS (Details

LONG-TERM INVESTMENTS (Details 2) $ in Thousands	1 Months Ended			6 Months Ended
	Mar. 31, 2016USD ($)	Nov. 30, 2015USD ($)cliniccity	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)
Xi'an Puhui
LONG-TERM INVESTMENTS
Percentage of equity interest owned- cost method		23.10%
Number of medical centers | clinic		15
Number of other cities in which acquiree's medical centers/clinics are located | city		6
Cash consideration- cost method		$ 32,090
American Well Corporation
LONG-TERM INVESTMENTS
Percentage of equity interest owned- cost method			1.80%	1.80%
Cash consideration- cost method				$ 13,500
Elysium Health, Inc.,
LONG-TERM INVESTMENTS
Percentage of equity interest owned- cost method			8.70%	8.70%
Cash consideration- cost method			$ 2,000
Shanghai Yimi Information Technology Co., Ltd.
LONG-TERM INVESTMENTS
Percentage of equity interest owned- cost method	4.00%
Cash consideration- cost method	$ 993

LONG-TERM INVESTMENTS (Detail79

LONG-TERM INVESTMENTS (Details 3) $ in Thousands	1 Months Ended			12 Months Ended
	Mar. 31, 2016USD ($)	Feb. 29, 2016USD ($)clinic	Sep. 30, 2015USD ($)director	Mar. 31, 2016USD ($)
Summary of the condensed financial information
Current assets	$ 187,583			$ 187,583
Non-current assets	32,618			32,618
Current liabilities	$ 26,196			26,196
Total revenues				52,185
Gross profits				16,580
Loss from operations				(23,094)
Net loss				(23,181)
Topsky
LONG-TERM INVESTMENTS
Percentage of equity interest owned- equity method			21.80%
Cash consideration- equity method			$ 10,372
Number of representatives to the board of directors | director			2
Number of board of directors | director			5
Loss from equity method investment				335
Worldcare International Inc.
LONG-TERM INVESTMENTS
Percentage of equity interest owned- equity method		20.00%
Cash consideration- equity method		$ 4,032
Loss from equity method investment				$ 43
Beijing MZ
LONG-TERM INVESTMENTS
Percentage of equity interest owned- equity method	40.00%			40.00%
Cash consideration- equity method	$ 124,070
NCI Health
LONG-TERM INVESTMENTS
Percentage of equity interest owned- equity method		45.00%
Cash consideration- equity method		$ 119,363
Loss from equity method investment				$ 1,354
Number of medical centers | clinic		16
Number of cities in which acquiree's medical centers/clinics are located | clinic		16

LONG-TERM INVESTMENTS (Detail80

LONG-TERM INVESTMENTS (Details 4) - USD ($) $ in Thousands	1 Months Ended
	Jun. 30, 2015	Mar. 31, 2016
Available-for-sale investments
Available for sale investments carrying amount		$ 7,083
Shanghai Shenmin Medical Technology Company Limited
Available-for-sale investments
Percentage of equity interest acquired	20.00%
Cash consideration to acquire available-for-sale security	$ 1,897
HDF
Available-for-sale investments
Percentage of equity interest acquired	1.00%
Cash consideration to acquire available-for-sale security	$ 5,000
Unrecognized gain or loss recognized	$ 186

ACQUIRED INTANGIBLE ASSETS, N81

ACQUIRED INTANGIBLE ASSETS, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Acquired intangible assets, net
Less: impairment	$ 410	$ 427
Intangible assets, net	37,179	30,634
Amortization expenses	10,769	5,221	$ 1,885
Future amortization expenses
2,017	10,346
2,018	7,151
2,019	4,600
2,020	2,616
2,021	617
thereafter	680
Impairment loss recognized on acquired intangible assets	0	0	$ 0
Customer relationship
Acquired intangible assets, net
Acquired intangible assets subject to amortization	38,708	23,286
Less: accumulated amortization	16,417	8,163
Operating licenses
Acquired intangible assets, net
Acquired intangible assets subject to amortization	5,670	4,566
Less: accumulated amortization	2,739	1,988
Favorable lease contracts
Acquired intangible assets, net
Acquired intangible assets subject to amortization	1,850	1,925
Less: accumulated amortization	765	433
Contract backlog
Acquired intangible assets, net
Acquired intangible assets subject to amortization	85	88
Less: accumulated amortization	85	88
Non-compete agreement
Acquired intangible assets, net
Acquired intangible assets subject to amortization	452	454
Less: accumulated amortization	339	189
Trade name
Acquired intangible assets, net
Acquired intangible assets not subject to amortization	$ 11,169	$ 11,603

GOODWILL (Details)

GOODWILL (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jan. 22, 2016	Dec. 17, 2015	Aug. 14, 2015	Jun. 02, 2015	May 29, 2015	Apr. 16, 2015
Changes in carrying amounts of goodwill
Gross amount, Beginning balance	$ 97,635	$ 66,936
Gross amount, Exchange difference	(3,519)	200
Gross amount, Ending balance	134,239	97,635
Accumulated impairment loss, Beginning balance	25,534	25,524
Accumulated impairment loss, Exchange difference	(134)	10
Accumulated impairment loss, Ending balance	25,400	25,534
Goodwill	108,839	72,101
Beijing Tianzhikangjian
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions	15,542
Yantai Hongkang
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions	3,690
Goodwill							$ 3,690
Yinchuan Ciming
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions	4,406
Goodwill						$ 4,406
Chengdu Ommay
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions	2,853
Goodwill								$ 2,853
Shandong Ciming Clinics
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions	2,361
Goodwill					$ 2,361
Xi'an iKang
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions	7,415
Goodwill				$ 7,415
iKang Wuhan Xiandai Sunny
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions	3,131
Guizhou Wishstar
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions	$ 725
Goodwill			$ 725
Shanghai Huajian Management
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions		14,032
iKang Shenyang Hospital
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions		982
iKang Shenyang Ningshan Hospital
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions		1,124
Gold iKang Shenyang Hospital
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions		3,464
iKang Tianjin Hedong Dongrun
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions		2,099
iKang Tianjin Hexi Fenghui
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions		1,228
WA HK
Changes in carrying amounts of goodwill
Gross amount, Additions for the year by acquisitions		$ 7,570

ACCRUED EXPENSES AND OTHER CU83

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Accrued expenses and other current liabilities
Acquisitions consideration payable	$ 13,093	$ 11,795
Accrued payroll and welfare	10,361	8,750
Accrued rental expense	5,498	5,737
Other payables	6,101	4,350
Collection received on behalf of and payable to the former shareholders of business acquired	2,786
Other taxes payable	3,641	2,788
Interest expense payable	2,838	100
Accrued social insurance	2,495	2,557
Accrued outsourcing cost	591	519
Dividend payable		194
Total	47,404	36,790
Beijing MZ
Accrued expenses and other current liabilities
Acquisitions consideration payable	3,743
Xi'an iKang
Accrued expenses and other current liabilities
Acquisitions consideration payable	3,484
Beijing Tianzhikangjian
Accrued expenses and other current liabilities
Acquisitions consideration payable	1,830
Yantai Hongkang
Accrued expenses and other current liabilities
Acquisitions consideration payable	1,480
Yinchuan Ciming
Accrued expenses and other current liabilities
Acquisitions consideration payable	465
iKang Wuhan Xiandai Sunny
Accrued expenses and other current liabilities
Acquisitions consideration payable	171
Shandong Ciming Clinics
Accrued expenses and other current liabilities
Acquisitions consideration payable	699
iKang Shanghai Jianwei
Accrued expenses and other current liabilities
Acquisitions consideration payable		129
Nanjing Aoyang
Accrued expenses and other current liabilities
Acquisitions consideration payable	155	161
Yuanhua
Accrued expenses and other current liabilities
Acquisitions consideration payable		292
Zhejiang Ailikang
Accrued expenses and other current liabilities
Acquisitions consideration payable		62
Shanghai Huajian Management
Accrued expenses and other current liabilities
Acquisitions consideration payable		7,203
Suzhou Aoyang
Accrued expenses and other current liabilities
Acquisitions consideration payable	217	1,032
iKang Tianjin Hedong Dongrun
Accrued expenses and other current liabilities
Acquisitions consideration payable	248	774
iKang Tianjin Hexi Fenghui
Accrued expenses and other current liabilities
Acquisitions consideration payable	248	774
Gold iKang Shenyang Hospital
Accrued expenses and other current liabilities
Acquisitions consideration payable	$ 353	368
WA HK
Accrued expenses and other current liabilities
Acquisitions consideration payable		$ 1,000

SHORT TERM BORROWINGS (Details)

SHORT TERM BORROWINGS (Details) $ in Thousands

1 Months Ended

2 Months Ended

12 Months Ended

Dec. 31, 2015USD ($)

Nov. 30, 2015USD ($)

Oct. 31, 2015USD ($)

Sep. 30, 2015USD ($)

Aug. 31, 2015USD ($)

Jul. 31, 2015USD ($)

Jun. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Aug. 31, 2014USD ($)

Jul. 31, 2014USD ($)loan

Jun. 30, 2014USD ($)

May 31, 2014USD ($)loan

Apr. 30, 2014USD ($)

Jun. 30, 2014USD ($)

Mar. 31, 2016USD ($)

Mar. 31, 2015USD ($)

Mar. 31, 2014USD ($)

Short term borrowings

Bank borrowings

$ 53,364

$ 56,772

Short term borrowing

53,364

56,772

Amount repaid

55,359

20,860

$ 7,383

Short-term bank borrowings

Short term borrowings

Interest expense

$ 1,734

$ 2,466

$ 827

Weighted average effective interest rate (as a percent)

3.30%

5.60%

7.00%

iKang Online | iKang Shanghai Xikang Road

Short term borrowings

Equity interest acquired (as a percent)

35.00%

35.00%

iKang Online | Xiamen International Bank

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 14,561

$ 14,561

Annual interest rate (as a percent)

2.585%

2.585%

Amount of collateralized restricted cash

$ 15,002

$ 15,002

iKang Online | One-year loan framework agreement with BEA signed in April 2014

Short term borrowings

Term of framework loan facility

1 year

Maximum borrowing capacity

$ 16,004

iKang Online | One-year loan framework agreement with BEA signed in April 2014 | Bank of East Asia

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 4,843

Variable rate basis

benchmark interest rate announced by the People's Bank of China

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

10.00%

Amount of collateralized restricted cash

$ 5,500

Number of loans borrowed | loan

2

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in June 2014

Short term borrowings

Term of framework loan facility

1 year

Maximum borrowing capacity

$ 32,099

32,099

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in June 2014 | Xiamen International Bank

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 17,537

Annual interest rate (as a percent)

2.585%

Amount of collateralized restricted cash

$ 18,067

Number of loans borrowed | loan

3

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in August 2014

Short term borrowings

Term of framework loan facility

1 year

Maximum borrowing capacity

$ 32,509

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in August 2014 | Xiamen International Bank

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 15,383

Annual interest rate (as a percent)

2.585%

Amount of collateralized restricted cash

$ 15,848

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in June 2015

Short term borrowings

Term of framework loan facility

1 year

Maximum borrowing capacity

$ 77,543

Annual interest rate (as a percent)

2.22%

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in June 2015 | Xiamen International Bank

Short term borrowings

Term of loan

1 year

1 year

1 year

Amount borrowed

$ 10,861

$ 13,958

Amount of collateralized restricted cash

$ 31,690

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in June 2015 | Bank Loan, Xiamen International Bank, July One

Short term borrowings

Amount borrowed

$ 3,040

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in June 2015 | Bank Loan, Xiamen International Bank, July Two

Short term borrowings

Amount borrowed

$ 3,018

iKang Online | One-year loan framework agreement with China Minsheng Bank signed in November 2015

Short term borrowings

Term of framework loan facility

1 year

Annual interest rate (as a percent)

4.35%

iKang Online | One-year loan framework agreement with China Minsheng Bank signed in November 2015 | China Minsheng Bank

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 2,481

iKang Online | One-year loan framework agreement with China Minsheng Bank signed in November 2015 | Bank Loan, China Minsheng Bank, November One

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 3,722

iKang Online | One-year loan framework agreement with China Minsheng Bank signed in November 2015 | Bank Loan, China Minsheng Bank, November Two

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 1,551

iKang Holding | Bank of China

Short term borrowings

Term of loan

1 year

1 year

1 year

Amount borrowed

$ 1,551

$ 3,102

$ 2,326

Annual interest rate (as a percent)

4.35%

4.60%

4.60%

iKang Holding | Two-year loan framework agreement with China Merchants Bank signed in May 2014

Short term borrowings

Term of framework loan facility

2 years

Maximum borrowing capacity

$ 8,060

iKang Holding | Two-year loan framework agreement with China Merchants Bank signed in May 2014 | China Merchants Bank

Short term borrowings

Term of loan

1 year

1 year

Amount borrowed

$ 1,437

$ 4,290

$ 1,437

Amount repaid

$ 1,084

$ 155

Variable rate basis

interest rate announced by the People's Bank of China

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

20.00%

iKang Holding | Ten-month loan framework agreement with China Merchants Bank signed in July 2015

Short term borrowings

Term of framework loan facility

10 months

Annual interest rate (as a percent)

7.20%

iKang Holding | Ten-month loan framework agreement with China Merchants Bank signed in July 2015 | China Merchants Bank

Short term borrowings

Term of loan

10 months

Amount borrowed

$ 7,754

LONG TERM BORROWINGS (Details)

LONG TERM BORROWINGS (Details) ¥ in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2015USD ($)item	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2015USD ($)
Long term borrowings
Long-term borrowings		$ 229,467
iKang Holding | Two year loan framework agreement with China Merchants bank signed in December 2015
Long term borrowings
Term of framework loan facility	2 years
Annual interest rate (as a percent)				4.75%	4.75%
Bank borrowings from China Merchants Bank
Long term borrowings
Long-term borrowings		12,345
Bank borrowings from China Merchants Bank | iKang Holding | Two year loan framework agreement with China Merchants bank signed in December 2015
Long term borrowings
Term of loan	2 years
Amount borrowed					$ 12,345
Interest expense		$ 145
Weighted average effective interest rate (as a percent)		4.75%
Long-term loans
Long term borrowings
Long-term borrowings		$ 217,122
Annual interest rate (as a percent)				5.00%	5.00%
Amount borrowed				¥ 1,400,000	$ 217,122
Number of third party investors | item	4
Interest expense		$ 2,869	$ 0
Weighted average effective interest rate (as a percent)		5.00%
Long-term loans | Privatization and convert before maturity date of the long-term loans
Long term borrowings
Interest expense	$ 0
Long-term loans | Privatization but not convert before maturity date of the long-term loans
Long term borrowings
Annual interest rate (as a percent)				5.00%	5.00%
Long-term loans | Minimum
Long term borrowings
Term of loan	18 months
Long-term loans | Minimum | Privatization not completed or failed to convert the loan before maturity date of convertible bonds
Long term borrowings
Annual interest rate (as a percent)				5.00%	5.00%
Long-term loans | Maximum
Long term borrowings
Term of loan	24 months
Long-term loans | Maximum | Privatization not completed or failed to convert the loan before maturity date of convertible bonds
Long term borrowings
Annual interest rate (as a percent)				20.00%	20.00%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Income Taxes
Income tax rate (as a percent)		25.00%	25.00%	25.00%
Individual income tax rate (as a percent)		35.00%	35.00%	35.00%
Hong Kong | Bayley & Jackson (Hong Kong)
Income Taxes
Income tax rate (as a percent)		16.50%
Hong Kong | Yuanhua HK (HongKong)
Income Taxes
Income tax rate (as a percent)		16.50%
Hong Kong | MediFast
Income Taxes
Income tax rate (as a percent)		16.50%
Hong Kong | WA HK
Income Taxes
Income tax rate (as a percent)		16.50%
PRC
Income Taxes
Income tax rate (as a percent)		25.00%
Withholding tax rate (as a percent)		10.00%
Minimum percentage of equity interest in a PRC-resident enterprise to be held by a qualified Hong Kong tax resident for reduced withholding tax rate		25.00%
Reduced withholding tax rate, if 25% or more equity interest in a PRC-resident enterprise is held by a qualified Hong Kong tax resident (as a percent)		5.00%
Aggregate undistributed earnings of Company's subsidiaries		$ 11,833
Accrued deferred tax liability		0
Aggregate undistributed earnings of the Company's VIEs and its VIEs' subsidiaries		$ 121,846
PRC | iKang Chengdu Waishuangnan
Income Taxes
Preferential tax rate (as a percent)		15.00%
PRC | iKang Chengdu Hongzhaobi
Income Taxes
Preferential tax rate (as a percent)		15.00%
PRC | Chengdu Gaoxin iKang West City
Income Taxes
Preferential tax rate (as a percent)		15.00%
PRC | iKang Chongqing
Income Taxes
Preferential tax rate (as a percent)		15.00%
PRC | iKang Shenzhen Nanshan
Income Taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Shenzhen Luohu
Income Taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Shenzhen Futian
Income Taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Shenzhen Kefa
Income Taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Health Cloud
Income Taxes
Period exempt from EIT under the "newly established software enterprise" ("NESE")	2 years
Preferential tax rate under NESE (as a percent)	12.50%
Period for preferential tax rate under NESE, after tax exempt period	3 years

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group's PRC subsidiaries and VIE entities
Current tax expenses	$ 13,778	$ 16,342	$ 12,048
Deferred tax benefits	(7,940)	(3,062)	(1,947)
Income tax expenses	5,838	13,280	$ 10,101
Current deferred tax assets:
Accrued expenses	2,337	2,151
Accrued payroll	2,476	2,076
Allowance for doubtful accounts	3,379	1,860
Less: Valuation allowance	(128)	(138)
Current deferred tax assets	8,064	5,949
Non-current deferred tax assets:
Depreciation and amortization	264	257
Impairment of long-lived assets	60	76
Net operating tax loss carry-forwards	9,527	4,369
Less: Valuation allowance	(1,774)	(2,490)
Non-current deferred tax assets	8,077	2,212
Non-current deferred tax liabilities:
Intangible assets	9,772	7,506
Non-current deferred tax liabilities	$ 9,772	$ 7,506

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
INCOME TAXES
Tax loss carry-forward	$ 38,560
Reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes
Income before provision for income taxes and (loss)/gain from equity method investments	$ 24,058	$ 40,155	$ 32,183
PRC statutory tax rate (as a percent)	25.00%	25.00%	25.00%
Income tax at statutory tax rate	$ 6,015	$ 10,039	$ 8,046
Change in valuation allowance	(726)	217	704
Expenses not deductible for tax purposes	1,565	593	440
Effect of income tax rate difference for entities under individual income tax rate of 35%	714	401	390
Loss utilized for entities under individual income tax rate of 35%		(315)	(99)
Effect of income tax rate differences in other jurisdictions	968	2,429	620
Tax holidays and preferential tax rates	(2,698)	(84)
Income tax expenses	$ 5,838	$ 13,280	$ 10,101
Individual income tax rate (as a percent)	35.00%	35.00%	35.00%

COMMON SHARE (Details)

COMMON SHARE (Details)	Dec. 02, 2015shares	May 09, 2014shares	Apr. 09, 2014shares	Apr. 30, 2014shares	Mar. 31, 2016Voteclass
Common share
Class B to Class A common share conversion ratio				1
Class A redesignated to Class C common shares (in shares)				805,100
Number of classes of authorized ordinary shares | class					2
Rights Plan
Common share
Common shares issued (in shares)	0
Minimum percentage of common shares required to exercise right	10.00%
Class A common shares
Common share
Number of vote each share entitled to | Vote					1
Common shares issued (in shares)			5,215,794
Conversion of convertible preferred shares to common shares (in shares)			20,781,515
Class A common shares | IPO
Common share
Common shares issued (in shares)			3,787,223
Class A common shares | Private placement
Common share
Common shares issued (in shares)			1,428,571
Class A common shares | Green Shoe
Common share
Common shares issued (in shares)		514,556
Class C common shares
Common share
Number of vote each share entitled to | Vote					15

CONVERTIBLE REDEEMABLE PREFER90

CONVERTIBLE REDEEMABLE PREFERRED SHARES (Details) $ / shares in Units, $ in Thousands	Apr. 09, 2014shares	Oct. 16, 2013USD ($)$ / sharesshares	Aug. 28, 2013USD ($)shares	Oct. 31, 2013USD ($)	Mar. 31, 2016USD ($)Vote	Mar. 31, 2014USD ($)	Mar. 31, 2013USD ($)shares	Mar. 31, 2012USD ($)
Convertible redeemable preferred shares
Issued amount | $						$ 25,181
Redemption premium amount upon issuance of series F | $						$ 17,763	$ 74,075
Rate of dividend on preferred stock (as a percent)					6.00%
Preferred stock conversion ratio					1
Liquidation payment as percentage of original purchase price					100.00%
If the IPO occurs on or before the first anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum pre-offering valuation amount | $					$ 555,000
If the IPO occurs after the first anniversary, but on or before the second anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum pre-offering valuation amount | $					675,000
If the IPO occurs after the second anniversary, but on or before the third anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum pre-offering valuation amount | $					723,000
If the IPO occurs after the third anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum pre-offering valuation amount | $					$ 740,000
Series A, B, C, D, E shares
Convertible redeemable preferred shares
Interest on preferred shares compounded annually (as a percent)					10.00%
Redemption premium amount recognized upon issuance | $					$ 26,353
Interest on preferred shares compounded annually upon issuance of series F preferred stock (as a percent)					10.00%
Series A convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							1,094,668
Shares converted into Class A common shares	1,094,668
Series B convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							686,368
Shares converted into Class A common shares	686,368
Series C1 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							794,250
Shares converted into Class A common shares	794,250
Series C2 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							126,286
Shares converted into Class A common shares	126,286
Series C3 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							1,024,318
Shares converted into Class A common shares	1,024,318
Series D1 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							3,538,864
Shares converted into Class A common shares	3,488,864
Series D2 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							2,307,536
Shares converted into Class A common shares	2,072,624
Series E convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							4,289,457
Shares converted into Class A common shares	4,289,457
Redemption premium amount | $								$ 2,312
Series F convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding							4,654,697
Shares issued			1,953,499
Issued amount | $			$ 25,181
Share price (in dollars per share) | $ / shares		$ 14.1792
Number of shares redesignated to		596,484
Difference amount received due to conversion | $				$ 1,281
Shares converted into Class A common shares	7,204,680
Restructuring period from expiry condition					18 months
Period in which restructuring to be completed from date of Restricted Venue Resolution					2 years
Interest on preferred shares compounded annually in the event of redemption for any event other than the restructuring not being completed and consummation of qualified initial public offering (as a percent)					10.00%
Interest on preferred shares compounded annually if qualified IPO has not been consummated (as a percent)					12.00%
Number of votes of the board directors required to approve redemption of preferred shares | Vote					5
Number of votes of the board directors | Vote					9
Minimum percentage of the outstanding preferred shares required to approve other public offering for qualified IPO					75.00%
Series F convertible redeemable participating preferred shares | If the IPO occurs on or before the first anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum percentage of the Original Purchase Price of preferred share, to calculate the pre-offering valuation amount as threshold for qualified IPO					50.00%
Series F convertible redeemable participating preferred shares | If the IPO occurs after the first anniversary, but on or before the second anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum percentage of the Original Purchase Price of preferred share, to calculate the pre-offering valuation amount as threshold for qualified IPO					35.00%
Series F convertible redeemable participating preferred shares | If the IPO occurs after the second anniversary, but on or before the third anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum percentage of the Original Purchase Price of preferred share, to calculate the pre-offering valuation amount as threshold for qualified IPO					25.00%
Series F convertible redeemable participating preferred shares | Minimum
Convertible redeemable preferred shares
Interest in consolidated revenue (as a percent)					3.00%
Interest in consolidated assets (as a percent)					3.00%
Class A common shares and Series D1 and D2 preferred shares
Convertible redeemable preferred shares
Number of shares sold		596,484
Share price (in dollars per share) | $ / shares		$ 12.0309
Total sold price | $		$ 7,176

NET INCOME (LOSS) PER SHARE (De

NET INCOME (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Net income (loss) per share
Net income attributable to iKang Guobin Healthcare Group, Inc.	$ 18,325	$ 27,113	$ 21,607
Deemed dividend		100	20,436
Undistributed earnings allocated to preferred shareholders		201	7,310
Net (loss)/income attributable to common and preferred shareholders of iKang Healthcare Group, Inc	$ 18,325	26,812	(6,139)
Numerator:
Net (loss) income attributed to common shareholders for computing net income per common share- basic and diluted		$ 26,812	$ (6,139)
Denominator:
Weighted average common shares outstanding used in computing diluted net income per common share-basic	33,583,005	32,884,357	6,340,005
Weighted average shares outstanding used in computing net income per common shares-diluted	34,235,542	34,114,872	6,340,005
Net (loss) income per common share attributable to iKang Guobin Healthcare Group, Inc.-basic (in dollars per share)	$ 0.55	$ 0.82	$ (0.97)
Net (loss) income per common share attributable to iKang Guobin Healthcare Group, Inc.-diluted (in dollars per share)	$ 0.54	$ 0.79	$ (0.97)
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect	0	0
Options
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			988,507
Series A convertible redeemable participating preferred shares
Net income (loss) per share
Deemed dividend		$ 5
Undistributed earnings allocated to preferred shareholders		3	$ 118
Numerator:
Total attribution to participating preferred stockholders		$ 8	$ 118
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		23,993	1,094,668
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.33	$ 0.11
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			1,094,668
Series B convertible redeemable participating preferred shares
Net income (loss) per share
Deemed dividend		$ 3
Undistributed earnings allocated to preferred shareholders		3	$ 130
Numerator:
Total attribution to participating preferred stockholders		$ 6	$ 130
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		15,044	686,368
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.40	$ 0.19
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			686,368
Series C shares
Net income (loss) per share
Deemed dividend		$ 9
Undistributed earnings allocated to preferred shareholders		6	$ 231
Numerator:
Total attribution to participating preferred stockholders		$ 15	$ 231
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		42,627	1,944,854
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.35	$ 0.12
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			1,944,954
Series D shares
Net income (loss) per share
Deemed dividend		$ 27	$ 1,945
Undistributed earnings allocated to preferred shareholders		19	789
Numerator:
Total attribution to participating preferred stockholders		$ 46	$ 2,734
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		121,896	5,717,326
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.38	$ 0.48
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			5,717,326
Series E convertible redeemable participating preferred shares
Net income (loss) per share
Deemed dividend		$ 21
Undistributed earnings allocated to preferred shareholders		33	$ 1,323
Numerator:
Total attribution to participating preferred stockholders		$ 54	$ 1,323
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		94,015	4,289,457
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.57	$ 0.31
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			4,289,457
Series F convertible redeemable participating preferred shares
Net income (loss) per share
Deemed dividend		$ 35	$ 18,491
Undistributed earnings allocated to preferred shareholders		137	4,719
Numerator:
Total attribution to participating preferred stockholders		$ 172	$ 23,210
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		157,911	6,075,702
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 1.09	$ 3.82
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			6,075,702

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - $ / shares	Feb. 27, 2015	Oct. 28, 2014	Aug. 01, 2014	Feb. 27, 2014	Sep. 12, 2013	Mar. 31, 2015	Mar. 31, 2014
Share-based compensation
Share options granted (in shares)						329,800	629,000
Exercise price (in dollars per share)						$ 15.20	$ 5.51
Director
Share-based compensation
Share options granted (in shares)					200,000
Exercise price (in dollars per share)					$ 6
Vesting period					3 years 6 months 18 days
Directors and employees | $5.13
Share-based compensation
Share options granted (in shares)		17,200		356,300
Exercise price (in dollars per share)		$ 5.13		$ 5.13
Vesting period		2 years		1 year 4 months 6 days
Directors and employees | $6.00
Share-based compensation
Share options granted (in shares)		8,600		72,700
Exercise price (in dollars per share)		$ 6		$ 6
Vesting period		2 years		1 year 10 months 28 days
Former shareholder
Share-based compensation
Share options granted (in shares)			300,000
Exercise price (in dollars per share)			$ 16.18
Former employee
Share-based compensation
Share options granted (in shares)	4,000
Exercise price (in dollars per share)	$ 5.13
Vesting period	2 years

SHARE-BASED COMPENSATION (Det93

SHARE-BASED COMPENSATION (Details 2) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Number of options
Outstanding at the beginning of the period (in shares)	1,900,479	1,888,698	1,284,698
Granted (in shares)		329,800	629,000
Exercised (in shares)	(995,255)	(277,319)
Forfeited (in shares)	(16,050)	(40,700)	(25,000)
Outstanding at the end of the period (in shares)	889,174	1,900,479	1,888,698
Weighted average exercise price per option
Outstanding at the beginning of the period (in dollars per share)	$ 6.63	$ 4.56	$ 4.13
Granted (in dollars per share)		15.20	5.51
Exercised (in dollars per share)	7.97	2.97
Forfeited (in dollars per share)	5.38	5.23	6
Outstanding at the end of the period (in dollars per share)	5.15	6.63	4.56
Weighted average fair value per option at grant date
Outstanding at the beginning of the period (in dollars per share)	12.36	9.24	6.08
Granted (in dollars per share)		24.69	15.61
Exercised (in dollars per share)	14.29	5.81
Forfeited (in dollars per share)	22.25	12.04	7.13
Outstanding at the end of the period (in dollars per share)	$ 10.02	$ 12.36	$ 9.24
Additional information
Vested options (in shares)	696,991
Options expected to vest (in shares)	192,183
Weighted-average exercise price of options expected to vest (in dollars per share)	$ 5.52
Aggregate intrinsic value of options expected to vest	$ 1,555

SHARE-BASED COMPENSATION (Det94

SHARE-BASED COMPENSATION (Details 3) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Option outstanding
Number outstanding (in shares) | shares	889,174
Aggregate intrinsic value | $	$ 34,295
Option exercisable
Number exercisable (in shares) | shares	696,991
Aggregate intrinsic value | $	$ 26,955
$ 0.01
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 0.01
Option outstanding
Number outstanding (in shares) | shares	30,000
Weighted average remaining contractual life in years	3 months 18 days
Weighted average Exercise price per option (in dollars per share)	$ 0.01
Aggregate intrinsic value | $	$ 1,311
Option exercisable
Number exercisable (in shares) | shares	30,000
Weighted average Exercise price per option (in dollars per share)	$ 0.01
Aggregate intrinsic value | $	$ 1,311
$1.00-$2.00
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 1
High end of range of exercise prices (in dollars per share)	$ 2
Option outstanding
Number outstanding (in shares) | shares	7,000
Weighted average remaining contractual life in years	1 year 3 months
Weighted average Exercise price per option (in dollars per share)	$ 1.25
Aggregate intrinsic value | $	$ 292
Option exercisable
Number exercisable (in shares) | shares	7,000
Weighted average Exercise price per option (in dollars per share)	$ 5.71
Aggregate intrinsic value | $	$ 292
$ 5.13
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 5.13
Option outstanding
Number outstanding (in shares) | shares	630,000
Weighted average remaining contractual life in years	6 years 7 months 13 days
Weighted average Exercise price per option (in dollars per share)	$ 5.13
Aggregate intrinsic value | $	$ 24,312
Option exercisable
Number exercisable (in shares) | shares	524,103
Weighted average Exercise price per option (in dollars per share)	$ 5.13
Aggregate intrinsic value | $	$ 20,226
$ 6
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 6
Option outstanding
Number outstanding (in shares) | shares	222,174
Weighted average remaining contractual life in years	7 years 6 months 11 days
Weighted average Exercise price per option (in dollars per share)	$ 6
Aggregate intrinsic value | $	$ 8,380
Option exercisable
Number exercisable (in shares) | shares	135,888
Weighted average Exercise price per option (in dollars per share)	$ 6
Aggregate intrinsic value | $	$ 5,126

SHARE-BASED COMPENSATION (Det95

SHARE-BASED COMPENSATION (Details 4) - USD ($) $ / shares in Units, $ in Thousands	Feb. 27, 2015	Oct. 28, 2014	Aug. 01, 2014	Feb. 27, 2014	Sep. 12, 2013	Mar. 18, 2013	Feb. 17, 2012	Jun. 08, 2011	Dec. 31, 2010	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Risk-free interest rate of return (as a percent)	3.33%	3.09%	3.09%	3.24%	3.22%	2.15%	2.99%	1.11%	4.67%
Contractual term	10 years	10 years	10 years	10 years	10 years	10 years	10 years	2 years 4 months 21 days	10 years
Volatility (as a percent)	58.87%	45.38%	40.00%	38.09%	38.20%	40.00%	41.00%	42.00%	40.90%
Exercise price (in dollars per share)	$ 5.13		$ 16.18		$ 6		$ 5.13	$ 0.01	$ 5.13
Additional disclosure
Share-based compensation										$ 1,949	$ 9,153	$ 930
Unrecognized compensation expense										$ 3,429
Period over which total unrecognized compensation expense relating to unvested share options will be recognized										2 years
Weighted-average remaining contractual term of options outstanding										6 years 7 months 6 days
Minimum
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Exercise price (in dollars per share)		$ 5.13		$ 5.13		$ 5.13
Maximum
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Exercise price (in dollars per share)		$ 6		$ 6		$ 6

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Foreign currency exchange forward contracts - Level 2 - Recurring basis $ in Thousands	12 Months Ended
	Mar. 31, 2015USD ($)
Fair Value Derivative Asset Measured on Recurring Basis [Roll Forward]
Balance at beginning of year	$ 6,377
Loss from forward contracts	(8)
Settled	$ (6,369)

FAIR VALUE MEASUREMENTS (Deta97

FAIR VALUE MEASUREMENTS (Details 2) $ in Thousands	Mar. 31, 2016USD ($)
Fair value measurements
Available-for-sale Investments	$ 7,083
Recurring basis
Fair value measurements
Available-for-sale Investments	7,083
Long-term loans	217,122
Long-term bank borrowings	12,345
Contingent consideration	2,846
Outstanding on March 31 year	239,396
Recurring basis | Level 1
Fair value measurements
Available-for-sale Investments	1,897
Outstanding on March 31 year	1,897
Recurring basis | Level 3
Fair value measurements
Available-for-sale Investments	5,186
Long-term loans	217,122
Long-term bank borrowings	12,345
Contingent consideration	2,846
Outstanding on March 31 year	$ 237,499

RELATED PARTY BALANCES AND TR98

RELATED PARTY BALANCES AND TRANSACTIONS (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2016USD ($)item
Amounts due from a related party - current:
Amounts due from related parties - current | $	$ 4,653
Number of company, owned by the non-controlling shareholder of one of the Group's subsidiaries, provided non-interest bearing loans | item	2

NONCONTROLLING INTEREST (Detail

NONCONTROLLING INTEREST (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Noncontrolling interest
Balance at the beginning of the period	$ 9,218	$ 3,818	$ 1,030
Addition of non-controlling interest	16,767
Capital contribution of non-controlling interest holder	457
Addition of non-controlling interest in connection with new establishments	733
Dividend distribution to non-controlling interest holder	(614)
Share of profit (loss)	(1,837)	283	319
Purchase of non-controlling interest	(1,664)		(142)
Other comprehensive income	(484)	24	(21)
Balance at the end of the period	22,576	9,218	3,818
iKang Zhejiang BVI
Noncontrolling interest
Balance at the beginning of the period	260	106	4
Share of profit (loss)	158	133	104
Other comprehensive income		21	(2)
Balance at the end of the period	418	260	106
WA HK
Noncontrolling interest
Balance at the beginning of the period	5,330
Addition of non-controlling interest		3,388
Capital contribution of non-controlling interest holder		1,984
Share of profit (loss)	(453)	(42)
Other comprehensive income	(199)
Balance at the end of the period	4,678	5,330
iKang Shanghai Gubei
Noncontrolling interest
Balance at the beginning of the period	1,034	824	639
Dividend distribution to non-controlling interest holder	(557)		(44)
Share of profit (loss)	9	210	236
Purchase of non-controlling interest	(486)
Other comprehensive income			(7)
Balance at the end of the period		1,034	824
iKang Shanghai Lujiazui
Noncontrolling interest
Balance at the beginning of the period			116
Share of profit (loss)			25
Purchase of non-controlling interest			(142)
Other comprehensive income			1
Fujian iKang
Noncontrolling interest
Balance at the beginning of the period	617	389	250
Share of profit (loss)	61	228	143
Other comprehensive income	(28)		(4)
Balance at the end of the period	650	617	389
Shenzhen Hospital Management
Noncontrolling interest
Balance at the beginning of the period	(52)	53	21
Share of profit (loss)	(789)	(105)	33
Other comprehensive income	13		(1)
Balance at the end of the period	(828)	(52)	53
Shanghai Jianwei Management
Noncontrolling interest
Balance at the beginning of the period	68	161
Addition of non-controlling interest			172
Capital contribution of non-controlling interest holder		50
Share of profit (loss)	(162)	(145)	(9)
Other comprehensive income		2	(2)
Balance at the end of the period	(94)	68	161
Beijing Jiandatong
Noncontrolling interest
Balance at the beginning of the period	94	45
Addition of non-controlling interest			82
Capital contribution of non-controlling interest holder		58
Share of profit (loss)	(27)	(9)	(36)
Other comprehensive income	(3)		(1)
Balance at the end of the period	64	94	45
MediFast
Noncontrolling interest
Balance at the beginning of the period	1,553	1,737
Addition of non-controlling interest			1,690
Dividend distribution to non-controlling interest holder	(57)	(387)
Share of profit (loss)	257	202	48
Other comprehensive income		1	(1)
Balance at the end of the period	1,753	1,553	1,737
iKang Changzhou
Noncontrolling interest
Balance at the beginning of the period	314	503
Addition of non-controlling interest			732
Share of profit (loss)	52	(189)	(225)
Other comprehensive income	(16)		(4)
Balance at the end of the period	350	$ 314	$ 503
Beijing Tianzhikangjian
Noncontrolling interest
Addition of non-controlling interest	5,050
Share of profit (loss)	(495)
Purchase of non-controlling interest	(1,178)
Other comprehensive income	(211)
Balance at the end of the period	3,166
Yinchuan Ciming
Noncontrolling interest
Addition of non-controlling interest	1,613
Share of profit (loss)	241
Other comprehensive income	(69)
Balance at the end of the period	1,785
Shandong Ciming Clinics
Noncontrolling interest
Addition of non-controlling interest	2,416
Share of profit (loss)	(399)
Other comprehensive income	(91)
Balance at the end of the period	1,926
Xi'an iKang
Noncontrolling interest
Addition of non-controlling interest	3,242
Capital contribution of non-controlling interest holder	457
Share of profit (loss)	(199)
Other comprehensive income	20
Balance at the end of the period	3,520
China Physician Alliance
Noncontrolling interest
Addition of non-controlling interest in connection with new establishments	551
Share of profit (loss)	(39)
Other comprehensive income	7
Balance at the end of the period	519
Wuhu
Noncontrolling interest
Addition of non-controlling interest in connection with new establishments	182
Share of profit (loss)	(56)
Other comprehensive income	3
Balance at the end of the period	129
Guizhou Winstar Medical Center
Noncontrolling interest
Addition of non-controlling interest	4,446
Share of profit (loss)	4
Other comprehensive income	90
Balance at the end of the period	$ 4,540

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2016USD ($)segment	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)
Segment information
Number of operating segments | segment	2
Net revenues:
Net revenues	$ 370,812	$ 290,781	$ 202,304
Cost of revenues:
Cost of revenues	210,909	154,943	106,405
Gross profit:
Gross profit	159,903	135,838	95,899
Operating expenses:
Selling and marketing expenses	64,763	41,059	28,879
General and administrative expenses	65,422	52,331	32,053
Research and development expenses	3,716	1,401	1,603
Total operating expenses	133,901	94,791	62,535
Income from operations	26,002	41,047	33,364
Medical examinations and other medical services
Net revenues:
Net revenues	364,635	285,292	202,304
Cost of revenues:
Cost of revenues	206,034	151,348	106,405
Gross profit:
Gross profit	158,601	133,944	95,899
Medical examinations and other medical services | Medical examinations
Net revenues:
Net revenues	308,053	244,945	173,903
Medical examinations and other medical services | Disease screening
Net revenues:
Net revenues	27,092	19,689	15,017
Medical examinations and other medical services | Other services
Net revenues:
Net revenues	29,490	20,658	$ 13,384
Dental services
Net revenues:
Net revenues	6,177	5,489
Cost of revenues:
Cost of revenues	4,875	3,595
Gross profit:
Gross profit	$ 1,302	$ 1,894

COMMITMENTS AND CONTINGENCIE101

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
COMMITMENTS AND CONTINGENCIES
Rental expenses under operating leases	$ 51,719	$ 37,733	$ 28,129
Future minimum lease payments
2,017	58,574
2,018	52,052
2,019	44,883
2,020	39,277
2,021	35,179
After 2,021	122,279
Total	$ 352,244

COMMITMENTS AND CONTINGENCIE102

COMMITMENTS AND CONTINGENCIES (Details 2) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Future minimum principal payments related to long-term borrowings
2,018	$ 229,467
Total	$ 229,467
Maximum
Contingent liabilities
Maximum exposure of lawsuits		$ 3,669

EMPLOYEE BENEFIT PLAN (Details)

EMPLOYEE BENEFIT PLAN (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
EMPLOYEE BENEFIT PLAN
Total provision under government-mandated defined contribution plan	$ 16,342	$ 10,417	$ 7,249

STATUTORY RESERVE AND RESTRI104

STATUTORY RESERVE AND RESTRICTED NET ASSETS (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
STATUTORY RESERVE AND RESTRICTED NET ASSETS
Percentage of after-tax profits required to be appropriated to general reserve	10.00%
General reserve as a percentage of registered capital up to which after-tax profit of PRC subsidiaries and VIEs shall be transferred	50.00%
Amount appropriated to statutory reserve	$ 3,130	$ 3,394	$ 2,738
Aggregate amounts of capital and statutory reserves restricted	$ 216,340
Restricted net assets of subsidiaries and VIE entities as a percentage of consolidated net assets of the Group	25.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent event - USD ($) $ / shares in Units, $ in Thousands	May 20, 2016	Jun. 06, 2016
Beijing Bohui
Subsequent events
Equity interest acquired (as a percent)	100.00%
Zhongpu Bohui
Subsequent events
Equity interest acquired (as a percent)	100.00%
Beijing Bohui and Zhongpu Bohui
Subsequent events
Cash consideration	$ 5,375
Class A common shares | Going Private Transaction | Yunfeng Capital
Subsequent events
Share price (in dollars per share)		$ 40
Class C common shares | Going Private Transaction | Yunfeng Capital
Subsequent events
Share price (in dollars per share)		50
ADS, Class A | Going Private Transaction | Yunfeng Capital
Subsequent events
Share price (in dollars per share)		20
ADS, Class C | Going Private Transaction | Yunfeng Capital
Subsequent events
Share price (in dollars per share)		$ 25

FINANCIAL STATEMENT SCHEDULE I

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Current assets:
Cash and cash equivalents	$ 108,111	$ 97,336	$ 30,221	$ 63,154
Amounts due from a related party	4,653
Prepaid expenses and other current assets	62,659	44,031
Total current assets	305,703	278,665
Property and equipment, net	130,170	105,022
Rental deposit and other non-current assets	13,565	10,238
TOTAL ASSETS	803,641	499,001
Current liabilities:
Accrued expenses and other current liabilities	47,404	36,790
Total current liabilities	199,000	163,147
Equity:
Additional paid-in capital	436,746	419,862
Accumulated other comprehensive income/(loss)	(7,577)	3,936
Total iKang Healthcare Group, Inc. shareholders' equity	342,826	319,130
TOTAL LIABILITIES AND EQUITY	803,641	499,001
PARENT COMPANY
Current assets:
Cash and cash equivalents	1,995	55,883	13,937	47,290
Amounts due from a related party	156,038	127,694
Prepaid expenses and other current assets	715	1,488
Total current assets	158,748	185,065
Investment in subsidiaries and VIE entities	181,858	136,670
Rental deposit and other non-current assets	5,740	740
TOTAL ASSETS	346,346	322,475
Current liabilities:
Accrued expenses and other current liabilities	1,658	2,151
Amount due to related party	1,862	1,194
Total current liabilities	3,520	3,345
Equity:
Additional paid-in capital	436,746	419,862
Accumulated deficit	(86,686)	(105,011)
Accumulated other comprehensive income/(loss)	(7,577)	3,936
Total iKang Healthcare Group, Inc. shareholders' equity	342,826	319,130	$ (126,957)	$ (124,195)
TOTAL LIABILITIES AND EQUITY	346,346	322,475
Class A common shares
Equity:
Common shares	335	335
Class A common shares | PARENT COMPANY
Equity:
Common shares	335	335
Class C common shares
Equity:
Common shares	8	8
Class C common shares | PARENT COMPANY
Equity:
Common shares	$ 8	$ 8

FINANCIAL STATEMENT SCHEDULE107

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details) (Parenthetical) - $ / shares	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)			$ 0.01
PARENT COMPANY
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)			$ 0.01
Class A common shares
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	37,648,485	37,648,485
Common shares, issued	33,556,439	33,556,439
Common shares, outstanding	33,556,439	33,556,439
Class A common shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	37,648,485	37,648,485
Common shares, issued	33,556,439	33,556,439
Common shares, outstanding	33,556,439	33,556,439
Class C common shares
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	2,000,000	2,000,000
Common shares, issued	805,100	805,100
Common shares, outstanding	805,100	805,100
Class C common shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	2,000,000	2,000,000
Common shares, issued	805,100	805,100
Common shares, outstanding	805,100	805,100

FINANCIAL STATEMENT SCHEDULE108

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
Selling and marketing expenses	$ 64,763	$ 41,059	$ 28,879
General and administrative expenses	65,422	52,331	32,053
Total operating expenses	133,901	94,791	62,535
Income from operations	26,002	41,047	33,364
Interest income	785	699	93
Interest expense	(4,603)	(2,466)	(1,331)
Income tax expenses	5,838	13,280	10,101
Net income attributable to iKang Healthcare Group, Inc.	18,325	27,113	21,607
PARENT COMPANY
Operating expenses:
Selling and marketing expenses		15
General and administrative expenses	5,000	10,536	2,457
Total operating expenses	5,000	10,551	2,457
Income from operations	(5,000)	(10,551)	(2,457)
Interest income	24	25	11
Interest expense	(2)		(18)
Equity in earnings of subsidiaries and VIE entities	23,303	37,639	24,071
(Loss)/gain from equity method investment	23,303	37,639	24,071
Income before provision for income taxes	18,325	27,113	21,607
Net income attributable to iKang Healthcare Group, Inc.	$ 18,325	$ 27,113	$ 21,607

FINANCIAL STATEMENT SCHEDULE109

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Other comprehensive income:
Net income	$ 18,325	$ 27,113	$ 21,607
Unrealized gain on available-for-sale investments	186
Unrealized gain (loss) available-for-sale securities, tax	0	0	0
Comprehensive income attributable iKang Healthcare Group, Inc.	6,808	27,285	20,849
PARENT COMPANY
Other comprehensive income:
Net income	18,325	27,113	21,607
Other comprehensive income, foreign currency translation adjustment	(11,703)	172	(758)
Unrealized gain on available-for-sale investments	186
Comprehensive income attributable iKang Healthcare Group, Inc.	$ 6,808	$ 27,285	$ 20,849

FINANCIAL STATEMENT SCHEDULE110

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 4) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2016		Mar. 31, 2015	Mar. 31, 2014
Increase (Decrease) in Stockholders' Equity
Balance		$ 319,130
Share-based compensation expenses		1,949		$ 9,153	$ 930
Conversion of participating convertible redeemable preferred shares to common shares				264,509
Redesignation to Series F convertible redeemable participating preferred shares					(3,749)
Addition of non-controlling interest in connection with acquisition		16,767
Issuance of common shares in connection with exercise of options		$ 8,035	[1]	$ 822
Issuance of common shares in connection with exercise of options (in shares)		995,255		277,319
Issuance of ordinary shares in connection with share-based compensation arrangements	[1]			$ 16
Capital contribution of non-controlling interest holder		$ 457
Settlement of acquisition payable of Huajian		7,206
Purchase of non-controlling interest		(1,664)			(142)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium				(100)	(20,436)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		186
Net income		18,325		27,113	21,607
Unrealized gain on available-for-sale investments		186
Balance		342,826		319,130
iKang Shanghai Lujiazui
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest					(326)
WA HK
Increase (Decrease) in Stockholders' Equity
Addition of non-controlling interest in connection with acquisition				3,388
iKang Shanghai Gubei
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(788)
PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance		319,130		(126,957)	(124,195)
Share-based compensation expenses		$ 1,949		9,153	930
Conversion of participating convertible redeemable preferred shares to common shares				264,509
Redesignation to Series F convertible redeemable participating preferred shares					(3,749)
Issuance of common shares in connection with exercise of options				822
Issuance of common shares in connection with exercise of options (in shares)		8,035,000
Issuance of ordinary shares in connection with share-based compensation arrangements				16
Settlement of acquisition payable of Huajian		$ 7,206
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium					(20,436)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		186
Net income		18,325		27,113	21,607
Foreign currency translation adjustment		(11,703)		172	(758)
Unrealized gain on available-for-sale investments		186
Balance		342,826		319,130	(126,957)
PARENT COMPANY | Shanghai Jianwei Management
Increase (Decrease) in Stockholders' Equity
Addition of non-controlling interest in connection with acquisition					(172)
Capital contribution of non-controlling interest holder				(50)
PARENT COMPANY | iKang Shanghai Lujiazui
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest					$ (184)
PARENT COMPANY | WA HK
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder				$ (1,984)
PARENT COMPANY | iKang Shanghai Gubei
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		$ (302)
Common
Increase (Decrease) in Stockholders' Equity
Balance (in shares)		34,361,539		6,169,674	6,481,245
Conversion of participating convertible redeemable preferred shares to common shares				$ 208
Conversion of participating convertible redeemable preferred shares to common shares (in shares)				20,781,515
iKang Healthcare Group, Inc. one common share of US$0.01 entered into a share swap agreement (in shares)					1
Redesignation to Series F convertible redeemable participating preferred shares					$ (4)
Redesignation to Series F convertible redeemable participating preferred shares (in shares)					(311,572)
Issuance of common shares in connection with exercise of options				$ 1
Issuance of common shares in connection with exercise of options (in shares)				80,000
Issuance of ordinary shares in connection with share-based compensation arrangements	[1]			$ 16
Issuance of ordinary shares in connection with share-based compensation arrangements (in shares)	[1]			1,600,000
Balance (in shares)		34,361,539		34,361,539	6,169,674
Common | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance		$ 343		$ 61	$ 65
Balance (in shares)		34,361,539		6,169,674	6,481,245
Conversion of participating convertible redeemable preferred shares to common shares				$ 208
Conversion of participating convertible redeemable preferred shares to common shares (in shares)				20,781,515
iKang Healthcare Group, Inc. one common share of US$0.01 entered into a share swap agreement (in shares)					1
Redesignation to Series F convertible redeemable participating preferred shares					$ (4)
Redesignation to Series F convertible redeemable participating preferred shares (in shares)					(311,572)
Issuance of common shares in connection with exercise of options				$ 1
Issuance of common shares in connection with exercise of options (in shares)				80,000
Issuance of ordinary shares in connection with share-based compensation arrangements				$ 16
Issuance of ordinary shares in connection with share-based compensation arrangements (in shares)				1,600,000
Balance		$ 343		$ 343	$ 61
Balance (in shares)		34,361,539		34,361,539	6,169,674
Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Share-based compensation expenses		$ 1,949		$ 9,153	$ 930
Conversion of participating convertible redeemable preferred shares to common shares				264,301
Redesignation to Series F convertible redeemable participating preferred shares					(3,745)
Issuance of common shares in connection with exercise of options		8,035	[1]	821
Settlement of acquisition payable of Huajian		7,202
Additional paid-in capital | Shanghai Jianwei Management
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder				(50)
Additional paid-in capital | iKang Shanghai Lujiazui
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest					(184)
Additional paid-in capital | WA HK
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder				(1,984)
Additional paid-in capital | iKang Shanghai Gubei
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(302)
Additional paid-in capital | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance		419,862		1,342	4,341
Share-based compensation expenses		$ 1,949		9,153	930
Conversion of participating convertible redeemable preferred shares to common shares				264,301
Redesignation to Series F convertible redeemable participating preferred shares					(3,745)
Issuance of common shares in connection with exercise of options				821
Issuance of common shares in connection with exercise of options (in shares)		8,035,000
Settlement of acquisition payable of Huajian		$ 7,202
Balance		436,746		419,862	1,342
Additional paid-in capital | PARENT COMPANY | Shanghai Jianwei Management
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder				(50)
Additional paid-in capital | PARENT COMPANY | iKang Shanghai Lujiazui
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest					(184)
Additional paid-in capital | PARENT COMPANY | WA HK
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder				(1,984)
Additional paid-in capital | PARENT COMPANY | iKang Shanghai Gubei
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(302)
Accumulated deficit | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance		(105,011)		(132,124)	(133,123)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium					(20,436)
Net income		18,325		27,113	21,607
Balance		(86,686)		(105,011)	(132,124)
Accumulated deficit | PARENT COMPANY | Shanghai Jianwei Management
Increase (Decrease) in Stockholders' Equity
Addition of non-controlling interest in connection with acquisition					(172)
Accumulated other comprehensive income
Increase (Decrease) in Stockholders' Equity
Settlement of acquisition payable of Huajian		4
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		186
Unrealized gain on available-for-sale investments		186
Accumulated other comprehensive income | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance		3,936		3,764	4,522
Settlement of acquisition payable of Huajian		4
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		186
Foreign currency translation adjustment		(11,703)		172	(758)
Unrealized gain on available-for-sale investments		186
Balance		$ (7,577)		3,936	$ 3,764
IPO
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				132,937
IPO | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				132,937
IPO | Common
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				$ 52
Issuance of common shares (in shares)				5,215,794
IPO | Common | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				$ 52
Issuance of common shares (in shares)				5,215,794
IPO | Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				$ 132,885
IPO | Additional paid-in capital | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				132,885
Green Shoe
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				13,399
Green Shoe | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				13,399
Green Shoe | Common
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				$ 5
Issuance of common shares (in shares)				514,556
Green Shoe | Common | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				$ 5
Issuance of common shares (in shares)				514,556
Green Shoe | Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				$ 13,394
Green Shoe | Additional paid-in capital | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares				$ 13,394
[1]	Shares were previously issued during the year ended March 31, 2015.

FINANCIAL STATEMENT SCHEDULE111

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 4) (Parenthetical) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY(DEFICIT)
Common shares, par value (in dollars per share)		$ 0.01
Offering costs	$ 2,882
PARENT COMPANY
CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY(DEFICIT)
Common shares, par value (in dollars per share)		$ 0.01
Offering costs	$ 2,882

FINANCIAL STATEMENT SCHEDULE112

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 5) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 18,325	$ 27,113	$ 21,607
Adjustments to reconcile net income to net cash provided by operating activities:
Share-based compensation expenses	1,949	9,153	930
Changes in assets and liabilities:
Prepaid expenses and other current assets	(10,069)	(5,300)	(1,193)
Accrued expenses and other current liabilities	3,979	2,123	2,884
Net cash generated from (used in) operating activities	43,602	41,097	34,303
CASH FLOWS FROM INVESTING ACTIVITIES
Loan provided to a related party	(4,719)		(4,306)
Repayment of loan provided to a related party		1,291	3,483
Payment for long-term investments	(204,414)
Payment of loan receivable	(1,000)	(740)
Payments for business acquisitions	(37,249)	(56,654)	(41,311)
Net cash used in investing activities	(261,533)	(147,062)	(96,714)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible redeemable preferred shares			25,181
Proceeds from redesignation of Class A common shares			612
Proceeds from redesignation of convertible redeemable preferred shares			669
Payment for convertible preferred shares transaction professional fees			(2,847)
Proceeds from issuance of common shares upon initial public offering		135,819
Proceeds from issuance of common shares upon Green Shoe		13,399
Payments of initial public offering expenses		(3,574)
Proceeds from exercise of share options	8,035	824
Payments for business acquisitions	(1,853)	(1,329)	(3,010)
Repayment of convertible loan			(2,000)
Net cash provided by financing activities	237,465	173,570	29,342
Net increase (decrease) in cash and cash equivalent	10,775	67,115	(32,933)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	97,336	30,221	63,154
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	108,111	97,336	30,221
PARENT COMPANY
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	18,325	27,113	21,607
Adjustments to reconcile net income to net cash provided by operating activities:
Investment income from subsidiaries	(23,303)	(37,639)	(24,071)
Share-based compensation expenses	1,949	9,153	930
Changes in assets and liabilities:
Prepaid expenses and other current assets	775	(410)	(315)
Amount due from related parties	(27,675)	(103,142)	(17,732)
Accrued expenses and other current liabilities	(494)	3,349	(2,409)
Net cash generated from (used in) operating activities	(30,423)	(101,576)	(21,990)
CASH FLOWS FROM INVESTING ACTIVITIES
Loan provided to a related party			(3,000)
Repayment of loan provided to a related party			3,000
Payment for long-term investments	(24,500)
Investment in subsidiaries	(6,000)
Payment of loan receivable	(1,000)	(740)
Payments for business acquisitions		(2,417)	(32,978)
Net cash used in investing activities	(31,500)	(3,157)	(32,978)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible redeemable preferred shares			25,181
Proceeds from redesignation of Class A common shares			669
Proceeds from redesignation of convertible redeemable preferred shares			612
Payment for convertible preferred shares transaction professional fees			(2,847)
Proceeds from issuance of common shares upon initial public offering		135,819
Proceeds from issuance of common shares upon Green Shoe		13,399
Payments of initial public offering expenses		(2,276)
Proceeds from exercise of share options	8,035	824
Payments for business acquisitions		(1,087)
Repayment of convertible loan			(2,000)
Net cash provided by financing activities	8,035	146,679	21,615
Net increase (decrease) in cash and cash equivalent	(53,888)	41,946	(33,353)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	55,883	13,937	47,290
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	$ 1,995	$ 55,883	$ 13,937